variant_id	variant_civic_url	gene	entrez_id	variant	summary	variant_groups	chromosome	start	stop	reference_bases	variant_bases	representative_transcript	ensembl_version	reference_build	chromosome2	start2	stop2	representative_transcript2	variant_types	hgvs_expressions	last_review_date
1	https://civic.genome.wustl.edu/links/variants/1	ABL1	25	BCR-ABL	The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and ponatinib) have seen some success in delivering a tumor response.		22	23522397	23632600			ENST00000305877.8	75	GRCh37	9	133729451	133763063	ENST00000318560.5	transcript_fusion		2016-03-08 23:24:25 UTC
2	https://civic.genome.wustl.edu/links/variants/2	ABL1	25	BCR-ABL T334I	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Imatinib Resistance,Imatinib Resistance	9	133748283	133748283	C	T	ENST00000372348.2	75	GRCh37					transcript_fusion,missense_variant	NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T	2016-03-11 20:34:23 UTC
3	https://civic.genome.wustl.edu/links/variants/3	ABL1	25	BCR-ABL E255K	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Imatinib Resistance	9	133738363	133738363	G	A	ENST00000318560.5	75	GRCh37					transcript_fusion,missense_variant	NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A	2016-01-22 19:40:46 UTC
4	https://civic.genome.wustl.edu/links/variants/4	AKT1	207	E17K	AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.		14	105246551	105246551	C	T	ENST00000407796.2	75	GRCh37					missense_variant	NC_000014.8:g.105246551C>T,NM_001014432.1:c.49G>A,NP_001014432.1:p.Glu17Lys,ENST00000407796.2:c.49G>A	2016-01-22 19:40:48 UTC
5	https://civic.genome.wustl.edu/links/variants/5	ALK	238	EML4-ALK	The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors.	ALK Fusions	2	42396490	42522656			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion		2016-09-02 19:51:58 UTC
6	https://civic.genome.wustl.edu/links/variants/6	ALK	238	EML4-ALK C1156Y	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, C1156Y has been shown to confer resistance to crizotinib. Case reports indicate that secondary mutations can modulate drug sensitivity. EML4-ALK C1156Y/L1196M maintained crizotinib resistance while the lorlatinib resistant combination EML4-ALK C1156Y/L1198F re-sensitized the tumor to crizotinib treatment.	ALK Fusions,Crizotinib Resistance	2	29445258	29445258	C	T	ENST00000389048.3	75	GRCh37					transcript_fusion,missense_variant	ENST00000389048.3:c.3467G>A,NC_000002.11:g.29445258C>T,NM_004304.4:c.3467G>A	2016-09-02 23:03:49 UTC
7	https://civic.genome.wustl.edu/links/variants/7	ALK	238	EML4-ALK L1196M	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, L1196M has been shown to confer resistance to crizotinib. This was also true in a patient with both EML4-ALK C1156Y & L1196M.	ALK Fusions,Crizotinib Resistance	2	29443631	29443631	G	T	ENST00000389048.3	75	GRCh37					transcript_fusion,missense_variant	ENST00000389048.3:c.3586C>A,NC_000002.11:g.29443631G>T,NM_004304.4:c.3586C>A,NP_004295.2:p.Leu1196Met	2016-07-26 16:04:58 UTC
8	https://civic.genome.wustl.edu/links/variants/8	ALK	238	F1174L	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Crizotinib Resistance	2	29443695	29443695	G	T	ENST00000389048.3	75	GRCh37					missense_variant	NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A	2016-01-22 19:40:47 UTC
9	https://civic.genome.wustl.edu/links/variants/9	ALK	238	R1275Q	ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.		2	29432664	29432664	C	T	ENST00000389048.3	75	GRCh37					missense_variant	NM_004304.4:c.3824G>A,NP_004295.2:p.Arg1275Gln,NC_000002.11:g.29432664C>T,ENST00000389048.3:c.3824G>A	2016-01-22 19:40:47 UTC
10	https://civic.genome.wustl.edu/links/variants/10	ARAF	369	S214C	ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.		X	47426121	47426121	C	G	ENST00000377045.4	75	GRCh37					missense_variant	NC_000023.10:g.47426121C>G	2016-01-22 19:40:47 UTC
11	https://civic.genome.wustl.edu/links/variants/11	BRAF	673	V600D	Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.	Other V600's	7	140453135	140453136	CA	TA	ENST00000288602.6	75	GRCh37					missense_variant	NC_000007.13:g.140453135_140453136delinsAT,NM_004333.4:c.1799_1800delTGinsAT,NP_004324.2:p.Val600Asp,ENST00000288602.6:c.1799_1800delTGinsAT	2017-05-18 15:52:10 UTC
12	https://civic.genome.wustl.edu/links/variants/12	BRAF	673	V600E	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.		7	140453136	140453136	A	T	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A	2016-02-18 22:20:12 UTC
13	https://civic.genome.wustl.edu/links/variants/13	BRAF	673	V600E+V600M	A case study of a single patient harboring both a V600E and a V600M mutation, dabrafenib was shown to acheive clinical response.	Other V600's	7	140453135	140453137			ENST00000288602.6	75	GRCh37					missense_variant		2016-01-22 19:40:46 UTC
14	https://civic.genome.wustl.edu/links/variants/14	BRAF	673	V600E AMPLIFICATION	Amplification of BRAF V600E has been shown to confer resistance to MEK inhibitors. For more information on the V600 locus, see the V600E entry.		7	140434279	140624564			ENST00000288602.6	75	GRCh37					transcript_amplification,missense_variant		2015-12-28 21:26:14 UTC
17	https://civic.genome.wustl.edu/links/variants/17	BRAF	673	V600	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutation pages on the left sidebar.	Other V600's	7	140453136	140453137			ENST00000288602.6	75	GRCh37					protein_altering_variant		2017-05-18 20:44:13 UTC
18	https://civic.genome.wustl.edu/links/variants/18	CCND1	595	AMPLIFICATION	CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer.		11	69455855	69469242			ENST00000227507.2	75	GRCh37					transcript_amplification		2016-01-22 19:40:46 UTC
19	https://civic.genome.wustl.edu/links/variants/19	CCND1	595	EXPRESSION	CCND1 expression, and its prognositc impact, is still in dispute. Three experiments in non-small cell lung cancer have shown it to have no impact on survival, but three additional studies have shown it results in poorer prognosis. There is also some ambiguity in how the boundaries between expression and overexpression are defined.		11	69455855	69469242			ENST00000227507.2	75	GRCh37					N/A		2016-01-22 19:40:46 UTC
20	https://civic.genome.wustl.edu/links/variants/20	CCND1	595	OVEREXPRESSION	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.		11	69455855	69469242			ENST00000227507.2	75	GRCh37					N/A		2016-01-22 19:40:46 UTC
21	https://civic.genome.wustl.edu/links/variants/21	CCND2	894	OVEREXPRESSION	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.		12	4382938	4414516			ENST00000261254.3	75	GRCh37					N/A		2016-01-22 19:40:49 UTC
22	https://civic.genome.wustl.edu/links/variants/22	CCND2	894	PROMOTER DEMETHYLATION	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.		12	4381437	4382937			ENST00000261254.3	75	GRCh37					N/A		2016-03-14 15:30:42 UTC
23	https://civic.genome.wustl.edu/links/variants/23	CCND3	896	LOSS	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are deregulated are widely variable, and range from genomic amplification to promoter methylation changes. Cyclin D3 loss has been reported in T-cell acute lymphoblastic leukemia (T-ALL), a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. Treating cyclin D3 knockout mice with the targeted therapeutic palbociclib significantly increased the median survival of a Notch-driven model of T-ALL.		6	41902671	41909586			ENST00000372991.4	75	GRCh37					loss_of_function_variant		2015-12-29 15:59:43 UTC
24	https://civic.genome.wustl.edu/links/variants/24	CCNE1	898	OVEREXPRESSION	Cyclin E, while currenly not as widely implicated as its counterpart, cyclin D, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, are correlated with later stage disease and have been shown to lead to poorer prognosis in gastic carcinoma. It has also been shown, in lung cancer specifically, that neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their lowly expressed counterparts.		19	30302805	30315215			ENST00000262643.3	75	GRCh37					N/A		2016-01-22 19:40:46 UTC
25	https://civic.genome.wustl.edu/links/variants/25	CDK4	1019	EXPRESSION	CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.		12	58141510	58146304			ENST00000257904.6	75	GRCh37					N/A		2016-01-22 19:40:46 UTC
27	https://civic.genome.wustl.edu/links/variants/27	CDKN2A	1029	PROMOTER HYPERMETHYLATION	CDKN2A loss has been shown to be a significant event in a number of cancer types. One mechanism by which this can occur is by hypermethylation of the CDKN2A promoter region. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. The prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have shown significant p-values suggesting poorer prognostic outcomes for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator.		9	21974827	21994591			ENST00000498124.1	75	GRCh37					N/A		2016-02-25 20:35:36 UTC
28	https://civic.genome.wustl.edu/links/variants/28	CEBPA	1050	N-TERMINAL FRAME SHIFT	CEBPA N-terminal frame shift mutations that result in a premature stop codon are associated with cytogenetically normal acute myeloid leukemia (CN-AML). CEBPA mutations are associated with a favorable prognosis; however, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications. N-terminal frame shift mutations within amino acids 1-120 have been shown to disrupt expression of the full-length 42kDa isoform while maintaining expression of a 30kDa isoform (translated from the AUG at full-length protein isoform amino acid M120). This 30kDa isoform exhibits dominant negative activity.		19	33792961	33793470			ENST00000498907.2	75	GRCh37					dominant_negative_variant,frameshift_truncation		2015-12-28 19:35:55 UTC
29	https://civic.genome.wustl.edu/links/variants/29	CEBPA	1050	MUTATION	CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.		19	33790840	33793470			ENST00000498907.2	75	GRCh37					loss_of_function_variant,transcript_variant		2016-01-22 19:40:46 UTC
30	https://civic.genome.wustl.edu/links/variants/30	CSF1R	1436	MEF2D-CSF1R	MEF2D-CSF1R is a fusion that has been observed in acute lymphocytic leukemia. In cell lines harboring this event, treatment with imatinib has shown notable sensitivity.		1	156446804	156470620			ENST00000348159.4	75	GRCh37	5	149433787	149441412	ENST00000286301.3	transcript_fusion		2016-11-04 19:31:33 UTC
31	https://civic.genome.wustl.edu/links/variants/31	PRKACA	5566	DNAJB1-PRKACA	This fusion has been found to be very recurrent in the rare form of adolescent liver cancer, fibrolamellar hepatocellular carcinoma. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity. The presence of this fusion may be used as a diagnostic marker for this rare tumor type.		19	14628951	14629232			ENST00000254322.2	75	GRCh37	19	14202500	14218221	ENST00000308677.4	transcript_fusion		2017-05-18 20:44:13 UTC
32	https://civic.genome.wustl.edu/links/variants/32	DNMT3A	1788	R882	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.		2	25457241	25457243			ENST00000264709.3	75	GRCh37					missense_variant		2016-01-22 19:40:49 UTC
33	https://civic.genome.wustl.edu/links/variants/33	EGFR	1956	L858R	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.		7	55259515	55259515	T	G	ENST00000275493.2	75	GRCh37					missense_variant	NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg	2017-05-14 21:10:17 UTC
34	https://civic.genome.wustl.edu/links/variants/34	EGFR	1956	T790M	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	EGFR TKI Resistance,EGFR TKI Resistance	7	55249071	55249071	C	T	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T	2016-09-01 23:19:34 UTC
35	https://civic.genome.wustl.edu/links/variants/35	ERBB2	2064	D769H	ERBB2 D769H was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines were shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37880261	37880261	G	C	ENST00000269571.5	75	GRCh37					missense_variant	NM_001289937.1:c.2305G>C,NP_001276866.1:p.Asp769His,ENST00000269571.5:c.2305G>C,NC_000017.104:g.37880261G>C	2017-05-15 18:33:15 UTC
36	https://civic.genome.wustl.edu/links/variants/36	ERBB2	2064	D769Y	ERBB2 D769Y was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37880261	37880261	G	T	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2305G>T, NC_000017.10:g.37880261G>T	2017-01-31 22:43:27 UTC
37	https://civic.genome.wustl.edu/links/variants/37	ERBB2	2064	DEL 755-759	ERBB2 in-frame deletion of 755-759 was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.		17	37880219	37880233	TTGAGGGAAAACACA		ENST00000269571.5	75	GRCh37					inframe_deletion	ENST00000269571.5:c.2263_2277del	2017-01-31 22:40:14 UTC
38	https://civic.genome.wustl.edu/links/variants/38	ERBB2	2064	G309A	ERBB2 G309A was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37868205	37868205	G	C	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.926G>C,NC_000017.10:g.37868205G>C	2017-01-31 22:39:18 UTC
39	https://civic.genome.wustl.edu/links/variants/39	ERBB2	2064	L755S	ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.		17	37880220	37880220	T	C	ENST00000269571.5	75	GRCh37					missense_variant		2017-01-30 17:39:49 UTC
40	https://civic.genome.wustl.edu/links/variants/40	ERBB2	2064	L755W	ERBB2 L755W was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.		17	37880220	37880220	T	G	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2264T>G	2017-01-31 22:38:40 UTC
41	https://civic.genome.wustl.edu/links/variants/41	ERBB2	2064	P780INS	ERBB2 P780 insertion was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37881011	37881012		GGCTCCCCA	ENST00000269571.5	75	GRCh37					inframe_insertion	ENST00000269571.5:c.2340_2341insGGCTCCCCA	2017-05-18 20:44:13 UTC
42	https://civic.genome.wustl.edu/links/variants/42	ERBB2	2064	R678Q	ERBB2 R678Q was shown to have NO functional effect in tissue culture assay (Bose et al 2013). This conclusion was confirmed by a second, independent lab.		17	37879658	37879658	G	A	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2033G>A	2016-10-03 22:21:41 UTC
43	https://civic.genome.wustl.edu/links/variants/43	ERBB2	2064	R896C	ERBB2 R896C was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37881616	37881616	C	T	ENST00000269571.5	75	GRCh37					missense_variant		2017-01-31 22:44:15 UTC
44	https://civic.genome.wustl.edu/links/variants/44	ERBB2	2064	V777L	ERBB2 V777L was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37881000	37881000	G	T	ENST00000269571.5	75	GRCh37					missense_variant	NM_004448.3:c.2329G>T,NP_004439.2:p.Val777Leu,ENST00000269571.5:c.2329G>T	2017-01-30 17:38:33 UTC
45	https://civic.genome.wustl.edu/links/variants/45	ERBB2	2064	V842I	ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37881332	37881332	G	A	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2524G>A	2017-01-30 17:37:52 UTC
46	https://civic.genome.wustl.edu/links/variants/46	ESR1	2099	L536Q	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y536Q is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain,ESR1 Ligand-Binding Domain	6	152419920	152419921	TC	AG	ENST00000440973.1	75	GRCh37					missense_variant		2016-01-22 19:40:48 UTC
47	https://civic.genome.wustl.edu/links/variants/47	ESR1	2099	D538G	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. D538G is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain,ESR1 Ligand-Binding Domain	6	152419926	152419926	A	G	ENST00000206249.3	75	GRCh37					missense_variant	NC_000006.11:g.152419926A>G	2016-01-22 19:40:46 UTC
48	https://civic.genome.wustl.edu/links/variants/48	ESR1	2099	Y537C	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537C is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain,ESR1 Ligand-Binding Domain	6	152419923	152419923	A	G	ENST00000206249.3	75	GRCh37					missense_variant	ENST00000206249.3:c.1610A>G	2016-01-22 19:40:47 UTC
49	https://civic.genome.wustl.edu/links/variants/49	ESR1	2099	Y537N	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537N is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain,ESR1 Ligand-Binding Domain	6	152419922	152419922	T	A	ENST00000206249.3	75	GRCh37					missense_variant	NC_000006.11:g.152419922T>A	2016-01-22 19:40:48 UTC
50	https://civic.genome.wustl.edu/links/variants/50	ESR1	2099	Y537S	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537S is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain,ESR1 Ligand-Binding Domain	6	152419923	152419923	A	C	ENST00000206249.3	75	GRCh37					missense_variant	NC_000006.11:g.152419923A>C	2016-01-22 19:40:48 UTC
52	https://civic.genome.wustl.edu/links/variants/52	FGFR2	2263	FGFR2-MGEA5	In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has idenified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. Cell lines harboring these fusions were shown to respond to pazopanib. Additionally, tumor size reduction was achieved by both ponatinib and pazopanib treatments administered separately in a single patient with intrahepatic cholangiocarcinoma and this fusion. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	FGFR fusions	10	123243212	123357917			ENST00000457416.2	75	GRCh37	10	103544209	103552700	ENST00000361464.3	transcript_fusion		2017-05-18 20:44:13 UTC
53	https://civic.genome.wustl.edu/links/variants/53	FGFR3	2261	FGFR3-BAIAP2L1	In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	FGFR fusions	4	1795039	1810599			ENST00000340107.4	75	GRCh37	7	97991744	97920963	ENST00000005260.8	transcript_fusion		2016-09-10 03:16:03 UTC
54	https://civic.genome.wustl.edu/links/variants/54	FGFR2	2263	FGFR2-TACC3	In a clinical sequencing program for advanced stage cancers, Wu et al has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	FGFR fusions	4	123243212	123357598			ENST00000358487.5	75	GRCh37	4	1723266	1741505	ENST00000313288.4	transcript_fusion		2017-05-18 20:44:13 UTC
55	https://civic.genome.wustl.edu/links/variants/55	FLT3	2322	ITD	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.		13	28608219	28608351			ENST00000241453.7	75	GRCh37					inframe_insertion		2016-07-04 18:22:23 UTC
56	https://civic.genome.wustl.edu/links/variants/56	FLT3	2322	TKD MUTATION	FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.		13	28592642	28592642	C	A	ENST00000241453.7	75	GRCh37					nonsynonymous_variant	NC_000013.10:g.28592642C>A	2016-03-10 01:20:57 UTC
57	https://civic.genome.wustl.edu/links/variants/57	GATA2	2624	EXPRESSION	GATA2 misregulation has been observed in a number of hematologic malignancies, as well as non-small cell lung cancer. Treatment of over-active GATA2 pathways using the proteasome inhibitor bortezomib has shown dramatic tumor regression in lung cancer.		3	128198270	128212028			ENST00000341105.2	75	GRCh37					N/A		2016-01-22 19:40:46 UTC
58	https://civic.genome.wustl.edu/links/variants/58	IDH1	3417	R132	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.		2	209113111	209113113			ENST00000415913.1	75	GRCh37					protein_altering_variant		2016-02-16 15:54:47 UTC
59	https://civic.genome.wustl.edu/links/variants/59	IDH1	3417	R132C	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.		2	209113113	209113113	G	A	ENST00000415913.1	75	GRCh37					missense_variant		2016-02-16 15:55:27 UTC
62	https://civic.genome.wustl.edu/links/variants/62	IDH2	3418	R140	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R140 mutants show mixed results affecting overall survival as compared to their wild-type counterparts. In myelodysplastic syndromes, however, no prognostic link was discovered between IDH2 mutation status and overall survival.		15	90631934	90631934			ENST00000330062.3	75	GRCh37					protein_altering_variant		2017-05-18 20:44:13 UTC
63	https://civic.genome.wustl.edu/links/variants/63	IDH2	3418	R172K	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R172K mutation has been linked with poorer prognosis and worse overall survival than IDH2 wild-type patients. However, in myelodisplastic syndromes, studies did not find a prognostic association between this variant and patient outcomes.		15	90631838	90631838	C	T	ENST00000330062.3	75	GRCh37					missense_variant	NM_002168.3:c.515G>A,NP_002159.2:p.Arg172Lys,NC_000015.9:g.90631838C>T,ENST00000330062.3:c.515G>A	2016-01-22 19:40:48 UTC
64	https://civic.genome.wustl.edu/links/variants/64	JAK2	3717	V617F	JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases, occuring in around half of all MPD's. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.		9	5073770	5073770	G	T	ENST00000381652.3	75	GRCh37					gain_of_function_variant,missense_variant	NC_000009.11:g.5073770G>T,NM_004972.3:c.1849G>T,NP_004963.1:p.Val617Phe,ENST00000381652.3:c.1849G>T	2016-01-22 19:40:48 UTC
65	https://civic.genome.wustl.edu/links/variants/65	KIT	3815	D816V	KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.	KIT Exon 17	4	55599321	55599321	A	T	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.2447A>T,NP_000213.1:p.Asp816Val,ENST00000288135.5:c.2447A>T,NC_000004.11:g.55599321A>T	2016-01-22 19:40:48 UTC
66	https://civic.genome.wustl.edu/links/variants/66	KIT	3815	EXON 11 MUTATION	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	KIT Exon 11,KIT Exon 11,KIT Exon 11,KIT Exon 11,KIT Exon 11,KIT Exon 11	4	55593582	55593708			ENST00000288135.5	75	GRCh37					coding_sequence_variant		2016-06-28 00:07:33 UTC
67	https://civic.genome.wustl.edu/links/variants/67	KIT	3815	INTERNAL DUPLICATION	c-KIT internal duplications have been observed in exon 11, within the juxtamembrane domain. In a case study of an anal melanoma patient harboring this event, imatinib confered marked response. Also, cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.	KIT Exon 11	4	55593582	55593708			ENST00000288135.5	75	GRCh37					inframe_insertion		2016-01-22 19:40:46 UTC
69	https://civic.genome.wustl.edu/links/variants/69	KIT	3815	EXON 14 MUTATION	c-KIT exon 14 mutations lie within the tyrosine kinase domain of the protein. While relatively rare in primary gastrointestinal tumors, they are notably more prevalent in refractory disease, suggesting a role in imatinib resistance. Unlike mutations in other KIT exons, exon 14 mutations seem relatively rare in melanoma.		4	55595501	55595651			ENST00000288135.5	75	GRCh37					exon_variant		2016-03-10 01:23:37 UTC
72	https://civic.genome.wustl.edu/links/variants/72	KIT	3815	L576P	KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.	KIT Exon 11,KIT Exon 11,KIT Exon 11	4	55593661	55593661	T	C	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.1727T>C,NP_000213.1:p.Leu576Pro,ENST00000288135.5:c.1727T>C,NC_000004.11:g.55593661T>C	2016-01-27 20:23:44 UTC
73	https://civic.genome.wustl.edu/links/variants/73	KIT	3815	V654A	KIT V654A is an exon 13 mutation that lies within the tyrosine kinase 1 domain of the protein. It has been shown to be an activating mutation by in vitro studies. This mutation is associated with imatinib resistance in melanoma patients. However, second generation TKI's such as sunitinib and midostaurin (PKC 412) have seen success in acheiving tumor response.	KIT Exon 11,KIT Exon 11	4	55594258	55594258	T	C	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.1961T>C,NP_000213.1:p.Val654Ala,ENST00000288135.5:c.1961T>C,NC_000004.11:g.55594258T>C	2016-01-22 19:40:48 UTC
75	https://civic.genome.wustl.edu/links/variants/75	KRAS	3845	EXON 2 MUTATION	Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.		12	25398208	25398329			ENST00000256078.4	75	GRCh37					missense_variant,exon_variant		2016-03-10 01:22:22 UTC
76	https://civic.genome.wustl.edu/links/variants/76	KRAS	3845	G12	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.		12	25398284	25398285			ENST00000256078.4	75	GRCh37					protein_altering_variant		2017-05-18 20:44:13 UTC
77	https://civic.genome.wustl.edu/links/variants/77	KRAS	3845	G12/G13	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.		12	25398280	25398285			ENST00000256078.4	75	GRCh37					protein_altering_variant		2016-05-26 19:47:44 UTC
78	https://civic.genome.wustl.edu/links/variants/78	KRAS	3845	G12C	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	EGFR TKI Resistance	12	25398285	25398285	C	A	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T	2016-07-14 03:36:26 UTC
79	https://civic.genome.wustl.edu/links/variants/79	KRAS	3845	G12D	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	EGFR TKI Resistance	12	25398284	25398284	C	T	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A	2016-05-17 17:12:36 UTC
80	https://civic.genome.wustl.edu/links/variants/80	KRAS	3845	G13	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.		12	25398281	25398282			ENST00000256078.4	75	GRCh37					inframe_insertion,missense_variant		2017-05-18 20:44:13 UTC
81	https://civic.genome.wustl.edu/links/variants/81	KRAS	3845	G13D	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.		12	25398281	25398281	C	T	ENST00000256078.4	75	GRCh37					missense_variant,coding_sequence_variant	NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A	2017-01-30 17:26:26 UTC
82	https://civic.genome.wustl.edu/links/variants/82	MAP2K1	5604	P124S	MAP2K1 P124S is a recurrent mutation in melanoma, and is seen in bladder and colon cancer to a lesser degree. The P124S mutation has been shown to contribute to AZD6244 resistance in melanoma cell lines, but considerably less so than its Q56P counterpart.		15	66729162	66729162	C	T	ENST00000307102.5	75	GRCh37					missense_variant	ENST00000307102.5:c.370C>T	2016-01-22 19:40:48 UTC
83	https://civic.genome.wustl.edu/links/variants/83	MAP2K1	5604	Q56P	MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This mutation has been shown to confer considerable resistance to AZD6244 treatment of melanoma cell lines.		15	66727451	66727451	A	C	ENST00000307102.5	75	GRCh37					missense_variant	ENST00000307102.5:c.167A>C	2016-01-22 19:40:48 UTC
85	https://civic.genome.wustl.edu/links/variants/85	MGMT	4255	PROMOTER METHYLATION	MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.		10	131264495	131265656			ENST00000306010.7	75	GRCh37					N/A		2015-12-29 17:39:05 UTC
86	https://civic.genome.wustl.edu/links/variants/86	NPM1	4869	EXON 12 MUTATION	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	NPM1 Exon 12	5	170837531	170837569			ENST00000517671.1	75	GRCh37					exon_variant		2016-03-10 01:17:28 UTC
87	https://civic.genome.wustl.edu/links/variants/87	NPM1	4869	W288FS	NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).	NPM1 Exon 12,NPM1 Exon 12,NPM1 Exon 12,NPM1 Exon 12	5	170837547	170837548		TCAG	ENST00000517671.1	75	GRCh37					frameshift_elongation		2017-05-18 20:44:13 UTC
92	https://civic.genome.wustl.edu/links/variants/92	NRAS	4893	G12	While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.		1	115258747	115258748			ENST00000369535.4	75	GRCh37					missense_variant		2016-01-22 19:40:47 UTC
93	https://civic.genome.wustl.edu/links/variants/93	NRAS	4893	G13D	While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.		1	115258744	115258744	C	T	ENST00000369535.4	75	GRCh37					missense_variant	NM_002524.4:c.38G>A,NP_002515.1:p.Gly13Asp,NC_000001.10:g.115258744C>T	2016-01-22 19:40:48 UTC
94	https://civic.genome.wustl.edu/links/variants/94	NRAS	4893	Q61	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.		1	115256528	115256530			ENST00000369535.4	75	GRCh37					missense_variant		2016-01-22 19:40:47 UTC
95	https://civic.genome.wustl.edu/links/variants/95	NRAS	4893	Q61L	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.		1	115256529	115256529	T	A	ENST00000369535.4	75	GRCh37					missense_variant	NP_002515.1:p.Gln61Leu,NC_000001.10:g.115256529T>A,NM_002524.4:c.182A>T	2016-02-22 23:48:27 UTC
96	https://civic.genome.wustl.edu/links/variants/96	NRAS	4893	Q61R	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.		1	115256529	115256529	T	C	ENST00000369535.4	75	GRCh37					missense_variant	NM_002524.4:c.182A>G,NP_002515.1:p.Gln61Arg,NC_000001.10:g.115256529T>C	2016-01-22 19:40:48 UTC
98	https://civic.genome.wustl.edu/links/variants/98	PDGFRA	5156	D842I	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152092	55152093	GA	AT	ENST00000257290.5	75	GRCh37					missense_variant	ENST00000257290.5:c.2524_2525delinsAT,NC_000004.11:g.55152092_55152093delinsAT,NP_006197.1:p.Asp842Ile,NM_006206.5:c.2524_2525delGAinsAT	2016-01-22 19:40:48 UTC
99	https://civic.genome.wustl.edu/links/variants/99	PDGFRA	5156	D842V	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance,Imatinib Resistance,Imatinib Resistance,Imatinib Resistance	4	55152093	55152093	A	T	ENST00000257290.5	75	GRCh37					missense_variant	NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T	2016-01-22 19:40:49 UTC
100	https://civic.genome.wustl.edu/links/variants/100	PDGFRA	5156	D842Y	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152092	55152092	G	T	ENST00000257290.5	75	GRCh37					missense_variant	ENST00000257290.5:c.2524G>T,NC_000004.11:g.55152092G>T,NM_006206.5:c.2524G>T,NP_006197.1:p.Asp842Tyr	2016-01-22 19:40:48 UTC
101	https://civic.genome.wustl.edu/links/variants/101	PDGFRA	5156	I843DEL	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152095	55152097	ATC		ENST00000257290.5	75	GRCh37					inframe_deletion	ENST00000257290.5:c.2527_2529delATC,NC_000004.11:g.55152095_55152097del	2016-12-28 22:33:02 UTC
102	https://civic.genome.wustl.edu/links/variants/102	PDGFRA	5156	DI842-843VM	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. The DI842-843VM variant is the result of a double point mutation. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152093	55152097	ACATC	TCATG	ENST00000257290.5	75	GRCh37					missense_variant	NC_000004.11:g.55152093_55152097delinsTCATG	2016-01-22 19:40:47 UTC
103	https://civic.genome.wustl.edu/links/variants/103	PIK3CA	5290	E542K	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with other PIK3CA variants or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.		3	178936082	178936082	G	A	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A	2016-01-22 19:40:48 UTC
104	https://civic.genome.wustl.edu/links/variants/104	PIK3CA	5290	E545K	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.		3	178936091	178936091	G	A	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A	2016-01-22 19:40:48 UTC
105	https://civic.genome.wustl.edu/links/variants/105	PIK3CA	5290	EXON 21 MUTATION	PIK3CA Exon 21 Mutations (e.g., H1047R; often referred to as Exon 20 mutations if counting only coding exons) are among the most recurrent mutations in cancer, especially breast cancer. Of PIK3CA mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between Exon 21 and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.		3	178951882	178952495			ENST00000263967.3	75	GRCh37					exon_variant		2016-01-28 17:51:27 UTC
106	https://civic.genome.wustl.edu/links/variants/106	PIK3CA	5290	EXON 10 MUTATION	PIK3CA Exon 10 Mutations (e.g. E545K/E542K; often referred to as Exon 9 mutations if counting only coding exons) are the second most recurrent PIK3CA mutations in breast cancer, and highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that exon 10 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.		3	178935998	178936122			ENST00000263967.3	75	GRCh37					exon_variant		2016-01-28 17:48:15 UTC
107	https://civic.genome.wustl.edu/links/variants/107	PIK3CA	5290	H1047R	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.		3	178952085	178952085	A	G	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G	2016-03-08 23:30:58 UTC
108	https://civic.genome.wustl.edu/links/variants/108	PML	5371	PML-RARA	The PML-RARA fusion is seen as a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA in APL patients harboring the PML-RARa fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.		15	74287058	74325755			ENST00000268058.3	75	GRCh37	17	38504568	38513048	ENST00000254066.5	transcript_fusion		2016-09-10 03:05:49 UTC
110	https://civic.genome.wustl.edu/links/variants/110	PTEN	5728	R233*	PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.	PTEN Loss-of-Function,PTEN Loss-of-Function	10	89717672	89717672	C	T	ENST00000371953.3	75	GRCh37					loss_of_function_variant,stop_gained	NM_000314.6:c.697C>T,NP_000305.3:p.Arg233Ter,ENST00000371953.3:c.697C>T,NC_000010.10:g.89717672C>T	2016-01-22 19:40:48 UTC
112	https://civic.genome.wustl.edu/links/variants/112	RET	5979	C634W	RET C634W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C634W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib.	Motesanib Resistance	10	43609950	43609950	C	G	ENST00000355710.3	75	GRCh37					missense_variant	NM_020975.4:c.1902C>G,NP_065681.1:p.Cys634Trp,ENST00000355710.3:c.1902C>G	2016-01-22 19:40:48 UTC
113	https://civic.genome.wustl.edu/links/variants/113	RET	5979	M918T	RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.	Motesanib Resistance	10	43617416	43617416	T	C	ENST00000355710.3	75	GRCh37					missense_variant	NM_020975.4:c.2753T>C,NP_065681.1:p.Met918Thr,ENST00000355710.3:c.2753T>C,NC_000010.10:g.43617416T>C	2016-01-22 19:40:48 UTC
114	https://civic.genome.wustl.edu/links/variants/114	SF3B1	23451	K666N	SF3B1 K666N is a variant found in myelodysplastic syndromes, chronic leukemias, and more recently, breast cancer. This somatic mutation has been linked to better overall outcome and event-free survival in MDS patients.	HEAT domain mutation	2	198267359	198267359	C	A	ENST00000335508.6	75	GRCh37					missense_variant	NM_012433.3:c.1998G>T,NP_036565.2:p.Lys666Asn,ENST00000335508.6:c.1998G>T	2016-01-22 19:40:48 UTC
116	https://civic.genome.wustl.edu/links/variants/116	TP53	7157	R175H	While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant.		17	7578406	7578406	C	T	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.524G>A,NP_000537.3:p.Arg175His	2016-01-22 19:40:48 UTC
117	https://civic.genome.wustl.edu/links/variants/117	TP53	7157	R248Q	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.		17	7577538	7577538	C	T	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.743G>A,NP_000537.3:p.Arg248Gln	2016-01-22 19:40:48 UTC
118	https://civic.genome.wustl.edu/links/variants/118	TP53	7157	R248W	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.		17	7577539	7577539	G	A	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.742C>T,NP_000537.3:p.Arg248Trp	2016-01-22 19:40:48 UTC
119	https://civic.genome.wustl.edu/links/variants/119	TP53	7157	R249	This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.		17	7577535	7577535	C	G	ENST00000269305.4	75	GRCh37					protein_altering_variant		2016-01-22 19:40:48 UTC
121	https://civic.genome.wustl.edu/links/variants/121	TP53	7157	R273C	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.		17	7577121	7577121	G	A	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.817C>T,NP_000537.3:p.Arg273Cys	2016-01-22 19:40:48 UTC
122	https://civic.genome.wustl.edu/links/variants/122	TP53	7157	R273H	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.		17	7577120	7577120	C	T	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.818G>A,NP_000537.3:p.Arg273His	2016-01-22 19:40:48 UTC
124	https://civic.genome.wustl.edu/links/variants/124	TSC1	7248	FRAMESHIFT TRUNCATION	In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.	TSC Loss,TSC Loss	9	135766735	135820008			ENST00000298552.3	75	GRCh37					frameshift_truncation		2016-05-02 22:10:48 UTC
125	https://civic.genome.wustl.edu/links/variants/125	TSC1	7248	LOSS-OF-FUNCTION	In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.	TSC Loss	9	135766735	135820008			ENST00000298552.3	75	GRCh37					loss_of_function_variant		2016-01-22 19:40:47 UTC
127	https://civic.genome.wustl.edu/links/variants/127	U2AF1	7307	Q157P/R	U2AF1 Q157P/R has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is less common than the S34F mutation, occurs in the second zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.		21	44514777	44514777	T	G	ENST00000291552.4	75	GRCh37					missense_variant		2016-01-22 19:40:49 UTC
128	https://civic.genome.wustl.edu/links/variants/128	U2AF1	7307	S34Y/F	U2AF1 S34Y/F has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is the most commonly identified variant in MDS, occurs in the first zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.		21	44524456	44524456	G	A	ENST00000291552.4	75	GRCh37					missense_variant	NC_000021.8:g.44524456G>A	2016-01-22 19:40:47 UTC
129	https://civic.genome.wustl.edu/links/variants/129	WT1	7490	EXON 7 MUTATION	WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.		11	32417803	32417953			ENST00000332351.3	75	GRCh37					exon_variant		2016-03-10 01:18:24 UTC
130	https://civic.genome.wustl.edu/links/variants/130	WT1	7490	EXON 9 MUTATION	WT1 exon 9 mutations have been shown to be recurrent in acute myeloid leukemia, although at a less frequent rate than their exon 7 counterparts. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 9 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.		11	32413518	32413610			ENST00000332351.3	75	GRCh37					exon_variant		2016-03-10 01:19:17 UTC
131	https://civic.genome.wustl.edu/links/variants/131	BRCA1	672	LOSS-OF-FUNCTION	BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	BRCA Germline Variants	17	41196312	41277387			ENST00000357654.3	75	GRCh37					loss_of_function_variant,loss_of_heterozygosity		2016-01-22 19:40:47 UTC
132	https://civic.genome.wustl.edu/links/variants/132	BRCA2	675	LOSS-OF-FUNCTION	BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	BRCA Germline Variants	13	32889611	32973347			ENST00000380152.3	75	GRCh37					loss_of_function_variant		2016-01-22 19:40:47 UTC
133	https://civic.genome.wustl.edu/links/variants/133	EGFR	1956	EXON 19 DELETION	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.		7	55242415	55242513			ENST00000275493.2	75	GRCh37					inframe_deletion	ENST00000275493.2:c.2185_2283del	2016-07-11 04:17:33 UTC
134	https://civic.genome.wustl.edu/links/variants/134	EGFR	1956	G719S	While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.		7	55241707	55241707	G	A	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2155G>A,NC_000007.13:g.55241707G>A	2016-01-22 19:40:47 UTC
135	https://civic.genome.wustl.edu/links/variants/135	NOTCH1	4851	D1642H	Activating mutations in NOTCH1, including D1642H, have been shown to be poor prognostic markers in lung cancer.		9	139399219	139399219	C	G	ENST00000277541.6	75	GRCh37					missense_variant	NC_000009.11:g.139399219C>G	2016-01-22 19:40:47 UTC
136	https://civic.genome.wustl.edu/links/variants/136	NOTCH1	4851	R2327W	Activating mutations in NOTCH1, including R2327W, have been shown to be poor prognostic markers in lung cancer.		9	139391212	139391212	G	A	ENST00000277541.6	75	GRCh37					missense_variant	NM_017617.4:c.6979C>T,NP_060087.3:p.Arg2327Trp	2016-01-22 19:40:47 UTC
137	https://civic.genome.wustl.edu/links/variants/137	NOTCH1	4851	V2444FS	Activating mutations in NOTCH1, including a frameshift insertion at V2444, have been shown to be poor prognostic markers in lung cancer.		9	139390861	139390861	G	TGT	ENST00000277541.6	75	GRCh37						ENST00000277541.6:c.7330delinsACA	2016-02-18 17:49:46 UTC
138	https://civic.genome.wustl.edu/links/variants/138	NOTCH1	4851	S2275FS	Activating mutations in NOTCH1, including a frameshift insertion at S2275, have been shown to be poor prognostic markers in lung cancer.		9	139391369	139391370		A	ENST00000277541.6	75	GRCh37					plus_1_frameshift_variant	ENST00000277541.6:c.6821_6822insT	2016-11-11 19:59:18 UTC
139	https://civic.genome.wustl.edu/links/variants/139	DDR2	4921	L63V	Activating mutations in DDR2, including L63V, has been shown to be sensitive to dasatinib in cell lines.		1	162724415	162724415	C	G	ENST00000367922.3	75	GRCh37					missense_variant	NM_006182.2:c.187C>G,NP_006173.2:p.Leu63Val,ENST00000367922.3:c.187C>G	2016-01-22 19:40:47 UTC
140	https://civic.genome.wustl.edu/links/variants/140	DDR2	4921	L239R	Activating mutations in DDR2, including L239R, has been shown to be sensitive to dasatinib in cell lines.		1	162729630	162729630	T	G	ENST00000367922.3	75	GRCh37					missense_variant	ENST00000367922.3:c.716T>G	2016-10-02 19:53:16 UTC
141	https://civic.genome.wustl.edu/links/variants/141	DDR2	4921	G253C	Activating mutations in DDR2, including G253C, has been shown to be sensitive to dasatinib in cell lines.		1	162729671	162729671	G	T	ENST00000367922.3	75	GRCh37					missense_variant	ENST00000367922.3:c.757G>T	2016-01-22 19:40:47 UTC
142	https://civic.genome.wustl.edu/links/variants/142	DDR2	4921	G505S	Activating mutations in DDR2, including G505S, has been shown to be sensitive to dasatinib in cell lines.		1	162741822	162741822	G	A	ENST00000367922.3	75	GRCh37					missense_variant	NM_006182.2:c.1513G>A,NP_006173.2:p.Gly505Ser,ENST00000367922.3:c.1513G>A	2016-01-22 19:40:47 UTC
143	https://civic.genome.wustl.edu/links/variants/143	DDR2	4921	I638F	DDR2 I638F has been shown to be a loss of function mutation, but also confers sensitivity to dasatinib in cell lines.		1	162745497	162745497	A	T	ENST00000367922.3	75	GRCh37					missense_variant	ENST00000367922.3:c.1912A>T	2016-01-22 19:40:47 UTC
144	https://civic.genome.wustl.edu/links/variants/144	DDR2	4921	G774V	Activating mutations in DDR2, including G774V, has been shown to be sensitive to dasatinib in cell lines.		1	162748407	162748407	G	T	ENST00000367922.3	75	GRCh37					missense_variant	ENST00000367922.3:c.2321G>T	2016-01-22 19:40:47 UTC
145	https://civic.genome.wustl.edu/links/variants/145	DDR2	4921	S768R	Activating mutations in DDR2, including S768R, has been shown to be sensitive to dasatinib in cell lines.		1	162748390	162748390	T	A	ENST00000367922.3	75	GRCh37					missense_variant	ENST00000367922.3:c.2304T>A	2016-01-22 19:40:47 UTC
148	https://civic.genome.wustl.edu/links/variants/148	KRAS	3845	G12A	KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.	EGFR TKI Resistance	12	25398284	25398284	C	G	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C	2016-01-22 19:40:47 UTC
151	https://civic.genome.wustl.edu/links/variants/151	BCL2	596	IGH-BCL2	The typically reciprocal t(14;18)(q32;q21) translocation involves rearrangement between the immunoglobulin heavy chain locus on chromosome 14 and the 3' UTR of BCL2 on chromosome 18, leading to the overexpression of BCL2. This rearrangment is observed in >80% of patients with follicular lymphoma.		14	106032614	107288051				75	GRCh37	18	60794268	60987019	ENST00000333681.4	transcript_regulatory_region_fusion		2016-05-27 19:14:21 UTC
152	https://civic.genome.wustl.edu/links/variants/152	BCL2	596	EXPRESSION			18	60790579	60987361			ENST00000398117.1	75	GRCh37					N/A		2016-01-22 19:40:47 UTC
153	https://civic.genome.wustl.edu/links/variants/153	FOXP1	27086	AMPLIFICATION	Amplication in FOXP1 has been shown to be associated with the ABC subtype of DLBCL.		3	71003844	71633140			ENST00000318789.4	75	GRCh37					transcript_amplification		2016-01-22 19:40:47 UTC
154	https://civic.genome.wustl.edu/links/variants/154	REL	5966	AMPLIFICATION			2	61108709	61149800			ENST00000295025.8	75	GRCh37					transcript_amplification		2016-01-22 19:40:47 UTC
155	https://civic.genome.wustl.edu/links/variants/155	RUNX1	861	MUTATION	RUNX1 mutations are associated with poor prognosis in patients with acute myeloid leukemia or adult T-cell acute lymphocytic leukemia. In younger (<60 years old) AML patients, allogeneic stem cell transplant at complete remission led to much better relapse-free survival than repetitive cycles of high-dose cytarabine.		21	36160098	36421641			ENST00000300305.3	75	GRCh37					loss_of_function_variant,transcript_variant		2016-06-28 00:38:16 UTC
156	https://civic.genome.wustl.edu/links/variants/156	IGF2	3481	OVEREXPRESSION			11	2150348	2170833			ENST00000300632.5	75	GRCh37					N/A		2016-01-22 19:40:47 UTC
157	https://civic.genome.wustl.edu/links/variants/157	TET2	54790	MUTATION			4	106067450	106200973			ENST00000513237.1	75	GRCh37					loss_of_function_variant,gene_variant		2016-01-22 19:40:47 UTC
158	https://civic.genome.wustl.edu/links/variants/158	AURKA	6790	EXPRESSION			20	54944446	54967393			ENST00000395913.3	75	GRCh37					N/A		2016-01-22 19:40:47 UTC
159	https://civic.genome.wustl.edu/links/variants/159	VHL	7428	LOSS-OF-FUNCTION			3	10182692	10193904			ENST00000256474.2	75	GRCh37					loss_of_function_variant		2016-01-22 19:40:47 UTC
160	https://civic.genome.wustl.edu/links/variants/160	VHL	7428	MUTATION			3	10182692	10193904			ENST00000256474.2	75	GRCh37					loss_of_function_variant,gene_variant		2016-01-22 19:40:47 UTC
161	https://civic.genome.wustl.edu/links/variants/161	PBRM1	55193	MUTATION			3	52581857	52719852			ENST00000394830.3	75	GRCh37					loss_of_function_variant,transcription_variant		2016-01-22 19:40:47 UTC
163	https://civic.genome.wustl.edu/links/variants/163	EZH2	2146	MUTATION			7	148504477	148581370			ENST00000320356.2	75	GRCh37					protein_altering_variant		2016-01-22 19:40:47 UTC
164	https://civic.genome.wustl.edu/links/variants/164	FLI1	2313	EWSR1-FLI1 Type 1	Although multiple fusion transcripts have been described, type 1 consists of EWSR1 exon 7 fused to FLI1 exon 6, the most common arrangement in Ewings Sarcoma.		22	29664007	29683123			ENST00000397938.2	75	GRCh37	11	128675261	128683162	ENST00000527786.2	transcript_fusion		2016-09-09 02:16:58 UTC
165	https://civic.genome.wustl.edu/links/variants/165	EZH2	2146	Y646	Mutations of Y646 are associated with a diagnosis of Germinal Center B type DLBCL and Follicular non-Hodgkin Lymphoma. In vitro experimental findings suggest that this may be due to reduced methyltransferase activity of EZH2 on protein H3K27 (Morin et al., 2010).		7	148508726	148508728			ENST00000320356.2	75	GRCh37					protein_altering_variant		2017-01-30 17:27:33 UTC
167	https://civic.genome.wustl.edu/links/variants/167	KMT2D	8085	LOSS-OF-FUNCTION			12	49412758	49449107			ENST00000301067.7	75	GRCh37					loss_of_function_variant		2016-01-22 19:40:48 UTC
168	https://civic.genome.wustl.edu/links/variants/168	BTK	695	C481S			X	100611165	100611165	A	T	ENST00000308731.7	75	GRCh37					missense_variant		2016-01-22 19:40:48 UTC
169	https://civic.genome.wustl.edu/links/variants/169	AKT1	207	Q79K			14	105243048	105243048	G	T	ENST00000407796.2	75	GRCh37					missense_variant		2016-01-22 19:40:48 UTC
170	https://civic.genome.wustl.edu/links/variants/170	ALK	238	EML4-ALK AMPLIFICATION			2	42396490	42528380			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion,transcript_amplification		2015-12-04 17:17:01 UTC
171	https://civic.genome.wustl.edu/links/variants/171	ALK	238	ALK FUSION G1202R	ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor  17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein.		2	29443613	29443613	C	T	ENST00000389048.3	75	GRCh37					transcript_fusion,missense_variant	ENST00000389048.3:c.3604G>A,NC_000002.11:g.29443613C>T	2016-06-30 14:04:49 UTC
172	https://civic.genome.wustl.edu/links/variants/172	ALK	238	EML4-ALK S1206Y		Crizotinib Resistance	2	29443600	29443600	G	T	ENST00000389048.3	75	GRCh37					transcript_fusion,missense_variant	ENST00000389048.3:c.3617C>A,NC_000002.11:g.29443600G>T,NM_004304.4:c.3617C>A,NP_004295.2:p.Ser1206Tyr	2016-01-22 19:40:48 UTC
173	https://civic.genome.wustl.edu/links/variants/173	ALK	238	EML4-ALK T1151INST	The ALK fusion variant with insertion of T at amino acid 1151 was found in an ALK rearranged lung adenocarcinoma which had progressed after responding to crizotinib treatment. The mutation was absent in tumor sample taken before crizotinib treatment. Characterization of the variant using cell lines expressing EML4-ALK with 1151 T insert found the variant to be highly crizotinib resistant, and other work demonstrated resistance to next generation inhibitor alectinib, while resistance to tool compound TAE684 indicates potential resistance to the next generation ALK inhibitor ceritinib which is derived from TAE684. Other experiments suggest theraputic potential for HSP90 inhibitors, as EML4-ALK T1151 Tins sensitivity to 17-AAG has been observed.		2	29445271	29445272		CGT	ENST00000389048.3	75	GRCh37					transcript_fusion,inframe_insertion	NC_000002.11:g.29445271_29445272insCGT	2016-07-06 19:37:56 UTC
174	https://civic.genome.wustl.edu/links/variants/174	APC	324	MUTATION			5	112043218	112181936			ENST00000457016.1	75	GRCh37							2016-01-22 19:40:48 UTC
175	https://civic.genome.wustl.edu/links/variants/175	AR	367	F877L			X	66943549	66943549	T	C	ENST00000374690.3	75	GRCh37					missense_variant	ENST00000374690.3:c.2629T>C	2016-01-22 19:40:47 UTC
176	https://civic.genome.wustl.edu/links/variants/176	AR	367	W742			X	66937370	66937372			ENST00000374690.3	75	GRCh37					missense_variant		2016-01-22 19:40:48 UTC
177	https://civic.genome.wustl.edu/links/variants/177	ASXL1	171023	MUTATION	ASXL1 mutations are most frequently observed in the absence of FLT3-ITD and NPM1 mutations in acute myeloid leukemia (AML) patients and seem to be enriched in older patients (>60 years). These mutations are associated with poor prognosis with respect to both survival and compete remission rates.		20	30946155	31027122			ENST00000375687.4	75	GRCh37					protein_altering_variant		2016-06-28 22:23:56 UTC
178	https://civic.genome.wustl.edu/links/variants/178	ATM	472	MUTATION			11	108093559	108239826			ENST00000278616.4	75	GRCh37					loss_of_function_variant,transcription_variant		2016-01-22 19:40:48 UTC
179	https://civic.genome.wustl.edu/links/variants/179	ATM	472	UNDEREXPRESSION			11	108093559	108239826			ENST00000278616.4	75	GRCh37					N/A		2016-01-22 19:40:48 UTC
180	https://civic.genome.wustl.edu/links/variants/180	AURKA	6790	AMPLIFICATION			20	54944446	54967393			ENST00000395913.3	75	GRCh37					transcript_amplification		2016-01-22 19:40:48 UTC
181	https://civic.genome.wustl.edu/links/variants/181	AURKA	6790	OVEREXPRESSION			20	54944446	54967393			ENST00000395913.3	75	GRCh37					N/A		2016-01-22 19:40:48 UTC
182	https://civic.genome.wustl.edu/links/variants/182	BAP1	8314	EXPRESSION			3	52435029	52444366			ENST00000460680.1	75	GRCh37					N/A		2016-01-22 19:40:48 UTC
183	https://civic.genome.wustl.edu/links/variants/183	BAP1	8314	MUTATION			3	52435029	52444366			ENST00000460680.1	75	GRCh37					loss_of_function_variant,protein_altering_variant		2016-01-22 19:40:48 UTC
184	https://civic.genome.wustl.edu/links/variants/184	BRAF	673	AKAP9-BRAF		BRAF Fusions	7	91570181	91625114			ENST00000356239.3	75	GRCh37	7	140434279	140487384	ENST00000288602.6	transcript_fusion		2016-03-22 15:25:59 UTC
185	https://civic.genome.wustl.edu/links/variants/185	BRCA1	672	MUTATION			17	41196312	41277387			ENST00000357654.3	75	GRCh37					loss_of_function_variant,gene_variant		2016-01-22 19:40:48 UTC
186	https://civic.genome.wustl.edu/links/variants/186	BRCA2	675	MUTATION			13	32889611	32973347			ENST00000380152.3	75	GRCh37					loss_of_function_variant,gene_variant		2016-01-22 19:40:48 UTC
187	https://civic.genome.wustl.edu/links/variants/187	CCNE1	898	AMPLIFICATION			19	30302805	30315215			ENST00000262643.3	75	GRCh37					transcript_amplification		2016-01-22 19:40:48 UTC
189	https://civic.genome.wustl.edu/links/variants/189	DNMT3A	1788	MUTATION	DNMT3A mutations occur in a variety of myeloid malignancies. These mutations are associated with adverse prognosis in acute myeloid leukemia (AML), particularly in the context of NPM1 and FLT3-ITD mutations, which often co-occur. Early results indicate AML patients with DNMT3A mutations may respond better to decitabine than those with wild-type. Shorter survival has been indicated in patients with T-cell acute lymphoblastic leukemia and myelodysplastic syndrome, however, larger cohorts are required to verify this finding. DNMT3A mutations have been suggested as a pre-leukemic lesion and found in older individuals with clonal hematopoiesis but no overt malignancy.		2	25455845	25565459			ENST00000264709.3	75	GRCh37					transcript_variant		2016-08-22 20:58:50 UTC
190	https://civic.genome.wustl.edu/links/variants/190	EGFR	1956	AMPLIFICATION			7	55086794	55279321			ENST00000275493.2	75	GRCh37					transcript_amplification		2016-01-22 19:40:48 UTC
191	https://civic.genome.wustl.edu/links/variants/191	EGFR	1956	COPY NUMBER VARIATION			7	55086794	55279321			ENST00000275493.2	75	GRCh37					copy_number_change		2016-01-22 19:40:49 UTC
193	https://civic.genome.wustl.edu/links/variants/193	EGFR	1956	OVEREXPRESSION			7	55086794	55279321			ENST00000275493.2	75	GRCh37					N/A		2016-01-22 19:40:48 UTC
194	https://civic.genome.wustl.edu/links/variants/194	ERG	2078	EWSR1-ERG	EWSR1-ERG is found in 5% of patients with Ewing Sarcoma and considered to be diagnostic of this disease, a small tumor more often found in bone, but less frequently in soft tissue. To better identify EWSR1-ERG in patients, conventional cytogenetics methods were analyzed: FISH and RT-PCR. Ultimately concluding that more than one method is needed to accurately diagnose patients due to the strengths and weaknesses of each individual method.		22	29664007	29683123			ENST00000397938.2	75	GRCh37	21	39751949	39755845	ENST00000398907.1	transcript_fusion		2016-03-11 01:45:05 UTC
195	https://civic.genome.wustl.edu/links/variants/195	ERG	2078	TMPRSS2-ERG	TMPRSS2 fusions are prevalent in Prostate Cancer. TMPRSS2 fusion with ETS family members such as ERG are among the most common. Fusion of TMPRSS2 with ERG may result in overexpression of ERG driven by the TMPRSS2 androgen-responsive promoter elements. Due to the high prevalence of this fusion, it may have diagnostic utility for prostate cancer, especially ERG expression positive prostate cancer.		21	42879877	42879992			ENST00000398585.3	75	GRCh37	21	39751949	39817544	ENST00000398910.1	transcript_fusion		2016-03-11 01:50:46 UTC
196	https://civic.genome.wustl.edu/links/variants/196	FGFR3	2261	Y375C			4	1806099	1806099	A	G	ENST00000340107.4	75	GRCh37					missense_variant		2016-01-22 19:40:48 UTC
197	https://civic.genome.wustl.edu/links/variants/197	FLI1	2313	EWSR1-FLI1			22	29664007	29683123			ENST00000397938.2	75	GRCh37	11	128651853	128683162	ENST00000527786.2	transcript_fusion		2016-09-02 22:50:28 UTC
198	https://civic.genome.wustl.edu/links/variants/198	FOXL2	668	C134W	The variant C134W on the FOXL2 gene was revealed to have a high frequency (95-97%) in the adult form of granulosa cell tumors that comprises 5% of ovarian cancers. Due to the mutation's high frequency, future therapeutics might target for this single apparent mechanism. However, the consequence of this mutation remain unknown.		3	138665163	138665163	G	C	ENST00000330315.3	75	GRCh37					missense_variant		2016-01-22 19:40:49 UTC
199	https://civic.genome.wustl.edu/links/variants/199	IDH2	3418	R172			15	90631837	90631839			ENST00000330062.3	75	GRCh37					protein_altering_variant		2016-01-22 19:40:48 UTC
200	https://civic.genome.wustl.edu/links/variants/200	IKZF1	10320	DELETION			7	50344378	50472799			ENST00000331340.3	75	GRCh37					transcript_ablation		2016-01-22 19:40:49 UTC
201	https://civic.genome.wustl.edu/links/variants/201	KIT	3815	M541L			4	55593464	55593464	A	C	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.1621A>C,NP_000213.1:p.Met541Leu,ENST00000288135.5:c.1621A>C,NC_000004.11:g.55593464A>C	2016-01-22 19:40:48 UTC
202	https://civic.genome.wustl.edu/links/variants/202	KIT	3815	V560DEL			4	55593612	55593614	GTT		ENST00000288135.5	75	GRCh37					inframe_deletion,amino_acid_deletion	NC_000004.11:g.55593612_55593614del	2016-01-22 19:40:49 UTC
203	https://civic.genome.wustl.edu/links/variants/203	KRAS	3845	Q61			12	25380275	25380277			ENST00000256078.4	75	GRCh37					protein_altering_variant		2017-05-18 20:44:13 UTC
204	https://civic.genome.wustl.edu/links/variants/204	NCOA3	8202	AMPLIFICATION			20	46130646	46285621			ENST00000372004.3	75	GRCh37					transcript_amplification		2016-01-22 19:40:48 UTC
205	https://civic.genome.wustl.edu/links/variants/205	NCOA3	8202	OVEREXPRESSION			20	46130646	46285621			ENST00000372004.3	75	GRCh37					N/A		2016-01-22 19:40:48 UTC
206	https://civic.genome.wustl.edu/links/variants/206	NOTCH1	4851	MUTATION			9	139388896	139440314			ENST00000277541.6	75	GRCh37					protein_altering_variant		2016-01-22 19:40:48 UTC
207	https://civic.genome.wustl.edu/links/variants/207	NOTCH1	4851	P2514FS	This mutation disrupts the C-terminal PEST domain that in normal conditions promotes degradation,  resulting in accumulation of an active NOTCH1 isoform sustaining deregulated signaling.		9	139390649	139390650			ENST00000277541.6	75	GRCh37					frameshift_truncation	NC_000009.11:g.139390649_139390650del	2017-05-18 20:44:13 UTC
208	https://civic.genome.wustl.edu/links/variants/208	NRAS	4893	MUTATION			1	115247090	115259515			ENST00000369535.4	75	GRCh37					gain_of_function_variant,transcript_variant		2016-01-22 19:40:48 UTC
209	https://civic.genome.wustl.edu/links/variants/209	PAX8	7849	PAX8-PPARG	PAX8-PPAR gamma is a oncogene caused by a translocation between 2q13 and 3p25 resulting in an in-frame fusion between the two genes. It has been observed in Follicular Thyroid Cancer (FTC) and is one of two known fusion products involving PPAR gamma in FTC indicating this region may be a breakpoint hotspot. Studies have indicated that the fusion product increases cell viability and proliferation and decreases apoptosis.		2	114036521	113992971			ENST00000429538.3	75	GRCh37	3	12329400	12475810	ENST00000397015.2	transcript_fusion		2016-11-04 19:27:50 UTC
210	https://civic.genome.wustl.edu/links/variants/210	PGR	5241	EXPRESSION			11	100900355	101001255			ENST00000325455.5	75	GRCh37					N/A		2016-01-22 19:40:48 UTC
212	https://civic.genome.wustl.edu/links/variants/212	PIK3CA	5290	AMPLIFICATION			3	178866311	178957881			ENST00000263967.3	75	GRCh37					transcript_amplification		2016-01-22 19:40:49 UTC
213	https://civic.genome.wustl.edu/links/variants/213	PTEN	5728	DELETION			10	89622870	89731687			ENST00000371953.3	75	GRCh37					transcript_ablation		2015-12-28 21:40:22 UTC
214	https://civic.genome.wustl.edu/links/variants/214	PTEN	5728	LOSS			10	89622870	89731687			ENST00000371953.3	75	GRCh37					loss_of_function_variant		2015-12-28 21:38:45 UTC
215	https://civic.genome.wustl.edu/links/variants/215	SF3B1	23451	MUTATION			2	198254508	198299815			ENST00000335508.6	75	GRCh37					protein_altering_variant		2016-01-22 19:40:48 UTC
216	https://civic.genome.wustl.edu/links/variants/216	SMAD4	4089	MUTATION			18	48556583	48611409			ENST00000342988.3	75	GRCh37					loss_of_function_variant,transcript_variant		2016-01-22 19:40:47 UTC
217	https://civic.genome.wustl.edu/links/variants/217	SMARCA4	6597	MUTATION			19	11071598	11172958			ENST00000358026.2	75	GRCh37					loss_of_function_variant,gene_variant		2016-01-22 19:40:47 UTC
218	https://civic.genome.wustl.edu/links/variants/218	SMARCA4	6597	INACTIVATING MUTATION			19	11071598	11172958			ENST00000358026.2	75	GRCh37					loss_of_function_variant		2016-01-22 19:40:47 UTC
219	https://civic.genome.wustl.edu/links/variants/219	TERT	7015	AMPLIFICATION			5	1253282	1295162			ENST00000310581.5	75	GRCh37					transcript_amplification		2016-01-22 19:40:47 UTC
220	https://civic.genome.wustl.edu/links/variants/220	TERT	7015	PROMOTER MUTATION			5	1295161	1295373			ENST00000310581.5	75	GRCh37					regulatory_region_variant		2016-02-05 00:48:14 UTC
221	https://civic.genome.wustl.edu/links/variants/221	TP53	7157	DELETERIOUS MUTATION			17	7571720	7590856			ENST00000269305.4	75	GRCh37							2016-03-10 23:51:32 UTC
222	https://civic.genome.wustl.edu/links/variants/222	TP53	7157	MUTATION			17	7571720	7590856			ENST00000269305.4	75	GRCh37					protein_altering_variant		2016-01-22 19:40:47 UTC
223	https://civic.genome.wustl.edu/links/variants/223	TP53	7157	TRUNCATING MUTATION			17	7573998	7579714			ENST00000269305.4	75	GRCh37					frameshift_truncation		2015-12-28 21:30:00 UTC
224	https://civic.genome.wustl.edu/links/variants/224	TTF1	7270	AMPLIFICATION			9	135251008	135282209			ENST00000334270.2	75	GRCh37					transcript_amplification		2016-01-22 19:40:47 UTC
230	https://civic.genome.wustl.edu/links/variants/230	CHEK2	11200	LOSS-OF-FUNCTION			22	29083732	29137832			ENST00000328354.6	75	GRCh37					loss_of_function_variant		2016-01-22 19:40:49 UTC
236	https://civic.genome.wustl.edu/links/variants/236	CDK12	51755	LOSS-OF-FUNCTION			17	37618292	37691399			ENST00000447079.4	75	GRCh37					loss_of_function_variant		2016-01-22 19:40:49 UTC
238	https://civic.genome.wustl.edu/links/variants/238	NT5C2	22978	R367Q			10	104852955	104852955	C	T	ENST00000343289.5	75	GRCh37					missense_variant		2016-01-22 19:40:49 UTC
239	https://civic.genome.wustl.edu/links/variants/239	NT5C2	22978	K359Q			10	104852980	104852980	T	G	ENST00000343289.5	75	GRCh37					missense_variant		2016-01-22 19:40:49 UTC
240	https://civic.genome.wustl.edu/links/variants/240	NT5C2	22978	D407A			10	104850745	104850745	T	G	ENST00000343289.5	75	GRCh37					missense_variant		2016-01-22 19:40:49 UTC
241	https://civic.genome.wustl.edu/links/variants/241	ABL1	25	BCR-ABL F317L	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Imatinib Resistance	9	133748288	133748288	T	C	ENST00000318560.5	75	GRCh37					transcript_fusion,missense_variant	NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C	2016-01-22 19:40:49 UTC
242	https://civic.genome.wustl.edu/links/variants/242	TP53	7157	DNA BINDING DOMAIN MUTATION			17	7577149	7578443			ENST00000269305.4	75	GRCh37							2016-01-22 19:40:49 UTC
243	https://civic.genome.wustl.edu/links/variants/243	ATM	472	V2288FS*1	A frameshift mutation predicted to cause truncation before the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain.		11	108196840	108196841		-	ENST00000278616.4	75	GRCh37					frameshift_truncation	ENST00000278616.4:c.6863_6864delTC	2017-05-18 20:44:13 UTC
244	https://civic.genome.wustl.edu/links/variants/244	ATM	472	N2875H	A missense mutation within the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain		11	108218044	108218044	A	C	ENST00000278616.4	75	GRCh37					missense_variant	ENST00000278616.4:c.8623A>C,NC_000011.9:g.108218044A>C	2016-01-22 19:40:49 UTC
245	https://civic.genome.wustl.edu/links/variants/245	NF2	4771	Y177FS			22	30051593	30051594		T	ENST00000338641.4	75	GRCh37					frameshift_elongation	ENST00000338641.4:c.527_528insT	2016-03-26 16:10:08 UTC
247	https://civic.genome.wustl.edu/links/variants/247	PDGFRA	5156	V561A			4	55141036	55141036	T	C	ENST00000257290.5	75	GRCh37					missense_variant	ENST00000257290.5:c.1682T>C,NC_000004.11:g.55141036T>C	2016-01-22 19:40:49 UTC
248	https://civic.genome.wustl.edu/links/variants/248	TERT	7015	C228T			5	1295228	1295228	G	A	ENST00000310581.5	75	GRCh37					regulatory_region_variant		2016-02-07 00:55:39 UTC
249	https://civic.genome.wustl.edu/links/variants/249	XRCC1	7515	R194W			19	44057574	44057574	G	A	ENST00000262887.5	75	GRCh37					missense_variant		2016-02-22 01:53:37 UTC
250	https://civic.genome.wustl.edu/links/variants/250	GSTP1	2950	DELETION			11	67351066	67354131			ENST00000398606.3	75	GRCh37					transcript_ablation		2015-12-07 00:37:03 UTC
251	https://civic.genome.wustl.edu/links/variants/251	BIRC7	79444	AMPLIFICATION			20	61867235	61871859			ENST00000217169.3	75	GRCh37					transcript_amplification		2015-12-04 21:10:42 UTC
252	https://civic.genome.wustl.edu/links/variants/252	EGFR	1956	EXON 4 DELETION			7	55214299	55214433			ENST00000275493.2	75	GRCh37					exon_loss_variant	ENST00000275493.2:c.425_559del	2015-12-07 00:39:25 UTC
253	https://civic.genome.wustl.edu/links/variants/253	EGFR	1956	3' UTR MUTATION															3_prime_UTR_variant		2015-12-02 22:43:29 UTC
254	https://civic.genome.wustl.edu/links/variants/254	KRAS	3845	RS61764370	Germline variant in the 3' UTR of KRAS that predicts resistance to platinum-based therapy.		12	25360224	25360224	A	C	ENST00000311936.3	75	GRCh37					3_prime_UTR_variant	NC_000012.11:g.25360224A>C	2016-03-10 17:21:52 UTC
255	https://civic.genome.wustl.edu/links/variants/255	ERCC5	2073	RS751402			13	103498198	103498199	A	G	ENST00000355739.4	75	GRCh37					5_prime_UTR_variant,SNP		2017-01-29 06:26:45 UTC
256	https://civic.genome.wustl.edu/links/variants/256	KIT	3815	3' UTR MUTATION			4	55604724	55606881			ENST00000288135.5	75	GRCh37					3_prime_UTR_variant		2015-12-28 20:57:03 UTC
257	https://civic.genome.wustl.edu/links/variants/257	EZH2	2146	INTRON 6 MUTATION			7	148524359	148525831			ENST00000320356.2	75	GRCh37					intron_variant		2015-12-29 15:47:55 UTC
258	https://civic.genome.wustl.edu/links/variants/258	MTHFR	4524	A222V			1	11856378	11856378	G	A	ENST00000376592.1	75	GRCh37					missense_variant	NM_005957.4:c.665C>T,NP_005948.3:p.Ala222Val,ENST00000376592.1:c.665G>A	2016-12-17 07:15:21 UTC
259	https://civic.genome.wustl.edu/links/variants/259	GSTP1	2950	I105V			11	67352689	67352689	A	G	ENST00000398606.3	75	GRCh37					missense_variant	NM_000852.3:c.313A>G,NP_000843.1:p.Ile105Val,ENST00000398606.3:c.313A>G	2015-12-04 21:32:01 UTC
260	https://civic.genome.wustl.edu/links/variants/260	ABCG2	9429	Q141K			4	89052323	89052323	G	T	ENST00000237612.3	75	GRCh37					missense_variant		2016-02-22 23:51:32 UTC
261	https://civic.genome.wustl.edu/links/variants/261	XRCC1	7515	Q399R			19	44055726	44055726	T	C	ENST00000262887.5	75	GRCh37					missense_variant	NM_006297.2:c.1196A>G,NP_006288.2:p.Gln399Arg	2016-06-28 21:26:14 UTC
262	https://civic.genome.wustl.edu/links/variants/262	ABCB1	5243	S893T			7	87160618	87160618	A	T	ENST00000265724.3	75	GRCh37					missense_variant	NM_000927.4:c.2677T>A,NP_000918.2:p.Ser893Thr,NC_000007.13:g.87160618A>T	2016-10-06 18:43:17 UTC
263	https://civic.genome.wustl.edu/links/variants/263	ABCB1	5243	I1145I			7	87138645	87138645	A	G	ENST00000265724.3	75	GRCh37					synonymous_variant	NM_000927.4:c.3435T>C,NP_000918.2:p.Ile1145=	2016-10-06 18:42:47 UTC
264	https://civic.genome.wustl.edu/links/variants/264	ERCC2	2068	K751Q			19	45854919	45854919	T	G	ENST00000391945.4	75	GRCh37					missense_variant		2016-02-22 00:16:52 UTC
265	https://civic.genome.wustl.edu/links/variants/265	TYMS	7298	5' TANDEM REPEAT			18	657604	657742			ENST00000323274.10	75	GRCh37					5_prime_UTR_variant,short_tandem_repeat_variation		2016-11-08 00:17:42 UTC
266	https://civic.genome.wustl.edu/links/variants/266	LRP1B	53353	EXON 1222 DELETION			2	141665446	141777671			ENST00000389484.3	75	GRCh37					exon_loss_variant		2016-02-03 17:49:37 UTC
267	https://civic.genome.wustl.edu/links/variants/267	FGFR1	2260	AMPLIFICATION	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al.). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al.). Clinical studies are currently ongoing (e.g. NCT01004224).		8	38268656	38325363			ENST00000425967.3	75	GRCh37					transcript_amplification		2016-12-16 03:25:15 UTC
268	https://civic.genome.wustl.edu/links/variants/268	FGFR1	2260	EXPRESSION	FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al.). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (Gke et. al.). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (Gke et. al.). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al.), HNSSC (Gke et. al.) and urothelial carcinoma (Lamont et. al.).		8	38268656	38325363			ENST00000425967.3	75	GRCh37					N/A		2016-12-17 06:29:10 UTC
269	https://civic.genome.wustl.edu/links/variants/269	ROS1	6098	REARRANGEMENT	ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement (Shaw et. al.,2014).		6	117609463	117747018			ENST00000368508.3	75	GRCh37					transcript_fusion		2017-01-07 01:38:14 UTC
270	https://civic.genome.wustl.edu/links/variants/270	MET	4233	AMPLIFICATION			7	116312459	116436396			ENST00000318493.6	75	GRCh37					transcript_amplification		2016-01-15 06:03:10 UTC
271	https://civic.genome.wustl.edu/links/variants/271	ATR	545	I774FS	Single A insertion or deletion in the 10 A mononucleotide run in exon 10 of ATR results in a frameshift of codon I774. In patients with endometrial cancer, this mutation has only been observed in patients with microsatellite instability.		3	142274740	142274740			ENST00000350721.4	75	GRCh37					frameshift_truncation	NC_000003.11:g.142274740del	2017-05-18 20:44:13 UTC
272	https://civic.genome.wustl.edu/links/variants/272	CDKN2A	1029	p16 EXPRESSION	CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.		9	21968055	21974865			ENST00000498124.1	75	GRCh37					N/A		2016-09-13 20:26:46 UTC
273	https://civic.genome.wustl.edu/links/variants/273	RET	5979	KIF5B-RET	In a study by Takeuchi et. al. a fusion screen was performed in 1529 lung cancer samples. 14 adenocarcinomas with KIF5B-RET and CCDC6-RET fusions were identified. (Takeuchi K et. al., 2012)		10	32306071	32345359			ENST00000302418.4	75	GRCh37	10	43609928	43625799	ENST00000355710.3	transcript_fusion		2017-05-12 04:30:59 UTC
274	https://civic.genome.wustl.edu/links/variants/274	HRAS	3265	G13D			11	534285	534285	C	T	ENST00000451590.1	75	GRCh37					missense_variant	NC_000011.9:g.534285C>T,NP_005334.1:p.Gly13Asp,NM_005343.3:c.38G>A,ENST00000451590.1:c.38G>A	2016-02-22 00:27:05 UTC
275	https://civic.genome.wustl.edu/links/variants/275	HRAS	3265	MUTATION			11	533873	534289			ENST00000451590.1	75	GRCh37					coding_transcript_variant		2016-01-28 17:53:58 UTC
276	https://civic.genome.wustl.edu/links/variants/276	CD274	29126	EXPRESSION			9	5450525	5470547			ENST00000381577.3	75	GRCh37					N/A		2016-01-15 06:05:46 UTC
277	https://civic.genome.wustl.edu/links/variants/277	MTOR	2475	MUTATION			1	11166592	11322564			ENST00000361445.4	75	GRCh37					protein_altering_variant		2016-01-28 00:20:12 UTC
278	https://civic.genome.wustl.edu/links/variants/278	AKT2	208	EXPRESSION			19	40736224	40791302			ENST00000392038.2	75	GRCh37					N/A		2016-01-28 00:30:18 UTC
279	https://civic.genome.wustl.edu/links/variants/279	NF2	4771	K159FS*16			22	30050673	30050675			ENST00000338641.4	75	GRCh37					frameshift_truncation		2016-11-04 22:59:20 UTC
281	https://civic.genome.wustl.edu/links/variants/281	FBXW7	55294	MUTATION			4	153245446	153332714			ENST00000281708.4	75	GRCh37					loss_of_function_variant,protein_altering_variant		2016-02-07 02:45:19 UTC
282	https://civic.genome.wustl.edu/links/variants/282	SMAD4	4089	UNDEREXPRESSION			18	48556583	48611409			ENST00000342988.3	75	GRCh37					N/A		2016-02-03 17:53:11 UTC
283	https://civic.genome.wustl.edu/links/variants/283	MTOR	2475	H1968Y			1	11188519	11188519	G	A	ENST00000361445.4	75	GRCh37					gain_of_function_variant,missense_variant	ENST00000361445.4:c.5902C>T	2016-02-09 00:25:46 UTC
284	https://civic.genome.wustl.edu/links/variants/284	MTOR	2475	P2213S			1	11184580	11184580	G	A	ENST00000361445.4	75	GRCh37					gain_of_function_variant,missense_variant		2016-02-10 05:38:52 UTC
285	https://civic.genome.wustl.edu/links/variants/285	BRAF	673	AGK-BRAF		BRAF Fusions	7	141250989	141255367			ENST00000355413.4	75	GRCh37	7	140434279	140494267	ENST00000288602.6	transcript_fusion		2016-01-27 19:56:06 UTC
286	https://civic.genome.wustl.edu/links/variants/286	BRAF	673	PAPSS1-BRAF		BRAF Fusions	4	108603171	108641608			ENST00000265174.4	75	GRCh37	7	140434279	140487384	ENST00000288602.6	transcript_fusion,gene_fusion		2016-01-29 02:31:32 UTC
287	https://civic.genome.wustl.edu/links/variants/287	BRAF	673	TRIM24-BRAF		BRAF Fusions	7	138145079	138239711			ENST00000343526.4	75	GRCh37	7	140434279	140487384	ENST00000288602.6	transcript_fusion		2016-01-29 03:24:36 UTC
288	https://civic.genome.wustl.edu/links/variants/288	BRAF	673	L597R		Other V600's	7	140453145	140453145	A	C	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1790T>G,NP_004324.2:p.Leu597Arg,NC_000007.13:g.140453145A>C,ENST00000288602.6:c.1790T>G	2016-02-04 21:40:10 UTC
289	https://civic.genome.wustl.edu/links/variants/289	ERBB3	2065	OVEREXPRESSION			12	56473645	56497289			ENST00000267101.3	75	GRCh37					N/A		2016-01-15 06:31:33 UTC
290	https://civic.genome.wustl.edu/links/variants/290	NT5E	4907	OVEREXPRESSION			6	86159809	86205496			ENST00000257770.3	75	GRCh37					N/A		2016-02-03 20:31:54 UTC
291	https://civic.genome.wustl.edu/links/variants/291	EZH2	2146	OVEREXPRESSION			7	148504477	148581370			ENST00000320356.2	75	GRCh37					N/A		2016-01-15 06:24:33 UTC
292	https://civic.genome.wustl.edu/links/variants/292	MYD88	4615	OVEREXPRESSION			3	38179969	38184510			ENST00000417037.2	75	GRCh37					N/A		2016-02-04 23:36:19 UTC
294	https://civic.genome.wustl.edu/links/variants/294	PIK3CA	5290	P471L			3	178928226	178928226	C	T	ENST00000263967.3	75	GRCh37					missense_variant	NC_000003.11:g.178928226C>T	2015-12-28 19:03:14 UTC
295	https://civic.genome.wustl.edu/links/variants/295	RET	5979	EXPRESSION			10	43572475	43625799			ENST00000355710.3	75	GRCh37					N/A		2015-12-24 22:41:22 UTC
296	https://civic.genome.wustl.edu/links/variants/296	RIT1	6016	OVEREXPRESSION			1	155870065	155880706			ENST00000368322.3	75	GRCh37					N/A		2016-01-15 06:14:42 UTC
297	https://civic.genome.wustl.edu/links/variants/297	RIT1	6016	MUTATION			1	155870065	155880706			ENST00000368322.3	75	GRCh37					transcript_variant		2016-01-19 16:56:12 UTC
298	https://civic.genome.wustl.edu/links/variants/298	MYCN	4613	AMPLIFICATION			2	16080686	16087129			ENST00000281043.3	75	GRCh37					transcript_amplification		2016-01-28 00:31:50 UTC
299	https://civic.genome.wustl.edu/links/variants/299	SMO	6608	D473H			7	128849189	128849189	G	C	ENST00000249373.3	75	GRCh37					missense_variant	NM_005631.4:c.1417G>A,NP_005622.1:p.Asp473His,ENST00000249373.3:c.1417G>A	2016-01-15 05:34:12 UTC
300	https://civic.genome.wustl.edu/links/variants/300	SMO	6608	MUTATION			7	128828713	128853386			ENST00000249373.3	75	GRCh37					coding_transcript_variant		2016-01-06 23:46:29 UTC
301	https://civic.genome.wustl.edu/links/variants/301	PTCH1	5727	MUTATION			9	98205262	98270943			ENST00000331920.6	75	GRCh37					loss_of_function_variant,gene_variant		2016-02-05 00:34:38 UTC
302	https://civic.genome.wustl.edu/links/variants/302	PTCH1	5727	LOH			9	98205262	98270943			ENST00000331920.6	75	GRCh37					loss_of_heterozygosity		2016-02-18 17:45:23 UTC
303	https://civic.genome.wustl.edu/links/variants/303	STK11	6794	EXON 1-2 MUTATION			19	1205740	1218499			ENST00000326873.7	75	GRCh37					exon_variant		2016-03-10 01:25:16 UTC
304	https://civic.genome.wustl.edu/links/variants/304	STK11	6794	UNDEREXPRESSION			19	1205740	1228428			ENST00000326873.7	75	GRCh37					N/A		2016-01-15 06:22:40 UTC
305	https://civic.genome.wustl.edu/links/variants/305	SYK	6850	OVEREXPRESSION			9	93564069	93660831			ENST00000375754.4	75	GRCh37					N/A		2016-02-04 23:33:09 UTC
306	https://civic.genome.wustl.edu/links/variants/306	ERBB2	2064	AMPLIFICATION	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.		17	37856333	37884915			ENST00000269571.5	75	GRCh37					transcript_amplification		2016-08-28 04:46:52 UTC
307	https://civic.genome.wustl.edu/links/variants/307	ALK	238	EML4-ALK L1152R			2	29445270	29445270	A	C	ENST00000389048.3	75	GRCh37					transcript_fusion,missense_variant	ENST00000389048.3:c.3455T>G,NC_000002.11:g.29445270A>C,NM_004304.4:c.3455T>G,NP_004295.2:p.Leu1152Arg	2016-02-23 21:52:33 UTC
308	https://civic.genome.wustl.edu/links/variants/308	ALK	238	EML4-ALK G1269A	The EML4-ALK G1269A mutation has been identified in non-small cell lung cancer patients resistant to crizotinib. Cell line data from multiple groups have shown this mutation enhances resistance to crizotinib treatment in vitro.		2	29432682	29432682	C	G	ENST00000389048.3	75	GRCh37					transcript_fusion,missense_variant	ENST00000389048.3:c.3806G>C,NC_000002.11:g.29432682C>G,NM_004304.4:c.3806G>C,NP_004295.2:p.Gly1269Ala	2016-09-02 23:06:35 UTC
309	https://civic.genome.wustl.edu/links/variants/309	EGFR	1956	AUTOCRINE ACTIVATION			7	55086794	55279321			ENST00000275493.2	75	GRCh37							2016-02-15 22:24:42 UTC
310	https://civic.genome.wustl.edu/links/variants/310	ERBB4	2066	MUTATION	ERBB4 mutations have been identified in melanoma, lung adenocarcinoma and medulloblastoma. In-vitro studies suggest that melanoma cell lines harboring an ERBB4 mutation are sensitive to ERBB4 inhibition with lapatinib.		2	212295697	212578308			ENST00000342788.4	75	GRCh37					gain_of_function_variant,transcript_variant		2016-10-12 03:24:20 UTC
311	https://civic.genome.wustl.edu/links/variants/311	PIK3CA	5290	MUTATION			3	178866311	178957881			ENST00000263967.3	75	GRCh37					gain_of_function_variant,transcript_variant		2016-01-28 17:42:59 UTC
312	https://civic.genome.wustl.edu/links/variants/312	EGFR	1956	VIII	The EGFRvIII variant is an oncogenic mutation that has been reported in several cancers including glioblastoma multiforme, breast, lung, head and neck, ovarian and prostate. In high-grade gliomas, EGFRvIII has been reported in about 30% of cases with EGFR amplification. The EGFRvIII mutation leads to deletion of the receptor ectodomain exons 2-7. The presence of this variant has been linked with clinical response to EGFR TKI. (Arteaga and Engelmann, 2014)		7	55087058	55223523			ENST00000275493.2	75	GRCh37							2017-01-31 21:34:19 UTC
313	https://civic.genome.wustl.edu/links/variants/313	PTEN	5728	EXPRESSION			10	89622870	89731687			ENST00000371953.3	75	GRCh37					N/A		2016-02-05 00:45:35 UTC
314	https://civic.genome.wustl.edu/links/variants/314	NRG1	3084	EXPRESSION			8	31497942	32622294			ENST00000523534.1	75	GRCh37					N/A		2016-02-04 22:37:43 UTC
315	https://civic.genome.wustl.edu/links/variants/315	AREG	374	EXPRESSION			4	75310851	75320726			ENST00000395748.3	75	GRCh37					N/A		2016-02-04 22:33:52 UTC
316	https://civic.genome.wustl.edu/links/variants/316	TGFA	7039	EXPRESSION			2	70674412	70781147			ENST00000295400.6	75	GRCh37					N/A		2016-02-03 20:34:24 UTC
317	https://civic.genome.wustl.edu/links/variants/317	EGFR	1956	G724S			7	55241722	55241722	G	A	ENST00000275493.2	75	GRCh37					missense_variant	NC_000007.13:g.55241722G>A	2016-02-16 15:39:49 UTC
318	https://civic.genome.wustl.edu/links/variants/318	EREG	2069	EXPRESSION			4	75230860	75254468			ENST00000244869.2	75	GRCh37					N/A		2016-02-15 22:55:37 UTC
319	https://civic.genome.wustl.edu/links/variants/319	EFNA2	1943	EXPRESSION			19	1286153	1301430			ENST00000215368.2	75	GRCh37					N/A		2016-02-15 22:33:34 UTC
320	https://civic.genome.wustl.edu/links/variants/320	MAPK1	5594	E322K			2	22127164	22127164	C	T	ENST00000215832.6	75	GRCh37					gain_of_function_variant,missense_variant	ENST00000215832.6:c.964G>A	2016-02-22 02:01:17 UTC
321	https://civic.genome.wustl.edu/links/variants/321	MAPK1	5594	AMPLIFICATION			22	22108789	22221919			ENST00000215832.6	75	GRCh37					transcript_amplification		2016-02-03 23:20:09 UTC
322	https://civic.genome.wustl.edu/links/variants/322	KRAS	3845	A146V			12	25378561	25378561	G	A	ENST00000256078.4	75	GRCh37					missense_variant	ENST00000256078.4:c.437C>T,NC_000012.11:g.25378561G>A,NP_004976.2:p.Ala146Val,NM_004985.4:c.437C>T	2016-02-04 23:31:53 UTC
323	https://civic.genome.wustl.edu/links/variants/323	MET	4233	MUTATION			7	116312459	116436396			ENST00000318493.6	75	GRCh37					gain_of_function_variant,transcription_variant		2016-01-28 01:33:03 UTC
324	https://civic.genome.wustl.edu/links/variants/324	MET	4233	EXON 14 SKIPPING MUTATION	Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).		7	116411903	116412043			ENST00000318493.6	75	GRCh37					exon_loss_variant		2017-02-06 18:00:51 UTC
325	https://civic.genome.wustl.edu/links/variants/325	FGFR3	2261	EXPRESSION			4	1795039	1810599			ENST00000440486.2	75	GRCh37					N/A		2016-02-05 00:29:18 UTC
326	https://civic.genome.wustl.edu/links/variants/326	CBLC	23624	EXPRESSION			19	45281126	45303891			ENST00000270279.3	75	GRCh37					N/A		2016-02-15 22:49:41 UTC
327	https://civic.genome.wustl.edu/links/variants/327	PTPRD	5789	MUTATION			9	8314246	10033790			ENST00000381196.4	75	GRCh37					loss_of_function_variant,transcript_variant		2016-02-18 17:51:07 UTC
328	https://civic.genome.wustl.edu/links/variants/328	DEFA1	1667	EXPRESSION			8	6835172	6837602			ENST00000382692.2	75	GRCh37					N/A		2016-02-07 02:08:32 UTC
329	https://civic.genome.wustl.edu/links/variants/329	ERCC1	2067	EXPRESSION			19	45916692	45926824			ENST00000013807.5	75	GRCh37					N/A		2016-02-15 22:46:42 UTC
330	https://civic.genome.wustl.edu/links/variants/330	NOTCH1	4851	AMPLIFICATION			9	139388896	139440314			ENST00000277541.6	75	GRCh37					transcript_amplification		2016-02-05 00:46:46 UTC
331	https://civic.genome.wustl.edu/links/variants/331	WEE1	7465	POLYMORPHISM															intron_variant,polymorphic_sequence_variant		2016-01-12 10:09:56 UTC
332	https://civic.genome.wustl.edu/links/variants/332	FNTB	2342	RS11623866			14	65453063	65453063	G	C	ENST00000246166.2	75	GRCh37					regulatory_region_variant		2016-08-22 22:50:02 UTC
333	https://civic.genome.wustl.edu/links/variants/333	PTPRT	11122	PROMOTER HYPERMETHYLATION															N/A		2016-01-12 10:29:36 UTC
334	https://civic.genome.wustl.edu/links/variants/334	VEGFA	7422	UNDEREXPRESSION			6	43738444	43752346			ENST00000372055.4	75	GRCh37					N/A		2016-02-07 01:47:48 UTC
335	https://civic.genome.wustl.edu/links/variants/335	DNMT1	1786	EXPRESSION			19	10244022	10305811			ENST00000340748.4	75	GRCh37					N/A		2016-02-04 22:31:27 UTC
336	https://civic.genome.wustl.edu/links/variants/336	KRAS	3845	MUTATION			12	25362365	25403737			ENST00000256078.4	75	GRCh37					protein_altering_variant		2016-02-05 00:31:28 UTC
337	https://civic.genome.wustl.edu/links/variants/337	PDCD4	27250	EXPRESSION	A new study, a retrospective analysis of 77 patients, has implicated PDCD4 expression in the sensitivity to paclitaxel. However, this finding came from a large proteome screen and has not yet been replicated in independent patient sets.		10	112631596	112659763			ENST00000393104.2	75	GRCh37					N/A		2016-02-04 21:58:55 UTC
338	https://civic.genome.wustl.edu/links/variants/338	MGMT	4255	RS16906252			10	131265545	131265545	C	T	ENST00000306010.7	75	GRCh37					synonymous_variant		2016-09-01 23:22:29 UTC
339	https://civic.genome.wustl.edu/links/variants/339	TFF3	7033	EXPRESSION			21	43731777	43735761			ENST00000518498.1	75	GRCh37					N/A		2016-02-04 21:42:09 UTC
340	https://civic.genome.wustl.edu/links/variants/340	DKK1	22943	NUCLEAR EXPRESSION			10	54074056	54077417			ENST00000373970.3	75	GRCh37					N/A		2016-02-22 00:22:02 UTC
341	https://civic.genome.wustl.edu/links/variants/341	CD44	960	ISOFORM EXPRESSION			11	35160728	35251574			ENST00000428726.2	75	GRCh37					N/A		2016-02-18 17:52:26 UTC
342	https://civic.genome.wustl.edu/links/variants/342	EGF	1950	EXPRESSION			4	110834047	110933422			ENST00000265171.5	75	GRCh37					N/A		2016-02-07 02:46:21 UTC
343	https://civic.genome.wustl.edu/links/variants/343	MDM2	4193	EXPRESSION			12	69201956	69239214			ENST00000462284.1	75	GRCh37					N/A		2016-02-04 21:05:57 UTC
344	https://civic.genome.wustl.edu/links/variants/344	HMOX1	3162	EXPRESSION			22	35776828	35790207			ENST00000216117.8	75	GRCh37					N/A		2016-02-15 22:45:13 UTC
345	https://civic.genome.wustl.edu/links/variants/345	SPHK1	8877	OVEREXPRESSION			17	74380731	74383936			ENST00000323374.4	75	GRCh37					N/A		2016-02-07 02:26:53 UTC
346	https://civic.genome.wustl.edu/links/variants/346	CASP8	841	EXPRESSION			2	202122759	202152434			ENST00000358485.4	75	GRCh37					N/A		2016-02-13 20:36:25 UTC
347	https://civic.genome.wustl.edu/links/variants/347	TYMS	7298	EXPRESSION			18	657604	673578			ENST00000323274.10	75	GRCh37					N/A		2016-01-15 06:45:14 UTC
348	https://civic.genome.wustl.edu/links/variants/348	PBK	55872	OVEREXPRESSION			8	27667137	27695612			ENST00000301905.4	75	GRCh37					N/A		2016-02-03 20:10:55 UTC
349	https://civic.genome.wustl.edu/links/variants/349	SMARCA4	6597	UNDEREXPRESSION			19	11071598	11172958			ENST00000358026.2	75	GRCh37					N/A		2016-02-16 16:07:44 UTC
350	https://civic.genome.wustl.edu/links/variants/350	SETBP1	26040	EXON 4 MUTATION			18	42531877	42531918			ENST00000282030.5	75	GRCh37					exon_variant		2016-02-22 01:56:22 UTC
351	https://civic.genome.wustl.edu/links/variants/351	SETBP1	26040	G870S			18	42531913	42531913	G	A	ENST00000282030.5	75	GRCh37					missense_variant	NM_015559.2:c.2608G>A,NP_056374.2:p.Gly870Ser,ENST00000282030.5:c.2608G>A	2016-02-04 23:26:01 UTC
352	https://civic.genome.wustl.edu/links/variants/352	ALK	238	EML4-ALK C1156YL1198F	EML4-ALK C1156Y alone is resistant to crizotinib in non-small cell lung cancer (NSCLC) which has been shown to be modulated (both increased sensitivity and resistance) by additional ALK mutations. A case report showed that an NSCLC harboring EML4-ALK C1156YL1198F was resistant to lorlatinib but this second mutation re-sensitized this tumor to crizotinib.		2	29443625	29445258			ENST00000389048.3	75	GRCh37					transcript_fusion,missense_variant		2016-09-02 23:05:32 UTC
354	https://civic.genome.wustl.edu/links/variants/354	EGFR	1956	EXPRESSION			7	55086794	55279321			ENST00000275493.2	75	GRCh37					N/A		2016-01-28 00:37:02 UTC
355	https://civic.genome.wustl.edu/links/variants/355	CDKN1A	1026	EXPRESSION			6	36646487	36655108			ENST00000405375.1	75	GRCh37					N/A		2016-02-15 22:31:47 UTC
356	https://civic.genome.wustl.edu/links/variants/356	ALCAM	214	EXPRESSION			3	105085753	105295744			ENST00000306107.5	75	GRCh37					N/A		2016-02-15 22:44:19 UTC
357	https://civic.genome.wustl.edu/links/variants/357	STMN1	3925	EXPRESSION			1	26211931	26232957			ENST00000426559.2	75	GRCh37					N/A		2016-02-15 22:47:52 UTC
358	https://civic.genome.wustl.edu/links/variants/358	RSF1	51773	AMPLIFICATION			11	77371041	77532063			ENST00000308488.6	75	GRCh37					transcript_amplification		2016-02-04 23:02:27 UTC
359	https://civic.genome.wustl.edu/links/variants/359	AR	367	OVEREXPRESSION			X	66764465	66950461			ENST00000374690.3	75	GRCh37					N/A		2016-01-28 00:07:00 UTC
360	https://civic.genome.wustl.edu/links/variants/360	CDKN1B	1027	CYTOPLASMIC MISLOCALIZATION			12	12870058	12875305			ENST00000228872.4	75	GRCh37					N/A		2016-02-16 16:14:30 UTC
361	https://civic.genome.wustl.edu/links/variants/361	ERBB3	2065	EXPRESSION			12	56473645	56497289			ENST00000267101.3	75	GRCh37					N/A		2016-01-15 06:30:31 UTC
362	https://civic.genome.wustl.edu/links/variants/362	AR	367	SPLICE VARIANT 7			X	66764662	66915917			ENST00000504326.1	75	GRCh37							2017-05-18 20:44:13 UTC
363	https://civic.genome.wustl.edu/links/variants/363	UGT1A	7361	EXPRESSION			2	234526291	234681956			ENST00000373450.4	75	GRCh37					N/A		2016-02-16 15:35:44 UTC
364	https://civic.genome.wustl.edu/links/variants/364	ERBB4	2066	NUCLEAR TRANSLOCATION			2	212240446	213403565			ENST00000342788.4	75	GRCh37					N/A		2016-02-16 15:59:20 UTC
365	https://civic.genome.wustl.edu/links/variants/365	ERBB4	2066	EXPRESSION			2	212240446	213403565			ENST00000342788.4	75	GRCh37					N/A		2016-02-07 02:29:30 UTC
366	https://civic.genome.wustl.edu/links/variants/366	SLFN11	91607	EXPRESSION			17	33677324	33700639			ENST00000394566.1	75	GRCh37					N/A		2016-02-04 20:40:13 UTC
367	https://civic.genome.wustl.edu/links/variants/367	RAC1	5879	P29S			7	6426892	6426892	C	T	ENST00000356142.4	75	GRCh37					missense_variant	ENST00000356142.4:c.85C>T	2016-02-16 15:53:19 UTC
368	https://civic.genome.wustl.edu/links/variants/368	BIRC5	332	NUCLEAR EXPRESSION			17	76210267	76221717			ENST00000301633.4	75	GRCh37					N/A		2016-02-22 00:10:08 UTC
369	https://civic.genome.wustl.edu/links/variants/369	TP53	7157	WILD TYPE			17	7571720	7590856			ENST00000269305.4	75	GRCh37					wild_type		2016-01-27 20:41:35 UTC
370	https://civic.genome.wustl.edu/links/variants/370	MRE11	4361	LOSS			11	94152895	94227074			ENST00000323929.3	75	GRCh37					loss_of_function_variant		2016-02-15 22:53:00 UTC
371	https://civic.genome.wustl.edu/links/variants/371	TOP1	7150	AMPLIFICATION			20	39657458	39753127			ENST00000361337.2	75	GRCh37					transcript_amplification		2016-02-04 23:05:38 UTC
372	https://civic.genome.wustl.edu/links/variants/372	CDKN1B	1027	EXPRESSION			12	12870058	12875305			ENST00000228872.4	75	GRCh37					N/A		2016-02-03 20:48:58 UTC
373	https://civic.genome.wustl.edu/links/variants/373	AGR2	10551	EXPRESSION			7	16831435	16844704			ENST00000419304.2	75	GRCh37					N/A		2016-02-15 22:43:08 UTC
374	https://civic.genome.wustl.edu/links/variants/374	NAPRT	93100	PROMOTER HYPERMETHYLATION															N/A		2016-01-15 15:52:29 UTC
375	https://civic.genome.wustl.edu/links/variants/375	EGFR	1956	EXON 18 OVEREXPRESSION			7	55237999	55238735			ENST00000344576.2	75	GRCh37					exon_variant		2016-02-25 20:34:37 UTC
376	https://civic.genome.wustl.edu/links/variants/376	ZEB1	6935	EXPRESSION			10	31608101	31818741			ENST00000361642.5	75	GRCh37					N/A		2016-02-15 22:48:49 UTC
377	https://civic.genome.wustl.edu/links/variants/377	TIMP1	7076	OVEREXPRESSION			X	47441712	47446188			ENST00000218388.4	75	GRCh37					N/A		2016-02-15 22:29:26 UTC
378	https://civic.genome.wustl.edu/links/variants/378	PTP4A3	11156	OVEREXPRESSION			8	142402093	142441394			ENST00000521578.1	75	GRCh37					N/A		2016-02-15 22:54:46 UTC
379	https://civic.genome.wustl.edu/links/variants/379	TYMS	7298	AMPLIFICATION			18	657604	673578			ENST00000323274.10	75	GRCh37					transcript_amplification		2016-01-28 01:43:16 UTC
380	https://civic.genome.wustl.edu/links/variants/380	IGF1R	3480	EXPRESSION			15	99192200	99507759			ENST00000268035.6	75	GRCh37					N/A		2016-02-15 22:41:59 UTC
381	https://civic.genome.wustl.edu/links/variants/381	EPHB4	2050	EXPRESSION			7	100400187	100425121			ENST00000358173.3	75	GRCh37					N/A		2016-02-13 20:22:33 UTC
382	https://civic.genome.wustl.edu/links/variants/382	TYMS	7298	UNDEREXPRESSION			18	657604	673578			ENST00000323274.10	75	GRCh37					N/A		2016-01-28 01:42:14 UTC
383	https://civic.genome.wustl.edu/links/variants/383	TOP2A	7153	EXPRESSION			17	38544768	38574202			ENST00000423485.1	75	GRCh37					N/A		2016-02-04 21:30:50 UTC
384	https://civic.genome.wustl.edu/links/variants/384	TOP1	7150	EXPRESSION			20	39657458	39753127			ENST00000361337.2	75	GRCh37					N/A		2016-02-04 23:13:54 UTC
385	https://civic.genome.wustl.edu/links/variants/385	PRKAA2	5563	T172 PHOSPHORYLATION			1	57159476	57159478			ENST00000371244.4	75	GRCh37					N/A		2016-03-08 20:44:39 UTC
386	https://civic.genome.wustl.edu/links/variants/386	HSPA5	3309	EXPRESSION			9	127997132	128003609			ENST00000324460.6	75	GRCh37					N/A		2016-02-04 21:55:51 UTC
387	https://civic.genome.wustl.edu/links/variants/387	EIF4EBP1	1978	PHOSPHORYLATION			8	37888200	37914663			ENST00000338825.4	75	GRCh37					N/A		2016-02-23 00:02:06 UTC
388	https://civic.genome.wustl.edu/links/variants/388	KIT	3815	MUTATION			4	55524085	55606881			ENST00000288135.5	75	GRCh37					gain_of_function_variant,transcript_variant		2016-02-22 23:52:51 UTC
389	https://civic.genome.wustl.edu/links/variants/389	TUBB3	10381	EXPRESSION			16	89989687	90002505			ENST00000315491.7	75	GRCh37					N/A		2016-02-16 16:12:35 UTC
390	https://civic.genome.wustl.edu/links/variants/390	EGFR	1956	Y1092 PHOSPHORYLATION	Although referred to as Y1068 in the literature, based on the recognition peptide described, this tyrosine occurs at Y1039 (ENST00000454757.2 v75) or Y1092 (ENST00000275493.2 v75).		7	55272951	55272953			ENST00000275493.2	75	GRCh37					N/A		2016-09-02 15:32:42 UTC
391	https://civic.genome.wustl.edu/links/variants/391	IGF1R	3480	NUCLEAR EXPRESSION			15	99192200	99507759			ENST00000268035.6	75	GRCh37					N/A		2016-02-22 00:08:10 UTC
392	https://civic.genome.wustl.edu/links/variants/392	CFLAR	8837	EXPRESSION			2	201980827	202041410			ENST00000309955.3	75	GRCh37					N/A		2016-02-04 21:26:05 UTC
393	https://civic.genome.wustl.edu/links/variants/393	PROM1	8842	EXPRESSION			4	15969857	16085324			ENST00000510224.1	75	GRCh37					N/A		2016-02-15 22:37:59 UTC
394	https://civic.genome.wustl.edu/links/variants/394	FOXP3	50943	EXPRESSION			X	49106897	49121288			ENST00000376207.4	75	GRCh37					N/A		2016-02-15 22:40:40 UTC
395	https://civic.genome.wustl.edu/links/variants/395	RPS6	6194	PHOSPHORYLATION			9	19376309	19376323			ENST00000380394.4	75	GRCh37					N/A		2016-02-22 02:04:05 UTC
396	https://civic.genome.wustl.edu/links/variants/396	JAK1	3716	OVEREXPRESSION			1	65298912	65432187			ENST00000342505.4	75	GRCh37					N/A		2016-02-07 02:16:31 UTC
397	https://civic.genome.wustl.edu/links/variants/397	BRCA1	672	EXPRESSION			17	41196312	41277387			ENST00000357654.3	75	GRCh37					N/A		2016-01-27 20:11:56 UTC
398	https://civic.genome.wustl.edu/links/variants/398	DUSP6	1848	EXPRESSION			12	89741009	89747048			ENST00000279488.7	75	GRCh37					N/A		2016-02-04 21:47:29 UTC
399	https://civic.genome.wustl.edu/links/variants/399	BRAF	673	MUTATION			7	140453136	140481403			ENST00000288602.6	75	GRCh37					gain_of_function_variant,gene_variant		2016-02-03 20:28:33 UTC
400	https://civic.genome.wustl.edu/links/variants/400	HSPB1	3315	EXPRESSION			7	75931861	75933612			ENST00000248553.6	75	GRCh37					N/A		2016-02-15 22:39:10 UTC
401	https://civic.genome.wustl.edu/links/variants/401	NQO1	1728	EXPRESSION			16	69743304	69760854			ENST00000320623.5	75	GRCh37					N/A		2016-02-18 17:53:28 UTC
402	https://civic.genome.wustl.edu/links/variants/402	NQO1	1728	P187S			16	69745145	69745145	G	A	ENST00000320623.5	75	GRCh37					missense_variant	NM_000903.2:c.559C>T,NP_000894.1:p.Pro187Ser	2016-03-12 02:22:56 UTC
403	https://civic.genome.wustl.edu/links/variants/403	BRCA1	672	UNDEREXPRESSION			17	41196312	41277387			ENST00000357654.3	75	GRCh37					N/A		2016-01-27 20:09:50 UTC
404	https://civic.genome.wustl.edu/links/variants/404	ABCB1	5243	EXPRESSION			7	87133175	87342564			ENST00000265724.3	75	GRCh37					N/A		2016-01-29 02:54:00 UTC
405	https://civic.genome.wustl.edu/links/variants/405	CXCR4	7852	EXPRESSION			2	136871919	136873813			ENST00000409817.1	75	GRCh37					N/A		2016-02-15 22:36:21 UTC
406	https://civic.genome.wustl.edu/links/variants/406	MAGEH1	28986	EXPRESSION			X	55478538	55479998			ENST00000342972.1	75	GRCh37					N/A		2016-02-15 22:59:37 UTC
407	https://civic.genome.wustl.edu/links/variants/407	ABCC3	8714	AMPLIFICATION			17	48712218	48769613			ENST00000285238.8	75	GRCh37					transcript_amplification		2016-02-04 23:03:53 UTC
408	https://civic.genome.wustl.edu/links/variants/408	ABCC10	89845	EXPRESSION			6	43395292	43418168			ENST00000372530.4	75	GRCh37					N/A		2016-02-07 01:51:12 UTC
409	https://civic.genome.wustl.edu/links/variants/409	ASNS	440	AMPLIFICATION			7	97481430	97501854			ENST00000175506.4	75	GRCh37					transcript_amplification		2016-02-04 23:15:19 UTC
410	https://civic.genome.wustl.edu/links/variants/410	CDX2	1045	EXPRESSION			13	28536274	28545276			ENST00000381020.7	75	GRCh37					N/A		2016-02-15 22:34:55 UTC
411	https://civic.genome.wustl.edu/links/variants/411	STAT3	6774	SH2 DOMAIN MUTATION			17	40465342	40475372			ENST00000264657.5	75	GRCh37							2016-02-21 23:44:14 UTC
412	https://civic.genome.wustl.edu/links/variants/412	POU5F1	5460	EXPRESSION			6	31132120	31138470			ENST00000259915.8	75	GRCh37					N/A		2016-03-10 22:49:02 UTC
413	https://civic.genome.wustl.edu/links/variants/413	ERBB2	2064	KINASE DOMAIN MUTATION			17	37879863	37882870			ENST00000269571.5	75	GRCh37					protein_altering_variant		2016-02-15 23:10:57 UTC
414	https://civic.genome.wustl.edu/links/variants/414	ERBB2	2064	M774INSAYVM	Mutations in the HER2 kinase domain occur at a 2-4% frequency in lung adenocarcinomas, the majority of which are in exon 20 as in-frame duplications or insertions in a small 8 codon region (774-781 or 775-782). These are analogous to the exon 20 alterations found in EGFR TK domain. The M774 insertion, M774insAYVM, represents 62.5% of all HER2 kinase domain mutations identified (when combined with the A775insYVMA mutations as they translate to the identical amino acid sequence changes). As demonstrated in mouse models (Perrera et al., PNAS 2009) and subsequent clinical trials in human lung adenocarcinoma with these insertions, HER2 YVMA mutants predict response to several targeted HER2 agonists such as afatinib, trastuzumab, neratinib and TDM-1 (trastuzumab emtansine) as monotherapy or combined with specific chemotherapies.		17	37880993	37880994		GCTTACGTGATG	ENST00000269571.5	75	GRCh37					inframe_insertion		2016-02-26 19:38:21 UTC
415	https://civic.genome.wustl.edu/links/variants/415	EGFR	1956	C797S			7	55249091	55249091	T	A	ENST00000275493.2	75	GRCh37					missense_variant	NC_000007.13:g.55249091T>A	2016-02-03 17:42:12 UTC
416	https://civic.genome.wustl.edu/links/variants/416	ERBB2	2064	SERUM LEVELS			17	37856333	37884915			ENST00000269571.5	75	GRCh37					N/A		2016-02-18 18:30:07 UTC
417	https://civic.genome.wustl.edu/links/variants/417	THBS2	7058	UNDEREXPRESSION			6	169615875	169654139			ENST00000366787.3	75	GRCh37					N/A		2016-02-15 23:00:42 UTC
419	https://civic.genome.wustl.edu/links/variants/419	NTRK1	4914	NTRK1 FUSIONS			1	156844175	156851434			ENST00000524377.1	75	GRCh37					transcript_fusion		2016-08-28 04:26:59 UTC
420	https://civic.genome.wustl.edu/links/variants/420	IDH1	3417	R132H	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.		2	209113112	209113112	C	T	ENST00000415913.1	75	GRCh37					missense_variant	NM_001282386.1:c.395G>A,NP_005887.2:p.Arg132His	2016-02-16 15:57:48 UTC
421	https://civic.genome.wustl.edu/links/variants/421	TERT	7015	RS2736100			5	1286516	1286516	C	A	ENST00000310581.5	75	GRCh37					coding_transcript_intron_variant,polymorphic_sequence_variant		2016-02-16 16:06:23 UTC
422	https://civic.genome.wustl.edu/links/variants/422	STAG2	10735	UNDEREXPRESSION			X	123095568	123236506			ENST00000371157.3	75	GRCh37					N/A		2016-02-15 22:51:27 UTC
423	https://civic.genome.wustl.edu/links/variants/423	HLA-DRA	3122	EXPRESSION			6	32407619	32412823			ENST00000395388.2	75	GRCh37					N/A		2016-02-15 22:58:42 UTC
424	https://civic.genome.wustl.edu/links/variants/424	MYD88	4615	L265P			3	38182641	38182641	T	C	ENST00000396334.3	75	GRCh37					gain_of_function_variant,missense_variant		2016-03-10 23:59:37 UTC
425	https://civic.genome.wustl.edu/links/variants/425	KRAS	3845	G12V			12	25398284	25398284	C	A	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T	2016-02-22 00:29:54 UTC
426	https://civic.genome.wustl.edu/links/variants/426	BRAF	673	WILD TYPE			7	140434279	140624564			ENST00000288602.6	75	GRCh37					wild_type		2016-02-22 00:18:19 UTC
427	https://civic.genome.wustl.edu/links/variants/427	NRAS	4893	Q61K			1	115256530	115256530	G	T	ENST00000369535.4	75	GRCh37					missense_variant	NM_002524.4:c.181C>A,NP_002515.1:p.Gln61Lys,NC_000001.10:g.115256530G>T	2016-02-22 00:06:20 UTC
428	https://civic.genome.wustl.edu/links/variants/428	MRE11	4361	FRAMESHIFT MUTATION			11	94152895	94227074			ENST00000323929.3	75	GRCh37					frameshift_variant		2016-03-11 01:28:23 UTC
429	https://civic.genome.wustl.edu/links/variants/429	KIT	3815	EXPRESSION			4	55524085	55606881			ENST00000288135.5	75	GRCh37					N/A		2016-02-22 00:47:41 UTC
431	https://civic.genome.wustl.edu/links/variants/431	CBFB	865	CBFB-MYH11	CBFB-MYH11 is the result of inv(16)(p13q22) or t(16;16)(p13;q22) and is sufficient for the diagnosis of acute myeloid leukemia (in the correct setting) according to WHO criteria, even when blast counts are <20% (Vardiman et al, Blood 2008). This fusion is typically associated with favorable prognosis relative to other AML subtypes (including cytogenetically normal); however, the impact of additional mutations in the context of this fusion is incompletely understood. AMLs with this fusion are often grouped with other rearrangements affecting genes encoding core binding factor subunits, referred to as CBF AMLs.		16	67063148	67116211			ENST00000412916.2	75	GRCh37	16	15797029	15820911	ENST00000396324.3	transcript_fusion		2016-06-28 21:24:58 UTC
432	https://civic.genome.wustl.edu/links/variants/432	KMT2A	4297	MLL-MLLT3															transcript_fusion		2016-02-17 21:51:30 UTC
433	https://civic.genome.wustl.edu/links/variants/433	HIF1A	3091	3' UTR Polymorphism			14	62213848	62213848	T	C	ENST00000394997.1	75	GRCh37					3_prime_UTR_variant,SNP		2016-05-02 22:51:39 UTC
434	https://civic.genome.wustl.edu/links/variants/434	HIF1A	3091	OVEREXPRESSION			14	62162258	62214976			ENST00000394997.1	75	GRCh37					N/A		2016-02-22 17:24:00 UTC
435	https://civic.genome.wustl.edu/links/variants/435	EPAS1	2034	OVEREXPRESSION			2	46524541	46613836			ENST00000263734.3	75	GRCh37					N/A		2016-02-22 17:23:35 UTC
436	https://civic.genome.wustl.edu/links/variants/436	VHL	7428	LOSS			3	10182692	10193904			ENST00000256474.2	75	GRCh37					loss_of_function_variant		2016-02-22 20:28:52 UTC
437	https://civic.genome.wustl.edu/links/variants/437	FLT3	2322	D835			13	28592642	28592642	C	A	ENST00000241453.7	75	GRCh37					protein_altering_variant		2016-02-22 00:45:36 UTC
438	https://civic.genome.wustl.edu/links/variants/438	PSMB8	5696	NUCLEAR EXPRESSION			6	32808494	32812480			ENST00000374881.2	75	GRCh37					N/A		2016-02-23 00:05:10 UTC
439	https://civic.genome.wustl.edu/links/variants/439	PBK	55872	NUCLEAR EXPRESSION			8	27667137	27695612			ENST00000301905.4	75	GRCh37					N/A		2016-02-23 00:06:28 UTC
440	https://civic.genome.wustl.edu/links/variants/440	PTTG1	9232	OVEREXPRESSION			5	159848829	159855748			ENST00000352433.5	75	GRCh37					N/A		2016-02-23 00:25:25 UTC
441	https://civic.genome.wustl.edu/links/variants/441	LEPR	3953	UNDEREXPRESSION			1	65886335	66107242			ENST00000349533.6	75	GRCh37					N/A		2016-02-23 00:27:08 UTC
442	https://civic.genome.wustl.edu/links/variants/442	EGFR	1956	MUTATION			7	55086794	55279321			ENST00000275493.2	75	GRCh37					inframe_variant		2016-03-14 15:12:58 UTC
443	https://civic.genome.wustl.edu/links/variants/443	EGFR	1956	G465R			7	55227926	55227926	G	A	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.1393G>A	2016-03-10 17:06:26 UTC
444	https://civic.genome.wustl.edu/links/variants/444	NEDD9	4739	EXPRESSION			6	11185051	11382581			ENST00000504387.1	75	GRCh37					N/A		2016-02-22 23:40:35 UTC
445	https://civic.genome.wustl.edu/links/variants/445	ETS2	2114	RS461155			21	40191638	40191638	A	G	ENST00000360214.3	75	GRCh37					synonymous_variant		2016-10-02 20:02:48 UTC
446	https://civic.genome.wustl.edu/links/variants/446	KRT18	3875	UNDEREXPRESSION			12	53342655	53346684			ENST00000388837.2	75	GRCh37					N/A		2016-02-22 23:42:14 UTC
447	https://civic.genome.wustl.edu/links/variants/447	FGF13	2258	CYTOPLASMIC EXPRESSION			X	137715011	138286269			ENST00000370603.3	75	GRCh37					N/A		2016-02-22 23:38:37 UTC
448	https://civic.genome.wustl.edu/links/variants/448	SSX1	6756	SS18-SSX1		SYT-SSX fusions													transcript_fusion		2016-02-22 16:58:42 UTC
449	https://civic.genome.wustl.edu/links/variants/449	SSX2	6757	SS18-SSX2		SYT-SSX fusions													transcript_fusion		2016-02-22 17:09:07 UTC
450	https://civic.genome.wustl.edu/links/variants/450	SSX4	6759	SS18-SSX4		SYT-SSX fusions	18	23612363	23670589			ENST00000415083.2	75	GRCh37	X	48261524	48265521	ENST00000376884.2	transcript_fusion		2016-03-11 01:55:33 UTC
451	https://civic.genome.wustl.edu/links/variants/451	ABCB1	5243	S893A/T	Refer to  https://www.pharmgkb.org/rsid/rs2032582  for more information.		7	87160618	87160618	A	C	ENST00000265724.3	75	GRCh37					missense_variant	NC_000007.13:g.87160618A>C	2017-01-29 06:37:51 UTC
453	https://civic.genome.wustl.edu/links/variants/453	EGFR	1956	S492R			7	55228009	55228009	C	A	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.1476C>A,NC_000007.13:g.55228009C>A,NP_005219.2:p.Ser492Arg	2016-03-09 19:52:03 UTC
454	https://civic.genome.wustl.edu/links/variants/454	EGFR	1956	R451C			7	55227884	55227884	C	T	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.1351C>T,NC_000007.13:g.55227884C>T	2016-03-08 23:40:30 UTC
455	https://civic.genome.wustl.edu/links/variants/455	EGFR	1956	K467T			7	55227933	55227933	A	C	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.1400A>C	2016-09-08 04:30:11 UTC
456	https://civic.genome.wustl.edu/links/variants/456	FCGR2A	2212	H167R			1	161479745	161479745	A	G	ENST00000271450.6	75	GRCh37					missense_variant	NM_001136219.1:c.500A>G,NP_001129691.1:p.His167Arg,ENST00000271450.6:c.500A>G	2016-03-26 13:42:53 UTC
457	https://civic.genome.wustl.edu/links/variants/457	FCGR3A	2214	F212V			1	161514542	161514542	A	C	ENST00000367969.3	75	GRCh37					missense_variant		2016-12-17 06:30:27 UTC
458	https://civic.genome.wustl.edu/links/variants/458	FCGR2B	2213	I232T			1	161643798	161643798	T	C	ENST00000358671.5	75	GRCh37					missense_variant		2016-12-17 06:06:31 UTC
460	https://civic.genome.wustl.edu/links/variants/460	EGFR	1956	P753S			7	55242487	55242487	C	T	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2257C>T,NC_000007.13:g.55242487C>T	2016-03-22 15:28:19 UTC
461	https://civic.genome.wustl.edu/links/variants/461	PML	5371	B2 DOMAIN MUTATION	The B2 domain in PML is the binding site for ATRA. Point mutations in this region have been associated with ATRA resistance in patients with APL.	PML-RARa B2 Domain	15	74315213	74315219			ENST00000268058.3	75	GRCh37					missense_variant		2016-02-25 17:25:42 UTC
462	https://civic.genome.wustl.edu/links/variants/462	PML	5371	PML-RARA A216V	A216V in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.	PML-RARa B2 Domain	15	74315213	74315213	C	T	ENST00000268058.3	75	GRCh37					missense_variant		2016-09-02 15:29:16 UTC
463	https://civic.genome.wustl.edu/links/variants/463	PML	5371	PML-RARA L218P	L218P in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.	PML-RARa B2 Domain	15	74315219	74315219	T	C	ENST00000268058.3	75	GRCh37					missense_variant		2016-09-02 15:30:54 UTC
464	https://civic.genome.wustl.edu/links/variants/464	MET	4233	EXON 14 MUTATION + AMPLIFICATION			7	116312459	116436396			ENST00000318493.6	75	GRCh37					transcript_amplification,exon_loss_variant		2016-03-08 19:32:03 UTC
465	https://civic.genome.wustl.edu/links/variants/465	ROS1	6098	CD74-ROS1 G2032R	The G2032R missense mutation has been observed in patients with crizotinib-resistant non-small cell lung cancer harboring CD74-ROS1 rearrangement. Independent in vitro studies have confirmed that this mutation confers marked resistance to crizotinib cells over CD74-ROS1 alone. Multiple groups have indicated CD74-ROS1 G2032R expressing cell lines are sensitive to both cabozantinib and foretinib individually administered in vitro. One group additionally showed this mutation conferred relative resistance to alectinib, brigatinib, ceritinib, and AZD3463 in vitro.		6	117638347	117638347	C	T	ENST00000368508.3	75	GRCh37					transcript_fusion,missense_variant		2016-06-23 20:39:06 UTC
466	https://civic.genome.wustl.edu/links/variants/466	FGFR1	2260	ZNF198-FGFR1															transcript_fusion		2016-02-24 22:22:32 UTC
467	https://civic.genome.wustl.edu/links/variants/467	KDR	3791	A1065T			4	55955969	55955969	C	T	ENST00000263923.4	75	GRCh37					missense_variant		2016-03-11 22:06:26 UTC
468	https://civic.genome.wustl.edu/links/variants/468	KDR	3791	D717V			4	55968180	55968180	T	A	ENST00000263923.4	75	GRCh37					missense_variant		2016-03-10 22:55:28 UTC
469	https://civic.genome.wustl.edu/links/variants/469	TSC2	7249	Q1178*			16	2130300	2130300	C	T	ENST00000219476.3	75	GRCh37					stop_gained	NM_000548.4:c.3532C>T,NP_000539.2:p.Gln1178Ter,ENST00000219476.3:c.3532C>T	2016-02-29 03:53:53 UTC
470	https://civic.genome.wustl.edu/links/variants/470	MTOR	2475	F2108L			1	11187094	11187094	G	T	ENST00000361445.4	75	GRCh37					missense_variant		2016-02-29 04:03:54 UTC
471	https://civic.genome.wustl.edu/links/variants/471	RAD51D	5892	R186*			17	33433425	33433425	G	A	ENST00000345365.6	75	GRCh37					stop_gained		2016-09-04 23:04:11 UTC
472	https://civic.genome.wustl.edu/links/variants/472	ALDH1A2	8854	EXPRESSION			15	58245622	58358616			ENST00000249750.4	75	GRCh37					N/A		2016-03-08 19:25:01 UTC
473	https://civic.genome.wustl.edu/links/variants/473	ALDH1A2	8854	UNDEREXPRESSION			15	58245622	58358616			ENST00000249750.4	75	GRCh37					N/A		2016-03-08 19:27:32 UTC
474	https://civic.genome.wustl.edu/links/variants/474	KIAA1524	57650	EXPRESSION			3	108268716	108308299			ENST00000295746.8	75	GRCh37					N/A		2016-03-08 19:23:24 UTC
475	https://civic.genome.wustl.edu/links/variants/475	KIAA1524	57650	UNDEREXPRESSION			3	108268716	108308299			ENST00000295746.8	75	GRCh37					N/A		2016-03-08 19:26:51 UTC
476	https://civic.genome.wustl.edu/links/variants/476	MIR218-1	407000	EXPRESSION			4	20529898	20530007			ENST00000384999.1	75	GRCh37					N/A		2016-09-04 23:23:09 UTC
477	https://civic.genome.wustl.edu/links/variants/477	BRCA1	672	P968FS			17	41244645	41244646		GA	ENST00000471181.2	75	GRCh37					frameshift_truncation	NM_007294.3:c.2902_2903insTC,NP_009225.1:p.Pro968Leufs	2017-05-18 20:44:13 UTC
479	https://civic.genome.wustl.edu/links/variants/479	KRAS	3845	Q22*			12	25398255	25398255	G	A	ENST00000256078.4	75	GRCh37					stop_gained	NC_000012.11:g.25398255G>A	2016-03-22 15:44:38 UTC
480	https://civic.genome.wustl.edu/links/variants/480	DNMT3A	1788	P904L			2	25457176	25457176	G	A	ENST00000264709.3	75	GRCh37					missense_variant		2016-03-11 22:29:18 UTC
481	https://civic.genome.wustl.edu/links/variants/481	DDX43	55510	OVEREXPRESSION			6	74104471	74127292			ENST00000370336.4	75	GRCh37					N/A		2016-03-01 23:59:10 UTC
482	https://civic.genome.wustl.edu/links/variants/482	KIT	3815	RS3733542			4	55602765	55602765	G	C	ENST00000288135.5	75	GRCh37					synonymous_variant	NM_000222.2:c.2586G>C,NP_000213.1:p.Leu862=,ENST00000288135.5:c.2586G>C,NC_000004.11:g.55602765G>C	2016-05-04 06:49:00 UTC
483	https://civic.genome.wustl.edu/links/variants/483	TBK1	29110	OVEREXPRESSION			12	64845660	64895888			ENST00000331710.5	75	GRCh37					N/A		2016-05-02 23:01:33 UTC
485	https://civic.genome.wustl.edu/links/variants/485	STK11	6794	LOSS			19	1205740	1228428			ENST00000326873.7	75	GRCh37					loss_of_function_variant		2016-05-04 07:26:45 UTC
486	https://civic.genome.wustl.edu/links/variants/486	HAVCR2	84868	OVEREXPRESSION			5	156512843	156536725			ENST00000307851.4	75	GRCh37					N/A		2016-05-02 22:55:51 UTC
487	https://civic.genome.wustl.edu/links/variants/487	MMP2	4313	SERUM LEVELS			16	55512883	55540603			ENST00000219070.4	75	GRCh37					N/A		2016-05-04 07:25:47 UTC
488	https://civic.genome.wustl.edu/links/variants/488	MMP9	4318	SERUM LEVELS			20	44637547	44645200			ENST00000372330.3	75	GRCh37					N/A		2016-05-04 07:24:37 UTC
490	https://civic.genome.wustl.edu/links/variants/490	HSPH1	10808	NUCLEAR EXPRESSION			13	31710765	31736064			ENST00000320027.5	75	GRCh37					N/A		2016-05-04 07:28:51 UTC
491	https://civic.genome.wustl.edu/links/variants/491	HSPH1	10808	T17 DELETION			13	31722621	31722637			ENST00000320027.5	75	GRCh37					short_tandem_repeat_variation		2016-11-07 19:03:41 UTC
492	https://civic.genome.wustl.edu/links/variants/492	ECSCR	641700	EXPRESSION															N/A		2016-03-10 08:51:52 UTC
493	https://civic.genome.wustl.edu/links/variants/493	ROBO4	54538	EXPRESSION			11	124753587	124768177			ENST00000306534.3	75	GRCh37					N/A		2016-05-02 23:02:32 UTC
494	https://civic.genome.wustl.edu/links/variants/494	PIM1	5292	NUCLEAR EXPRESSION			6	37137979	37143202			ENST00000373509.5	75	GRCh37					N/A		2016-05-04 07:27:38 UTC
495	https://civic.genome.wustl.edu/links/variants/495	MDM2	4193	SNP309			12	69202580	69202580	T	G	ENST00000462284.1	75	GRCh37					coding_transcript_intron_variant		2016-06-28 06:53:43 UTC
496	https://civic.genome.wustl.edu/links/variants/496	ERBB2	2064	L866M	This mutation was shown to be an activating mutation and conferred sensitivity to a combination of trastuzumab with neratinib or lapatinib in colorectal cancer patient-derived xenografts.		17	37881404	37881404	C	A	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2596C>A	2016-03-22 16:06:17 UTC
497	https://civic.genome.wustl.edu/links/variants/497	ERBB2	2064	S310F/Y	ERBB2 S310F/Y was one of the first ERBB2 variants to be functionally classified (Greulich et al. 2012). This mutation was shown to be an activating mutation (through hyperphosphorylation) in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in murine Ba/F3 cells have been shown to be sensitive to the ERBB2 inhibitors (afatinib, lapatinib and neratinib). More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.		17	37868208	37868208	C	T	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.929C>T	2016-10-12 03:39:38 UTC
498	https://civic.genome.wustl.edu/links/variants/498	MIR218-1	407000	UNDEREXPRESSION			4	20529898	20530007			ENST00000384999.1	75	GRCh37					N/A		2016-05-02 22:19:39 UTC
499	https://civic.genome.wustl.edu/links/variants/499	ALK	238	ALK FUSIONS	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	ALK Fusions	2	29415640	29446394			ENST00000389048.3	75	GRCh37					transcript_fusion		2016-07-14 03:32:25 UTC
500	https://civic.genome.wustl.edu/links/variants/500	ALK	238	EML4-ALK E20;A20	EML4-ALK variant 2 consists of a fusion of the ALK kinase domain (exons 20-29) with EML4 exons 1-20. Variant 2 has cytoplasmic distribution and makes up ~10% of EML4-ALK fusions found in NSCLC,. Although the specific variant is not consistently reported, single cases demonstrating response to crizotinib treatment in NSCLC and a differentiated malignant neoplasm of unknown origin have been reported. In vitro, this variant has shown greater sensitivity to ALK inhibition with TAE684 and crizotinib than the EML4-ALK variants 1 (E13;A20), 3a (E6;A20) and 3b (E6ins33;A20). The variant was reported to be less stable in cells than other variants, and may be a client protein of Hsp90. Along these lines the variant has shown preclinical sensitivity to Hsp90 inhibition.	ALK Fusions	2	42396490	42552694			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion		2016-06-28 06:23:20 UTC
501	https://civic.genome.wustl.edu/links/variants/501	ALK	238	EML4-ALK E2;A20		ALK Fusions	2	42396490	42472827			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion		2016-06-28 21:21:37 UTC
502	https://civic.genome.wustl.edu/links/variants/502	KDR	3791	R961W			4	55961059	55961059	G	A	ENST00000263923.4	75	GRCh37					missense_variant		2016-05-03 15:00:57 UTC
503	https://civic.genome.wustl.edu/links/variants/503	ALK	238	EML4-ALK E6;A20	The EML4-ALK variant 3a consists of the ALK kinase domain fused to EML4 exons 1-6, while the 3b variant has an additional 33bp of intronic EML4 sequence between EML4 and ALK regions. The two variants were found to originate from a single genomic rearrangement, and 3a/3b is found in ~ 30% of EML4-ALK positive NSCLC. Variant 3a has cytoplasmic and nuclear distribution. In vitro, these variants have shown sensitivity to ALK inhibitors TAE684 and crizotinib but less sensitive than other EML4-ALK variants. The H2228 cell line contains 3a and 3b variants and is described as having cyctostatic response to ALK inhibition as opposed to apoptotic. In a study of 31 NSCLC patients with EML4-ALK rearrangements, 4/5 patients with the 3a variant showed a partial response while 1 showed progressive disease (the only PD observed). In cells the 3a variant was reported to be more stable than other variants, less sensitive to crizotinib and not to respond to Hsp90 inhibition.	ALK Fusions	2	42396490	42491871			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion		2016-09-02 19:53:02 UTC
504	https://civic.genome.wustl.edu/links/variants/504	TP53	7157	P47S			17	7579548	7579548	G	A	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.139C>T,NP_000537.3:p.Pro47Ser	2016-05-04 07:22:37 UTC
505	https://civic.genome.wustl.edu/links/variants/505	GNAQ	2776	MUTATION			9	80331003	80646374			ENST00000286548.4	75	GRCh37							2016-05-04 06:54:51 UTC
506	https://civic.genome.wustl.edu/links/variants/506	GNA11	2767	MUTATION			19	3094408	3124002			ENST00000078429.4	75	GRCh37							2016-05-04 06:53:39 UTC
507	https://civic.genome.wustl.edu/links/variants/507	GNAQ	2776	Q209			9	80409487	80409489			ENST00000286548.4	75	GRCh37					protein_altering_variant		2016-05-04 07:11:01 UTC
508	https://civic.genome.wustl.edu/links/variants/508	PMS2	5395	K706FS*19			7	6022512	6022512			ENST00000265849.7	75	GRCh37					minus_1_frameshift_variant	NM_000535.6:c.2117delA,NP_000526.2:p.Lys706Serfs,NC_000007.13:g.6022512del	2017-05-18 20:44:13 UTC
509	https://civic.genome.wustl.edu/links/variants/509	KIT	3815	EXON 9 MUTATION	In patients with gastrointestinal stromal tumors (GIST), imatinib has improved outcomes for patients with KIT mutations. However, acquired resistance to imatinib is common. Patients harboring exon 9 KIT mutations may benefit from higher imatinib doses (800mg/daily). Similarly, imatinib-refractory tumors showed sensitivity to sunitinib treatment. Improved responses to either treatment were not observed in patients with exon 11 mutations.		4	55592023	55592216			ENST00000288135.5	75	GRCh37					exon_variant		2016-06-28 00:13:22 UTC
510	https://civic.genome.wustl.edu/links/variants/510	PTEN	5728	MUTATION			10	89622870	89731687			ENST00000371953.3	75	GRCh37					protein_altering_variant		2016-05-03 14:55:13 UTC
511	https://civic.genome.wustl.edu/links/variants/511	FGFR2	2263	MUTATION			10	123239371	123357917			ENST00000457416.2	75	GRCh37					gain_of_function_variant,transcript_variant		2016-09-26 02:15:19 UTC
512	https://civic.genome.wustl.edu/links/variants/512	ALK	238	MUTATION			2	29415640	30144432			ENST00000389048.3	75	GRCh37					gain_of_function_variant,gene_variant		2016-10-12 05:13:59 UTC
513	https://civic.genome.wustl.edu/links/variants/513	ALK	238	NPM-ALK		ALK Fusions	5	170814120	170818803			ENST00000517671.1	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion		2016-07-10 08:57:55 UTC
514	https://civic.genome.wustl.edu/links/variants/514	ALK	238	RANBP2-ALK		ALK Fusions	2	109335937	109375004			ENST00000283195.6	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion		2016-07-13 18:21:27 UTC
515	https://civic.genome.wustl.edu/links/variants/515	FGFR1	2260	N546K			8	38274849	38274849	G	T	ENST00000341462.5	75	GRCh37					missense_variant	NM_023110.2:c.1638C>A,NP_075598.2:p.Asn546Lys,ENST00000341462.5:c.1638C>A	2016-05-04 07:32:57 UTC
516	https://civic.genome.wustl.edu/links/variants/516	ROS1	6098	CD74-ROS1 L2026M	The L2026M mutation is considered a gatekeeper mutation located in the inhibitor binding pocket of ROS1 and corresponding to L1196M in ALK and T790M in EGFR. This mutation has not been reportedly observed in a patient but inferred as a variant likely to emerge in crizotinib-resistant tumors. In vitro kinase activity, structural predictions and growth inhibition assays indicate the L2026M mutation in the CD74-ROS1 fusion provides crizotinib resistance. Additional preclinical assays have indicated that crizotinib resistant cells harboring this mutation are sensitive to PF-06463922 and foretinib.		6	117638365	117638365	G	T	ENST00000368508.3	75	GRCh37					transcript_fusion,missense_variant		2016-06-23 18:54:23 UTC
517	https://civic.genome.wustl.edu/links/variants/517	ROS1	6098	CD74-ROS1 L2155S			6	117630062	117630062	A	G	ENST00000368508.3	75	GRCh37					transcript_fusion,missense_variant		2016-05-02 22:54:30 UTC
518	https://civic.genome.wustl.edu/links/variants/518	ROS1	6098	CD74-ROS1 G2101A			6	117631376	117631376	C	G	ENST00000368508.3	75	GRCh37					transcript_fusion,missense_variant		2016-04-24 21:04:24 UTC
519	https://civic.genome.wustl.edu/links/variants/519	FLT3	2322	MUTATION			13	28577411	28674729			ENST00000241453.7	75	GRCh37					gain_of_function_variant,transcript_variant		2017-05-18 20:44:13 UTC
520	https://civic.genome.wustl.edu/links/variants/520	ALK	238	CLTC-ALK	The t(2;17)(p23;q23) translocation results in the CLTC-ALK fusion protein, the most common ALK fusion observed in diffuse large B cell lymphoma (DLBCL). ALK-rearranged DLBCL is less responsive to CHOP chemotherapy. Preclinical work indicates that CLTC-ALK DLBCL is responsive to ALK inhibition in cell lines and mouse models, and two case studies show short response followed by progression when heavily pretreated and advanced ALK-positive DLBCL is treated with crizotinib (one case CLTC-ALK, one case an unknown ALK fusion).	ALK Fusions	17	57697219	57768072			ENST00000269122.3	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion		2016-09-02 19:55:06 UTC
521	https://civic.genome.wustl.edu/links/variants/521	U2AF1	7307	MUTATION			21	44513066	44527697			ENST00000291552.4	75	GRCh37					protein_altering_variant		2016-09-11 01:14:09 UTC
522	https://civic.genome.wustl.edu/links/variants/522	BRAF	673	DEL 485-490			7	140477838	140477855			ENST00000288602.6	75	GRCh37					inframe_deletion	ENST00000288602.6:c.1453_1470del	2016-10-18 18:29:53 UTC
524	https://civic.genome.wustl.edu/links/variants/524	DUX4	100288687	DUX4 FUSIONS															transcript_fusion		2016-04-19 08:06:54 UTC
525	https://civic.genome.wustl.edu/links/variants/525	B4GALT1	2683	EXPRESSION			9	33110635	33167354			ENST00000379731.4	75	GRCh37					N/A		2016-05-04 06:56:12 UTC
526	https://civic.genome.wustl.edu/links/variants/526	BCL2L11	10018	DELETION POLYMORPHISM			2	111883195	111886097			ENST00000393256.3	75	GRCh37					polymorphic_sequence_variant		2016-10-20 06:38:38 UTC
527	https://civic.genome.wustl.edu/links/variants/527	ALK	238	ALK FUSION I1171	Multiple case reports indicate that the I1171T missense mutation in ALK-rearranged non-small cell lung cancer (NSCLC) confers resistance to crizotinib and alectinib but is sensitive to ceritinib treatment. These results have been validated in vitro. In vitro evidence indicates this mutation interferes with alectinib binding the active site of ALK and may explain the sensitivity to the structurally distinct ALK inhibitor ceritinib.		2	29445213	29445213	A	G	ENST00000389048.3	75	GRCh37					transcript_fusion,missense_variant	ENST00000389048.3:c.3512T>C,NC_000002.11:g.29445213A>G	2016-09-02 19:58:12 UTC
528	https://civic.genome.wustl.edu/links/variants/528	ALK	238	EML4-ALK  V1180L	The V1180L missense mutation was identified in a mutagenesis screen to find mutations that conferred resistance to alectinib in a non-small cell lung cancer cell line. This mutation shows resistance to crizotinib and alectinib but sensitivity to TAE684, ceritinib and more mild sensitivity to brigatinib. Similar to I1171T, it resides in the ATP pocket of ALK and likely interferes with alectinib and crizotinib binding as a mechanism of resistance.		2	29443679	29443679	C	G	ENST00000389048.3	75	GRCh37					transcript_fusion,missense_variant	ENST00000389048.3:c.3538G>C,NC_000002.11:G.29443679C>G	2016-08-07 00:36:21 UTC
529	https://civic.genome.wustl.edu/links/variants/529	SIRT1	23411	OVEREXPRESSION			10	69644427	69678147			ENST00000212015.6	75	GRCh37					N/A		2016-05-04 06:57:27 UTC
530	https://civic.genome.wustl.edu/links/variants/530	KRAS	3845	G12R			12	25398285	25398285	C	G	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.34G>C,NP_004976.2:p.Gly12Arg,NC_000012.11:g.25398285C>G,ENST00000256078.4:c.34G>C	2016-05-04 07:02:37 UTC
531	https://civic.genome.wustl.edu/links/variants/531	TP53	7157	P72R	This polymorphism is relatively widely studied across cancer types, but meta-analyses in breast, lung and cervical cancer cohorts have so far been inconclusive as to the significance of a patient's genotype at this locus as it relates to cancer susceptibility and prognosis.		17	7579472	7579472	G	C	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.215C>G,NP_000537.3:p.Pro72Arg	2016-06-08 22:21:43 UTC
532	https://civic.genome.wustl.edu/links/variants/532	PALB2	79728	BIALLELIC INACTIVATION			16	23614491	23652631			ENST00000261584.4	75	GRCh37					loss_of_function_variant		2016-09-13 21:28:19 UTC
533	https://civic.genome.wustl.edu/links/variants/533	SMAD4	4089	EXPRESSION			18	48556583	48611409			ENST00000342988.3	75	GRCh37					N/A		2016-05-08 03:45:01 UTC
534	https://civic.genome.wustl.edu/links/variants/534	FANCC	2176	LOSS-OF-FUNCTION			9	97861336	98079984			ENST00000289081.3	75	GRCh37					loss_of_function_variant		2016-06-28 03:34:05 UTC
535	https://civic.genome.wustl.edu/links/variants/535	PDGFRB	5159	EBF1-PDGFRB	EBF1-PDGFRB fusions are associated with Ph-like acute lymphoblastic leukemia lacking the BCR-ABL fusion. Case reports have shown positive responses to imatinib treatment.														transcript_fusion		2016-09-04 03:36:07 UTC
536	https://civic.genome.wustl.edu/links/variants/536	SULT1E1	6783	SNP																	2016-05-09 07:32:24 UTC
537	https://civic.genome.wustl.edu/links/variants/537	RB1	5925	EXPRESSION			13	48877911	49056122			ENST00000267163.4	75	GRCh37					N/A		2016-06-28 04:31:56 UTC
538	https://civic.genome.wustl.edu/links/variants/538	MLH1	4292	METHYLATION															N/A		2016-05-10 16:15:13 UTC
539	https://civic.genome.wustl.edu/links/variants/539	PTPN11	5781	EXPRESSION			12	112856718	112947717			ENST00000351677.2	75	GRCh37					N/A		2016-09-10 03:04:52 UTC
540	https://civic.genome.wustl.edu/links/variants/540	FLT3	2322	T227M	FLT3 T227M (rs1933437) is a common polymorphism with a GMAF around .60 based on the Exome Aggregation Consortium (ExAC) data. Its role in cancer predisposition is still unknown, however it may be associated with the development of leukopenia in patients treated with sunitinib.		13	28624294	28624294	G	A	ENST00000241453.7	75	GRCh37					missense_variant,SNP	NM_004119.2:c.680C>T,NP_004110.2:p.Thr227Met	2016-06-28 04:49:54 UTC
541	https://civic.genome.wustl.edu/links/variants/541	PALB2	79728	L531FS*30			16	23646276	23646276			ENST00000261584.4	75	GRCh37					minus_1_frameshift_variant,SNP		2017-05-18 20:44:13 UTC
542	https://civic.genome.wustl.edu/links/variants/542	MTOR	2475	S2215Y			1	11184573	11184573	G	T	ENST00000361445.4	75	GRCh37					missense_variant		2016-06-28 04:57:53 UTC
543	https://civic.genome.wustl.edu/links/variants/543	MTOR	2475	C1483Y			1	11217230	11217230	C	T	ENST00000361445.4	75	GRCh37					missense_variant		2016-06-28 04:44:19 UTC
544	https://civic.genome.wustl.edu/links/variants/544	MTOR	2475	E1799K			1	11190804	11190804	C	T	ENST00000361445.4	75	GRCh37					missense_variant	NM_004958.3:c.5395G>A,NP_004949.1:p.Glu1799Lys	2016-06-23 21:39:40 UTC
545	https://civic.genome.wustl.edu/links/variants/545	FGFR2	2263	N550K			10	123258034	123258034	A	T	ENST00000457416.2	75	GRCh37					gain_of_function_variant,missense_variant	NC_000010.10:g.123258034A>T	2016-09-13 20:43:05 UTC
546	https://civic.genome.wustl.edu/links/variants/546	ACTA1	58	EXPRESSION			1	229566992	229569841			ENST00000366684.3	75	GRCh37					N/A		2017-05-18 20:44:13 UTC
547	https://civic.genome.wustl.edu/links/variants/547	RB1	5925	OVEREXPRESSION			13	48877911	49056122			ENST00000267163.4	75	GRCh37					N/A		2016-06-28 05:12:08 UTC
548	https://civic.genome.wustl.edu/links/variants/548	PPP1R15A	23645	RS557806			19	49377242	49377242	G	C	ENST00000200453.5	75	GRCh37					missense_variant,polymorphic_sequence_variant	NM_014330.3:c.752G>C,NP_055145.3:p.Arg251Pro,ENST00000200453.5:c.752G>C,NC_000019.9:g.49377242G>C	2016-10-12 05:05:24 UTC
549	https://civic.genome.wustl.edu/links/variants/549	ALK	238	F1245C			2	29436859	29436859	A	C	ENST00000389048.3	75	GRCh37					missense_variant	NM_004304.4:c.3734T>G,NP_004295.2:p.Phe1245Cys,NC_000002.11:g.29436859A>C	2016-06-28 03:32:11 UTC
550	https://civic.genome.wustl.edu/links/variants/550	ALK	238	DEL4-11			2	29497965	29754982			ENST00000389048.3	75	GRCh37					inframe_deletion		2016-09-02 23:07:04 UTC
551	https://civic.genome.wustl.edu/links/variants/551	ALK	238	ALK FUSION F1245C	In neuroblastoma, F1245 is one of three hotspot ALK mutations found at a high frequency. In a case study, a pretreated non-small cell lung cancer (NSCLC) patient with EML4-ALK F1245C mutation responded well to ceritinib after slow disease progression during crizotinib treatment. Crizotinib resistance was attributed to the F1245C mutation, although the ALK-rearrangement was not sequenced prior to crizotinib treatment. The patient's slow onset of disease progression during crizotinib treatment mirrors preclinical findings that indicate ALK-fusion with F1245C has moderate resistance to crizotinib compared to the fusion alone.		2	29436859	29436859	A	C	ENST00000389048.3	75	GRCh37					transcript_fusion,missense_variant	NM_004304.4:c.3734T>G,NP_004295.2:p.Phe1245Cys,NC_000002.11:g.29436859A>C	2016-06-28 06:17:00 UTC
552	https://civic.genome.wustl.edu/links/variants/552	ALK	238	ALK FUSION G1269A			2	29432682	29432682	C	G	ENST00000389048.3	75	GRCh37					transcript_fusion,missense_variant	ENST00000389048.3:c.3806G>C,NC_000002.11:g.29432682C>G	2016-10-05 23:21:29 UTC
553	https://civic.genome.wustl.edu/links/variants/553	CDK4	1019	AMPLIFICATION			12	58141510	58146304			ENST00000257904.6	75	GRCh37					transcript_amplification		2016-09-10 23:58:01 UTC
554	https://civic.genome.wustl.edu/links/variants/554	CDKN2A	1029	LOSS			9	21967752	21994623			ENST00000579755.1	75	GRCh37					loss_of_function_variant		2016-10-18 04:34:06 UTC
555	https://civic.genome.wustl.edu/links/variants/555	CDKN2B	1030	LOSS			9	22002902	22009362			ENST00000276925.6	75	GRCh37					transcript_ablation		2016-09-10 02:45:00 UTC
556	https://civic.genome.wustl.edu/links/variants/556	CDK4	1019	R24C			12	58145431	58145431	G	A	ENST00000257904.6	75	GRCh37					missense_variant	NM_000075.3:c.70C>T,NP_000066.1:p.Arg24Cys,ENST00000257904.6:c.70C>T	2016-09-10 23:56:50 UTC
557	https://civic.genome.wustl.edu/links/variants/557	ASXL1	171023	EXON 12 MUTATION			20	31021087	31021720			ENST00000375687.4	75	GRCh37					exon_variant		2016-09-11 00:53:00 UTC
558	https://civic.genome.wustl.edu/links/variants/558	GNA11	2767	Q209			19	3118942	3118942			ENST00000078429.4	75	GRCh37					missense_variant		2017-05-18 20:44:13 UTC
559	https://civic.genome.wustl.edu/links/variants/559	CALR	811	EXON 9 FRAMESHIFT	Exon 9 insertions and deletions have become part of the WHO diagnostic criteria for essential thrombocythemia (ET) and primary myelofibrosis (PMF) (Arber et al, 2016). These mutations are typically heterozygous and in the absence of JAK2 and MPL mutations. Approximately 80% of observed mutations are type 1 (p.L367fs*46), the result of a 52bp deletion, or type 2 (p.K385fs*47), the result of a 5-bp TTGTC insertion, and studies have suggested phenotypic and prognostic differences between them. In PMF patients, CALR exon 9 mutations have been associated with improved median survival.		19	13054527	13054727			ENST00000316448.5	75	GRCh37					exon_variant		2016-09-23 22:45:59 UTC
560	https://civic.genome.wustl.edu/links/variants/560	CSF3R	1441	MUTATION			1	36932096	36933444			ENST00000373106.1	75	GRCh37					protein_altering_variant		2016-09-13 21:48:21 UTC
562	https://civic.genome.wustl.edu/links/variants/562	EGFR	1956	S768I			7	55249005	55249005	G	T	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2303G>T,NC_000007.13:g.55249005G>T,NM_005228.4:c.2303G>T,NP_005219.2:p.Ser768Ile	2016-09-10 23:50:06 UTC
563	https://civic.genome.wustl.edu/links/variants/563	BRAF	673	V600K		Other V600's	7	140453136	140453137	AC	TT	ENST00000288602.6	75	GRCh37					missense_variant	ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys	2016-09-11 00:47:39 UTC
564	https://civic.genome.wustl.edu/links/variants/564	SMAD4	4089	LOSS			18	48556583	48611409			ENST00000342988.3	75	GRCh37					loss_of_function_variant		2016-09-10 02:43:47 UTC
565	https://civic.genome.wustl.edu/links/variants/565	SF3B1	23451	K700E		HEAT domain mutation	2	198266834	198266834	T	C	ENST00000335508.6	75	GRCh37					missense_variant		2016-09-11 00:58:16 UTC
566	https://civic.genome.wustl.edu/links/variants/566	MAP2K7	5609	E116K			19	7975157	7975157	G	A	ENST00000397979.3	75	GRCh37					missense_variant		2016-09-10 03:19:44 UTC
567	https://civic.genome.wustl.edu/links/variants/567	PDGFRA	5156	PDGFRA FUSIONS															transcript_fusion		2016-06-28 21:47:55 UTC
568	https://civic.genome.wustl.edu/links/variants/568	PDGFRB	5159	PDGFRB FUSIONS															transcript_fusion		2016-06-28 21:49:42 UTC
569	https://civic.genome.wustl.edu/links/variants/569	FGFR1	2260	FGFR1 FUSIONS															transcript_fusion		2016-06-28 21:56:54 UTC
570	https://civic.genome.wustl.edu/links/variants/570	IDH2	3418	MUTATION			15	90626277	90645736			ENST00000330062.3	75	GRCh37					protein_altering_variant		2017-05-18 20:44:13 UTC
571	https://civic.genome.wustl.edu/links/variants/571	JAK2	3717	PCM1-JAK2										GRCh37					transcript_fusion		2016-11-25 18:12:44 UTC
572	https://civic.genome.wustl.edu/links/variants/572	MTOR	2475	E2014K + E2419K			1	11174420	11187857			ENST00000361445.4	75	GRCh37					missense_variant		2016-09-03 00:19:07 UTC
573	https://civic.genome.wustl.edu/links/variants/573	RICTOR	253260	AMPLIFICATION			5	38938021	39074510			ENST00000357387.3	75	GRCh37					transcript_amplification		2016-09-08 04:11:26 UTC
574	https://civic.genome.wustl.edu/links/variants/574	PDGFRA	5156	FIP1L1-PDGFRA	Prospective trials of patients with hypereosinophilic syndrome harboring the FIP1L1-PDGFRA fusion identified marked response to imatinib treatment (Gotlib and Cool, Leukemia 2008). Imatinib is FDA approved for the treatment of &quot;adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR fusion kinase&quot; (NDA021588).		4	54243812	54294350			ENST00000337488.6	75	GRCh37	4	55141008	55164414	ENST00000257290.5	transcript_fusion		2016-11-07 23:28:23 UTC
576	https://civic.genome.wustl.edu/links/variants/576	ROS1	6098	TFG-ROS1			3	100428269	100447702			ENST00000240851.4	75	GRCh37	6	117609463	117642557	ENST00000368508.3	transcript_fusion		2016-09-13 21:16:19 UTC
577	https://civic.genome.wustl.edu/links/variants/577	PDGFRA	5156	FIP1L1-PDGFRA T674I	A case study of relapsed myeloproliferative hypereosinophilic syndrome suggests that a T674I mutation in the PDGFRA split kinase domain of FIP1L1-PDGFRA fusions may confer resistance to imatinib.		4	55144547	55144547	C	T	ENST00000257290.5	75	GRCh37					transcript_fusion,missense_variant	NC_000004.11:g.55144547C>T,ENST00000257290.5:c.2021C>T	2016-10-05 23:01:26 UTC
578	https://civic.genome.wustl.edu/links/variants/578	BIRC5	332	OVEREXPRESSION			17	76210267	76221717			ENST00000301633.4	75	GRCh37					N/A		2016-09-11 00:18:07 UTC
579	https://civic.genome.wustl.edu/links/variants/579	BRAF	673	D594A		Kinase Dead BRAF Mutation	7	140453154	140453154	T	G	ENST00000288602.6	75	GRCh37					missense_variant	ENST00000288602.6:c.1781A>C,NC_000007.13:g.140453154T>G,NM_004333.4:c.1781A>C,NP_004324.2:p.Asp594Ala	2016-09-11 00:33:23 UTC
580	https://civic.genome.wustl.edu/links/variants/580	BRAF	673	D594V		Kinase Dead BRAF Mutation	7	140453154	140453154	T	A	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1781A>T,NP_004324.2:p.Asp594Val,NC_000007.13:g.140453154T>A,ENST00000288602.6:c.1781A>T	2016-09-11 00:36:07 UTC
581	https://civic.genome.wustl.edu/links/variants/581	BRAF	673	K483M	The K483M variant is a kinase dead loss-of-function variant in the catalytic site of BRAF. This engineered variant is often used as a control when evaluating other BRAF variants.	Kinase Dead BRAF Mutation	7	140477859	140477860	TT	CA	ENST00000288602.6	75	GRCh37					loss_of_function_variant,missense_variant	NC_000007.13:g.140477859_140477860delinsCA,ENST00000288602.6:c.1448_1449delinsGT	2016-11-07 21:17:14 UTC
582	https://civic.genome.wustl.edu/links/variants/582	BRAF	673	L597S			7	140453145	140453146	AG	GA	ENST00000288602.6	75	GRCh37					missense_variant	NC_000007.13:g.140453145_140453146delinsGA	2016-09-03 00:16:47 UTC
583	https://civic.genome.wustl.edu/links/variants/583	BRAF	673	L597Q			7	140453145	140453145	A	T	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1790T>A,NP_004324.2:p.Leu597Gln,NC_000007.13:g.140453145A>T	2016-09-11 00:44:06 UTC
584	https://civic.genome.wustl.edu/links/variants/584	BRAF	673	K601E			7	140453134	140453134	T	C	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1801A>G,NP_004324.2:p.Lys601Glu	2016-09-11 01:00:31 UTC
585	https://civic.genome.wustl.edu/links/variants/585	BRAF	673	L597V			7	140453146	140453146	G	C	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1789C>G,NP_004324.2:p.Leu597Val,NC_000007.13:g.140453146G>C	2016-09-11 00:39:33 UTC
586	https://civic.genome.wustl.edu/links/variants/586	KIT	3815	AMPLIFICATION			4	55524085	55606881			ENST00000288135.5	75	GRCh37					transcript_amplification		2016-09-11 00:17:15 UTC
587	https://civic.genome.wustl.edu/links/variants/587	NF1	4763	MUTATION			17	29421945	29704695			ENST00000358273.4	75	GRCh37					loss_of_function_variant,protein_altering_variant		2016-09-23 20:26:00 UTC
588	https://civic.genome.wustl.edu/links/variants/588	ALK	238	HIP1-ALK I1171N			2	29445213	29445213	A	T	ENST00000389048.3	75	GRCh37					transcript_fusion,missense_variant	ENST00000389048.3:c.3512T>A,NC_000002.11:g.29445213A>T,NM_004304.4:c.3512T>A,NP_004295.2:p.Ile1171Asn	2016-10-18 02:14:54 UTC
589	https://civic.genome.wustl.edu/links/variants/589	ALK	238	EML4-ALK I1171S			2	29445213	29445213	A	C	ENST00000389048.3	75	GRCh37					transcript_fusion,missense_variant	ENST00000389048.3:c.3512T>G,NC_000002.11:g.29445213A>C	2016-10-12 05:32:27 UTC
590	https://civic.genome.wustl.edu/links/variants/590	BIRC3	330	TRUNCATING MUTATION			11	102201730	102207833			ENST00000263464.3	75	GRCh37					frameshift_variant		2016-11-03 06:51:51 UTC
591	https://civic.genome.wustl.edu/links/variants/591	RAF1	5894	AMPLIFICATION			3	12625100	12705725			ENST00000251849.4	75	GRCh37					transcript_amplification		2016-09-08 04:14:54 UTC
592	https://civic.genome.wustl.edu/links/variants/592	KRAS	3845	AMPLIFICATION			12	25362365	25403737			ENST00000256078.4	75	GRCh37					transcript_amplification		2016-09-08 04:18:45 UTC
594	https://civic.genome.wustl.edu/links/variants/594	CEBPA	1050	BIALLELIC INACTIVATION			19	33790840	33793470			ENST00000498907.2	75	GRCh37					loss_of_function_variant		2016-09-13 21:31:31 UTC
595	https://civic.genome.wustl.edu/links/variants/595	SRSF2	6427	MUTATION			17	74732402	74733113			ENST00000392485.2	75	GRCh37							2016-11-11 23:20:17 UTC
596	https://civic.genome.wustl.edu/links/variants/596	NRAS	4893	G12/G13			1	115258744	115258748			ENST00000369535.4	75	GRCh37					protein_altering_variant		2016-10-12 05:19:18 UTC
597	https://civic.genome.wustl.edu/links/variants/597	RET	5979	OVEREXPRESSION			10	43572475	43625799			ENST00000355710.3	75	GRCh37					N/A		2016-09-08 04:13:18 UTC
599	https://civic.genome.wustl.edu/links/variants/599	CTLA4	1493	CTLA4-CD28	A survey of 115 T-cell lymphoma samples of diverse subtypes identified this fusion in 26 of 45 cases of angioimmunoblastic T-cell lymphomas (58%), nine of 39 peripheral T-cell lymphomas, not otherwise specified (23%), and nine of 31 extranodal NK/T cell lymphomas (29%).		2	204732509	204736210			ENST00000302823.3	75	GRCh37	2	204599507	204603635	ENST00000324106.8	transcript_fusion		2016-10-05 14:51:34 UTC
600	https://civic.genome.wustl.edu/links/variants/600	AR	367	MUTATION			X	66764465	66950461			ENST00000374690.3	75	GRCh37					transcript_variant		2016-09-11 01:02:19 UTC
601	https://civic.genome.wustl.edu/links/variants/601	NOTCH1	4851	LOSS-OF-FUNCTION			9	139388896	139440314			ENST00000277541.6	75	GRCh37					loss_of_function_variant		2016-10-13 05:18:37 UTC
602	https://civic.genome.wustl.edu/links/variants/602	CDK6	1021	OVEREXPRESSION			7	92234235	92463231			ENST00000265734.4	75	GRCh37					N/A		2016-09-08 04:26:28 UTC
603	https://civic.genome.wustl.edu/links/variants/603	FLT3	2322	OVEREXPRESSION			13	28577411	28674729			ENST00000241453.7	75	GRCh37					N/A		2016-09-08 04:27:53 UTC
604	https://civic.genome.wustl.edu/links/variants/604	GNAQ	2776	Q209P			9	80409488	80409488	T	G	ENST00000286548.4	75	GRCh37					missense_variant		2016-09-11 00:26:53 UTC
605	https://civic.genome.wustl.edu/links/variants/605	PTEN	5728	V317FS			10	89720799	89720802		-	ENST00000371953.3	75	GRCh37					frameshift_variant	ENST00000371953.3:c.950_953delTACT	2017-05-18 20:44:13 UTC
606	https://civic.genome.wustl.edu/links/variants/606	RB1	5925	LOSS-OF-FUNCTION			13	48877911	49056122			ENST00000267163.4	75	GRCh37					loss_of_function_variant		2016-09-10 02:33:10 UTC
607	https://civic.genome.wustl.edu/links/variants/607	ESR1	2099	OVEREXPRESSION			6	152128686	152424406			ENST00000206249.3	75	GRCh37					N/A		2016-10-24 04:54:36 UTC
608	https://civic.genome.wustl.edu/links/variants/608	ALK	238	EML4-ALK C1156YL1196M			2	29443631	29445258			ENST00000389048.3	75	GRCh37					transcript_fusion,missense_variant		2017-05-18 20:44:13 UTC
609	https://civic.genome.wustl.edu/links/variants/609	MTOR	2475	M2327I			1	11177096	11177096	C	A	ENST00000361445.4	75	GRCh37					missense_variant		2016-11-03 05:20:29 UTC
610	https://civic.genome.wustl.edu/links/variants/610	MTOR	2475	A2034V			1	11187796	11187796	G	A	ENST00000361445.4	75	GRCh37					missense_variant		2016-09-13 21:40:49 UTC
611	https://civic.genome.wustl.edu/links/variants/611	BRAF	673	D594G			7	140453154	140453154	T	C	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1781A>G,NP_004324.2:p.Asp594Gly,NC_000007.13:g.140453154T>C	2016-09-03 00:12:36 UTC
612	https://civic.genome.wustl.edu/links/variants/612	FLT3	2322	D835H			13	28592642	28592642	C	G	ENST00000241453.7	75	GRCh37					missense_variant	NM_004119.2:c.2503G>C,NP_004110.2:p.Asp835His	2016-09-10 23:47:34 UTC
613	https://civic.genome.wustl.edu/links/variants/613	FLT3	2322	D835H/Y			13	28592642	28592642	C	G/A	ENST00000241453.7	75	GRCh37					missense_variant		2016-09-13 21:51:58 UTC
614	https://civic.genome.wustl.edu/links/variants/614	JAK1	3716	Q503*			1	65321333	65321333	G	A	ENST00000342505.4	75	GRCh37					stop_gained	NC_000001.10:g.65321333G>A	2016-09-13 21:36:48 UTC
615	https://civic.genome.wustl.edu/links/variants/615	JAK2	3717	Exon 12 splice site insertion			9	5070053	5070054		G	ENST00000381652.3	75	GRCh37							2017-05-18 20:44:13 UTC
616	https://civic.genome.wustl.edu/links/variants/616	B2M	567	S14FS			15	45003786	45003789	TCTT		ENST00000558401.1	75	GRCh37					frameshift_truncation		2016-11-25 18:08:58 UTC
617	https://civic.genome.wustl.edu/links/variants/617	BRAF	673	PPFIBP2-BRAF		BRAF Fusions	11	7535001	7586998			ENST00000299492.4	75	GRCh37	7	140434279	140481493	ENST00000288602.6	transcript_fusion		2016-10-19 04:16:20 UTC
618	https://civic.genome.wustl.edu/links/variants/618	BRAF	673	KIAA1549-BRAF		BRAF Fusions	7	138545885	138666064			ENST00000440172.1	75	GRCh37	7	140434279	140487384	ENST00000288602.6	transcript_fusion		2016-11-08 00:20:59 UTC
619	https://civic.genome.wustl.edu/links/variants/619	PTGS2	5743	OVEREXPRESSION			1	186640923	186649559			ENST00000367468.5	75	GRCh37					N/A		2017-05-18 20:44:13 UTC
621	https://civic.genome.wustl.edu/links/variants/621	MET	4233	OVEREXPRESSION			7	116312459	116436396			ENST00000318493.6	75	GRCh37					N/A		2016-09-08 04:16:34 UTC
623	https://civic.genome.wustl.edu/links/variants/623	POT1	25913	MUTATION			7	124462440	124570035			ENST00000357628.3	75	GRCh37					loss_of_function_variant,protein_altering_variant		2016-10-25 01:43:34 UTC
624	https://civic.genome.wustl.edu/links/variants/624	MKI67	4288	EXPRESSION			10	129894923	129924649			ENST00000368654.3	75	GRCh37					N/A		2016-09-10 03:04:07 UTC
625	https://civic.genome.wustl.edu/links/variants/625	RAD23B	5887	EXPRESSION			9	110045560	110094475			ENST00000358015.3	75	GRCh37					N/A		2016-10-18 02:10:38 UTC
626	https://civic.genome.wustl.edu/links/variants/626	RET	5979	CCDC6-RET															transcript_fusion		2016-08-15 11:05:33 UTC
627	https://civic.genome.wustl.edu/links/variants/627	MAP2K1	5604	C121S			15	66729154	66729154	G	C	ENST00000307102.5	75	GRCh37					missense_variant		2016-10-06 05:00:46 UTC
628	https://civic.genome.wustl.edu/links/variants/628	FGFR3	2261	S249C			4	1803568	1803568	C	G	ENST00000340107.4	75	GRCh37					missense_variant		2016-09-13 21:45:36 UTC
629	https://civic.genome.wustl.edu/links/variants/629	FGFR2	2263	AMPLIFICATION			10	123239371	123357917			ENST00000457416.2	75	GRCh37					transcript_amplification		2016-09-13 20:33:25 UTC
630	https://civic.genome.wustl.edu/links/variants/630	FGF3	2248	AMPLIFICATION			11	69624992	69633792			ENST00000334134.2	75	GRCh37					transcript_amplification		2016-10-18 03:49:02 UTC
631	https://civic.genome.wustl.edu/links/variants/631	VHL	7428	R200W (c.598C>T)			3	10191605	10191605	C	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.598C>T,NP_000542.1:p.Arg200Trp,ENST00000256474.2:c.598C>T,NC_000003.11:g.10191605C>T	2017-02-01 03:13:13 UTC
632	https://civic.genome.wustl.edu/links/variants/632	RB1	5925	PHOSPHORYLATION			13	48877911	49056122			ENST00000267163.4	75	GRCh37					N/A		2016-09-13 21:20:38 UTC
633	https://civic.genome.wustl.edu/links/variants/633	PIK3R1	5295	MUTATION			5	67511548	67597649			ENST00000521381.1	75	GRCh37					gain_of_function_variant,missense_variant		2016-11-07 23:42:20 UTC
634	https://civic.genome.wustl.edu/links/variants/634	STK11	6794	D194E			19	1220489	1220489	C	A	ENST00000326873.7	75	GRCh37					loss_of_heterozygosity,missense_variant		2016-10-05 23:01:46 UTC
635	https://civic.genome.wustl.edu/links/variants/635	AKT2	208	AMPLIFICATION			19	40736224	40791302			ENST00000392038.2	75	GRCh37					transcript_amplification		2016-11-03 05:27:04 UTC
636	https://civic.genome.wustl.edu/links/variants/636	PTEN	5728	R130*			10	89692904	89692904	C	T	ENST00000371953.3	75	GRCh37					stop_gained	NM_000314.6:c.388C>T,NP_000305.3:p.Arg130Ter,ENST00000371953.3:c.388C>T,NC_000010.10:g.89692904C>T	2016-10-12 05:22:24 UTC
637	https://civic.genome.wustl.edu/links/variants/637	FBXW7	55294	LOSS-OF-FUNCTION			4	153242410	153457253			ENST00000281708.4	75	GRCh37					loss_of_function_variant		2016-11-03 05:28:19 UTC
638	https://civic.genome.wustl.edu/links/variants/638	RB1	5925	M695FS*26			13	49033946	49033947		A	ENST00000267163.4	75	GRCh37					frameshift_truncation	ENST00000267163.4:c.2083_2084insA,NC_000013.10:g.49033946_49033947insA	2016-10-18 04:14:15 UTC
639	https://civic.genome.wustl.edu/links/variants/639	JUN	3725	OVEREXPRESSION			1	59246465	59249785			ENST00000371222.2	75	GRCh37					N/A		2016-11-03 05:18:33 UTC
640	https://civic.genome.wustl.edu/links/variants/640	FOS	2353	OVEREXPRESSION			14	75745477	75748933			ENST00000303562.4	75	GRCh37					N/A		2016-11-03 05:32:15 UTC
641	https://civic.genome.wustl.edu/links/variants/641	CDKN2A	1029	RS3814960			9	21975017	21975017	C	T	ENST00000498124.1	75	GRCh37					5_prime_UTR_exon_variant	NC_000009.11:g.21975017C>T	2016-11-04 22:56:46 UTC
642	https://civic.genome.wustl.edu/links/variants/642	MDM2	4193	RS34886328			12	69234988	69234988			ENST00000462284.1	75	GRCh37					3_prime_UTR_truncation		2017-05-18 20:44:13 UTC
643	https://civic.genome.wustl.edu/links/variants/643	CBLB	868	RS2305035			3	105439026	105439026	G	A	ENST00000264122.4	75	GRCh37					synonymous_variant,polymorphic_sequence_variant		2016-10-12 04:54:29 UTC
644	https://civic.genome.wustl.edu/links/variants/644	PRDM1	639	MUTATION			6	106534195	106557813			ENST00000369096.4	75	GRCh37					loss_of_function_variant,transcript_variant		2016-11-03 04:06:28 UTC
645	https://civic.genome.wustl.edu/links/variants/645	IDH1	3417	MUTATION			2	209101803	209116275			ENST00000415913.1	75	GRCh37					transcript_variant		2016-11-11 23:24:19 UTC
646	https://civic.genome.wustl.edu/links/variants/646	SMAD4	4089	DELETION			18	48556583	48611409			ENST00000342988.3	75	GRCh37					transcript_ablation		2016-09-23 22:46:14 UTC
647	https://civic.genome.wustl.edu/links/variants/647	LRP1B	53353	DELETION			2	140988992	142889270			ENST00000389484.3	75	GRCh37					transcript_ablation		2016-11-03 05:07:10 UTC
648	https://civic.genome.wustl.edu/links/variants/648	ATRX	546	UNDEREXPRESSION			X	76760356	77041702			ENST00000373344.5	75	GRCh37					N/A		2016-11-03 05:29:56 UTC
649	https://civic.genome.wustl.edu/links/variants/649	MET	4233	D1228N			7	116423407	116423407	G	A	ENST00000397752.3	75	GRCh37					missense_variant		2016-10-20 05:58:36 UTC
650	https://civic.genome.wustl.edu/links/variants/650	CASP8	841	D302H			2	202149589	202149589	G	C	ENST00000264275.5	75	GRCh37					missense_variant,polymorphic_sequence_variant	NM_001228.4:c.904G>C,NP_001219.2:p.Asp302His,ENST00000264275.5:c.904G>C	2016-10-24 04:35:53 UTC
651	https://civic.genome.wustl.edu/links/variants/651	AXL	558	EXPRESSION			19	41725108	41767671			ENST00000301178.4	75	GRCh37					N/A		2016-10-06 05:49:24 UTC
652	https://civic.genome.wustl.edu/links/variants/652	GAS6	2621	EXPRESSION			13	114523524	114567046			ENST00000357389.3	75	GRCh37					N/A		2016-10-12 04:40:02 UTC
653	https://civic.genome.wustl.edu/links/variants/653	ETV4	2118	OVEREXPRESSION			17	41605212	41623800			ENST00000319349.5	75	GRCh37					N/A		2016-09-23 20:21:27 UTC
654	https://civic.genome.wustl.edu/links/variants/654	STAG3	10734	UNDEREXPRESSION			7	99775186	99812003			ENST00000426455.1	75	GRCh37					N/A		2016-11-03 05:24:49 UTC
655	https://civic.genome.wustl.edu/links/variants/655	MAP2K1	5604	Q56_V60 DELETION			15	66727449	66727463	CCAGAAGCAGAAGGT		ENST00000307102.5	75	GRCh37							2016-10-20 06:13:02 UTC
656	https://civic.genome.wustl.edu/links/variants/656	BRAF	673	BRAF-CUL1		BRAF Fusions	7	140434279	140487384			ENST00000288602.6	75	GRCh37	7	148395737	148457588	ENST00000602748.1	transcript_fusion		2016-10-18 03:47:28 UTC
657	https://civic.genome.wustl.edu/links/variants/657	BRAF	673	ZKSCAN1-BRAF		BRAF Fusions	7	99613222	99627575			ENST00000426572.1	75	GRCh37	7	140434279	140482957	ENST00000288602.6	transcript_fusion		2016-10-05 23:02:40 UTC
658	https://civic.genome.wustl.edu/links/variants/658	BRAF	673	L505H			7	140477794	140477794	A	T	ENST00000288602.6	75	GRCh37					missense_variant	ENST00000288602.6:c.1514T>A,NC_000007.13:g.140477794A>T	2016-09-23 22:45:18 UTC
659	https://civic.genome.wustl.edu/links/variants/659	NF2	4771	MUTATION			22	29999547	30094587			ENST00000338641.4	75	GRCh37					transcript_variant		2016-10-24 04:41:13 UTC
660	https://civic.genome.wustl.edu/links/variants/660	HIF1A	3091	EXPRESSION			14	62164340	62214489			ENST00000539097.1	75	GRCh37					N/A		2016-10-18 04:21:11 UTC
661	https://civic.genome.wustl.edu/links/variants/661	BRCA2	675	D3095E			13	32968854	32968854	C	A	ENST00000544455.1	75	GRCh37					missense_variant	NM_000059.3:c.9285C>A,NP_000050.2:p.Asp3095Glu,ENST00000544455.1:c.9285C>A,NC_000013.10:g.32968854C>A	2016-10-28 23:48:53 UTC
662	https://civic.genome.wustl.edu/links/variants/662	MLH1	4292	EXPRESSION			3	37034823	37092409			ENST00000231790.2	75	GRCh37					N/A		2016-10-12 05:26:59 UTC
663	https://civic.genome.wustl.edu/links/variants/663	BCOR	54880	MUTATION			X	39910501	40036582			ENST00000342274.4	75	GRCh37					transcript_variant		2016-10-11 23:42:29 UTC
664	https://civic.genome.wustl.edu/links/variants/664	CDH1	999	MUTATION			16	68771128	68869451			ENST00000261769.5	75	GRCh37					transcription_variant		2016-10-10 22:04:46 UTC
665	https://civic.genome.wustl.edu/links/variants/665	RHOA	387	MUTATION			3	49412898	49405977			ENST00000418115.1	75	GRCh37					gain_of_function_variant,transcription_variant		2016-10-10 22:20:55 UTC
666	https://civic.genome.wustl.edu/links/variants/666	ERBB2	2064	MUTATION			17	37868196	37881332			ENST00000269571.5	75	GRCh37					missense_variant		2016-09-23 22:44:57 UTC
667	https://civic.genome.wustl.edu/links/variants/667	MEN1	4221	FRAMESHIFT TRUNCATION			11	64572092	64572092	C		ENST00000337652.1	75	GRCh37					frameshift_truncation		2016-11-27 19:10:51 UTC
668	https://civic.genome.wustl.edu/links/variants/668	KMT2C	58508	MUTATION			7	151832010	152133090			ENST00000262189.6	75	GRCh37					loss_of_function_variant,transcription_variant		2016-11-03 05:36:02 UTC
669	https://civic.genome.wustl.edu/links/variants/669	STAG2	10735	MUTATION			X	123176418	123217308			ENST00000218089.9	75	GRCh37					protein_altering_variant		2016-09-23 22:45:43 UTC
670	https://civic.genome.wustl.edu/links/variants/670	MYCL	4610	EXPRESSION			1	40361098	40367685			ENST00000397332.2	75	GRCh37					N/A		2016-10-18 04:18:51 UTC
671	https://civic.genome.wustl.edu/links/variants/671	HGF	3082	EXPRESSION			7	81328322	81399514			ENST00000222390.5	75	GRCh37					N/A		2016-11-03 05:31:07 UTC
672	https://civic.genome.wustl.edu/links/variants/672	SOX10	6663	LOSS			22	38368307	38380544			ENST00000396884.2	75	GRCh37					loss_of_function_variant		2016-10-05 23:01:38 UTC
673	https://civic.genome.wustl.edu/links/variants/673	FGF2	2247	EXPRESSION			4	123747863	123819391			ENST00000264498.3	75	GRCh37					N/A		2017-05-18 20:44:13 UTC
674	https://civic.genome.wustl.edu/links/variants/674	EIF1AX	1964	MUTATION			X	20156713	20159754			ENST00000379607.5	75	GRCh37					transcript_variant		2016-11-25 18:15:14 UTC
683	https://civic.genome.wustl.edu/links/variants/683	PAX8	7849	EXPRESSION			2	113973574	114036527			ENST00000429538.3	75	GRCh37					N/A		2016-10-18 04:24:39 UTC
691	https://civic.genome.wustl.edu/links/variants/691	ERRFI1	54206	E384*			1	8073509	8073509	C	A	ENST00000377482.5	75	GRCh37					loss_of_function_variant,stop_gained		2016-11-03 05:45:48 UTC
692	https://civic.genome.wustl.edu/links/variants/692	ESR1	2099	S463P			6	152415537	152415537	T	C	ENST00000440973.1	75	GRCh37					missense_variant	NC_000006.11:g.152415537T>C	2016-11-03 05:43:13 UTC
693	https://civic.genome.wustl.edu/links/variants/693	SGK1	6446	OVEREXPRESSION			6	134490384	134639196			ENST00000367858.5	75	GRCh37					N/A		2016-11-04 19:28:00 UTC
694	https://civic.genome.wustl.edu/links/variants/694	BRAF	673	G596C			7	140453149	140453149	C	A	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1786G>T,NP_004324.2:p.Gly596Cys,NC_000007.13:g.140453149C>A	2016-11-11 23:28:45 UTC
695	https://civic.genome.wustl.edu/links/variants/695	SMARCB1	6598	UNDEREXPRESSION			22	24129150	24176703			ENST00000344921.6	75	GRCh37					N/A		2016-11-15 16:44:40 UTC
696	https://civic.genome.wustl.edu/links/variants/696	SMARCB1	6598	DELETION			22	24129150	24176703			ENST00000344921.6	75	GRCh37					transcript_ablation		2016-11-08 16:20:32 UTC
697	https://civic.genome.wustl.edu/links/variants/697	NF2	4771	LOSS			22	29999547	30094587			ENST00000338641.4	75	GRCh37					loss_of_function_variant		2016-11-11 23:05:41 UTC
698	https://civic.genome.wustl.edu/links/variants/698	NF1	4763	LOSS			17	29421945	29704695			ENST00000358273.4	75	GRCh37					loss_of_function_variant		2016-11-11 23:03:32 UTC
699	https://civic.genome.wustl.edu/links/variants/699	SH2B3	10019	RS3184504			12	111884608	111884608	T	C	ENST00000341259.2	75	GRCh37					missense_variant,polymorphic_sequence_variant		2016-11-11 21:21:46 UTC
700	https://civic.genome.wustl.edu/links/variants/700	KIF23	9493	EXPRESSION			15	69706688	69740756			ENST00000260363.4	75	GRCh37					N/A		2016-11-27 17:26:05 UTC
701	https://civic.genome.wustl.edu/links/variants/701	ERBB3	2065	V104M			12	56478854	56478854	G	A	ENST00000267101.3	75	GRCh37					missense_variant		2017-02-21 16:31:47 UTC
702	https://civic.genome.wustl.edu/links/variants/702	ERBB3	2065	R103G			12	56478851	56478851	C	G	ENST00000267101.3	75	GRCh37					missense_variant		2016-12-17 06:44:06 UTC
703	https://civic.genome.wustl.edu/links/variants/703	ERBB3	2065	G284R			12	56481922	56481922	G	A	ENST00000267101.3	75	GRCh37					missense_variant		2016-12-17 06:59:08 UTC
705	https://civic.genome.wustl.edu/links/variants/705	GADD45A	1647	1506T>C																	2016-11-18 05:26:57 UTC
706	https://civic.genome.wustl.edu/links/variants/706	EWSR1	2130	EWSR1-FLI1	In approximately 90% of Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) a translocation t(11;22)(q24; q12) is identified, fusing the 5 exons (containing the transactivatin domain, at least exon 1-7) of EWSR1, with the 3 exons (from exon 9, coding the DNA binding domain) of FLI1.		22	29664307	29688158			ENST00000414183.2	75	GRCh37	11	128638013	128683162	ENST00000527786.2	transcript_fusion		2017-01-17 05:24:21 UTC
707	https://civic.genome.wustl.edu/links/variants/707	TMPRSS2	7113	TMPRSS2-ERG			21	42879877	42879992			ENST00000398585.3	75	GRCh37	21	39751949	39817544	ENST00000398910.1	transcript_fusion		2016-11-27 19:17:32 UTC
708	https://civic.genome.wustl.edu/links/variants/708	BRCA2	675	TRUNCATING MUTATION																	2016-12-01 14:08:13 UTC
709	https://civic.genome.wustl.edu/links/variants/709	BRCA1	672	TRUNCATING MUTATION																	2016-12-01 14:12:10 UTC
711	https://civic.genome.wustl.edu/links/variants/711	KLLN	100144748	PROMOTER METHYLATION																	2016-12-01 15:29:59 UTC
712	https://civic.genome.wustl.edu/links/variants/712	EGFR	1956	D761Y			7	55242511	55242511	G	T	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2281G>T,NM_005228.4:c.2281G>T,NP_005219.2:p.Asp761Tyr,NC_000007.13:g.55242511G>T	2016-12-18 02:05:17 UTC
713	https://civic.genome.wustl.edu/links/variants/713	CRBN	51185	MUTATION																	2016-12-01 17:13:31 UTC
714	https://civic.genome.wustl.edu/links/variants/714	TSC1	7248	R1062W			9	135771933	135771933	G	A	ENST00000298552.3	75	GRCh37					missense_variant	NM_000368.3:c.3184C>T,NP_000359.1:p.Arg1062Trp,ENST00000298552.3:c.3184C>T,NC_000009.11:g.135771933G>A	2016-12-18 02:32:57 UTC
715	https://civic.genome.wustl.edu/links/variants/715	STK11	6794	MUTATION			19	1205740	1223074			ENST00000326873.7	75	GRCh37					gene_variant		2017-02-06 23:30:55 UTC
716	https://civic.genome.wustl.edu/links/variants/716	PDGFRA	5156	AMPLIFICATION			4	55095264	55164414			ENST00000257290.5	75	GRCh37					transcript_amplification		2016-12-18 02:34:25 UTC
717	https://civic.genome.wustl.edu/links/variants/717	DDIT3	1649	EWSR1-DDIT3			22	29664307	29687588			ENST00000414183.2	75	GRCh37	12	57910376	57911536	ENST00000346473.3	transcript_fusion		2017-01-22 22:04:12 UTC
718	https://civic.genome.wustl.edu/links/variants/718	EGFR	1956	G719			7	55241707	55241708			ENST00000275493.2	75	GRCh37					protein_altering_variant		2016-12-18 02:01:17 UTC
719	https://civic.genome.wustl.edu/links/variants/719	BRD4	23476	BRD4-NUTM1																	2016-12-02 10:26:24 UTC
720	https://civic.genome.wustl.edu/links/variants/720	EGFR	1956	S720			7	55241710	55241711			ENST00000275493.2	75	GRCh37					protein_altering_variant		2016-12-18 02:12:17 UTC
721	https://civic.genome.wustl.edu/links/variants/721	CYP2D6	1565	LOSS-OF-FUNCTION			22	42522501	42526908			ENST00000360608.5	75	GRCh37					loss_of_function_variant		2016-12-18 01:54:27 UTC
722	https://civic.genome.wustl.edu/links/variants/722	DDIT3	1649	FUS-DDIT3																	2016-12-02 10:32:09 UTC
723	https://civic.genome.wustl.edu/links/variants/723	EGFR	1956	K757R			7	55242500	55242500	A	G	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2270A>G	2016-12-18 02:08:53 UTC
724	https://civic.genome.wustl.edu/links/variants/724	EGFR	1956	E746G			7	55242467	55242467	A	G	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2237A>G,NC_000007.13:g.55242467A>G	2016-12-18 02:07:32 UTC
725	https://civic.genome.wustl.edu/links/variants/725	MLH1	4292	E13FS*3			3	37035075	37035075	G		ENST00000231790.2	75	GRCh37					frameshift_truncation	NM_000249.3:c.37delG,NP_000240.1:p.Glu13Argfs,ENST00000231790.2:c.37delG,NC_000003.11:g.37035075del	2016-12-28 21:33:42 UTC
726	https://civic.genome.wustl.edu/links/variants/726	EGFR	1956	EXON 20 INSERTION			7	55248991	55249022			ENST00000275493.2	75	GRCh37					inframe_insertion		2017-01-19 01:02:47 UTC
727	https://civic.genome.wustl.edu/links/variants/727	MSH2	4436	R383*			2	47656951	47656951	C	T	ENST00000233146.2	75	GRCh37					stop_gained	NM_000251.2:c.1147C>T,NP_000242.1:p.Arg383Ter,ENST00000233146.2:c.1147C>T,NC_000002.11:g.47656951C>T	2017-01-17 01:49:08 UTC
728	https://civic.genome.wustl.edu/links/variants/728	MLH1	4292	V534R			3	37081718	37081719	GT	AG	ENST00000231790.2	75	GRCh37					missense_variant	ENST00000231790.2:c.1600_1601delinsAG,NC_000003.11:g.37081718_37081719delinsAG	2016-12-18 01:07:53 UTC
729	https://civic.genome.wustl.edu/links/variants/729	UGT1A1	54658	UGT1A1*28			2	234668881	234668882		TATATATATATATA	ENST00000305208.5	75	GRCh37					microsatellite	NC_000002.11:g.234668881_234668882TA[5][6][7][8]	2017-01-20 23:34:53 UTC
730	https://civic.genome.wustl.edu/links/variants/730	MLH1	4292	G606FS*2			3	37089094	37089095	GG		ENST00000231790.2	75	GRCh37					frameshift_truncation	ENST00000231790.2:c.1816_1817delGG,NC_000003.11:g.37089094_37089095del	2016-12-28 21:32:26 UTC
731	https://civic.genome.wustl.edu/links/variants/731	MLH1	4292	790+1G>A																	2016-12-02 10:54:44 UTC
732	https://civic.genome.wustl.edu/links/variants/732	UGT1A1	54658	UGT1A1*60																	2016-12-02 10:54:54 UTC
733	https://civic.genome.wustl.edu/links/variants/733	MLH1	4292	K618DEL			3	37089130	37089132	AAG		ENST00000231790.2	75	GRCh37					inframe_deletion	NC_000003.11:g.37089130_37089132del,ENST00000231790.2:c.1852_1854delAAG,NM_000249.3:c.1852_1854delAAG,NP_000240.1:p.Lys618del	2016-12-28 21:29:03 UTC
734	https://civic.genome.wustl.edu/links/variants/734	MLH1	4292	P138T																	2016-12-02 10:59:22 UTC
735	https://civic.genome.wustl.edu/links/variants/735	MLH1	4292	R687FS			3	37090464	37090464	C		ENST00000231790.2	75	GRCh37					frameshift_variant	NM_000249.3:c.2059delC,NP_000240.1:p.Arg687Glyfs,ENST00000231790.2:c.2059delC,NC_000003.11:g.37090464del	2017-01-23 02:41:31 UTC
736	https://civic.genome.wustl.edu/links/variants/736	EGFR	1956	V769_770INSASV			7	55249009	55249010			ENST00000275493.2	75	GRCh37					insertion	NM_005228.4:c.2300_2308dupCCAGCGTGG	2017-05-17 02:15:35 UTC
737	https://civic.genome.wustl.edu/links/variants/737	DPYD	1806	DPYD*2A HOMOZYGOSITY			1	97915614	97915614	C	T	ENST00000370192.3	75	GRCh37					splice_donor_variant		2017-02-01 01:26:08 UTC
738	https://civic.genome.wustl.edu/links/variants/738	DPYD	1806	DPYD*13 HOMOZYGOSITY			1	97981343	97981343	A	C	ENST00000370192.3	75	GRCh37					missense_variant	NM_000110.3:c.1679T>G,NP_000101.2:p.Ile560Ser,ENST00000370192.3:c.1679T>G	2017-01-22 00:38:17 UTC
739	https://civic.genome.wustl.edu/links/variants/739	FOS	2353	FOS TRUNCATING FUSION																	2016-12-02 11:04:52 UTC
740	https://civic.genome.wustl.edu/links/variants/740	DPYD	1806	RS67376798 HOMOZYGOSITY																	2016-12-02 11:05:47 UTC
741	https://civic.genome.wustl.edu/links/variants/741	MLH1	4292	R100*			3	37042536	37042536	C	T	ENST00000231790.2	75	GRCh37					stop_gained	NM_000249.3:c.298C>T,NP_000240.1:p.Arg100Ter,ENST00000231790.2:c.298C>T,NC_000003.11:g.37042536C>T	2016-12-28 21:15:50 UTC
742	https://civic.genome.wustl.edu/links/variants/742	WWTR1	25937	WWTR1-CAMTA1			3	149235022	149290787			ENST00000465804.1	75	GRCh37	1	7721786	7829766	ENST00000303635.7	transcript_fusion		2017-01-21 00:18:23 UTC
743	https://civic.genome.wustl.edu/links/variants/743	MLH1	4292	T117M			3	37045935	37045935	C	T	ENST00000231790.2	75	GRCh37					missense_variant	NM_000249.3:c.350C>T,NP_000240.1:p.Thr117Met,ENST00000231790.2:c.350C>T,NC_000003.11:g.37045935C>T	2016-12-18 01:11:46 UTC
744	https://civic.genome.wustl.edu/links/variants/744	MLH1	4292	Q426FS			3	37067365	37067365	C		ENST00000231790.2	75	GRCh37					frameshift_truncation	ENST00000231790.2:c.1276delC,NC_000003.11:g.37067365del	2017-01-22 22:35:23 UTC
745	https://civic.genome.wustl.edu/links/variants/745	MLH1	4292	V49A			3	37038139	37038139	T	C	ENST00000231790.2	75	GRCh37					missense_variant	ENST00000231790.2:c.146T>C,NC_000003.11:g.37038139T>C	2016-12-18 01:10:33 UTC
746	https://civic.genome.wustl.edu/links/variants/746	MLH1	4292	D667FS			3	37090406	37090406	C		ENST00000231790.2	75	GRCh37						ENST00000231790.2:c.2001delC,NC_000003.11:g.37090406delC	2017-01-22 22:58:34 UTC
747	https://civic.genome.wustl.edu/links/variants/747	MLH1	4292	M1L			3	37035039	37035039	A	T	ENST00000231790.2	75	GRCh37					missense_variant	ENST00000231790.2:c.1A>T,NC_000003.11:g.37035039A>T	2016-12-18 01:31:13 UTC
748	https://civic.genome.wustl.edu/links/variants/748	MLH1	4292	*757L			3	37092143	37092143	A	T	ENST00000231790.2	75	GRCh37					stop_lost	ENST00000231790.2:c.2270A>T	2016-12-28 21:02:08 UTC
749	https://civic.genome.wustl.edu/links/variants/749	MLH1	4292	R265G			3	37058999	37058999	C	G	ENST00000231790.2	75	GRCh37					missense_variant	ENST00000231790.2:c.793C>G,NC_000003.11:g.37058999C>G	2016-12-28 21:12:25 UTC
750	https://civic.genome.wustl.edu/links/variants/750	MLH1	4292	V213FS			3	37053551	37053551	T		ENST00000231790.2	75	GRCh37					frameshift_truncation	ENST00000231790.2:c.638delT,NC_000003.11:g.37053551del	2016-12-28 21:05:17 UTC
751	https://civic.genome.wustl.edu/links/variants/751	MLH1	4292	N551T			3	37081770	37081770	A	C	ENST00000231790.2	75	GRCh37					missense_variant	NM_000249.3:c.1652A>C,NP_000240.1:p.Asn551Thr,ENST00000231790.2:c.1652A>C,NC_000003.11:g.37081770A>C	2016-12-18 01:15:15 UTC
752	https://civic.genome.wustl.edu/links/variants/752	MLH1	4292	A424T			3	37067359	37067359	G	A	ENST00000231790.2	75	GRCh37					missense_variant	NM_000249.3:c.1270G>A,NP_000240.1:p.Ala424Thr,ENST00000231790.2:c.1270G>A,NC_000003.11:g.37067359G>A	2016-12-18 01:19:27 UTC
753	https://civic.genome.wustl.edu/links/variants/753	MLH1	4292	Q149*			3	37048546	37048546	C	T	ENST00000231790.2	75	GRCh37					stop_gained	NM_000249.3:c.445C>T,NP_000240.1:p.Gln149Ter,ENST00000231790.2:c.445C>T,NC_000003.11:g.37048546C>T	2016-12-28 21:16:45 UTC
754	https://civic.genome.wustl.edu/links/variants/754	MLH1	4292	R226*			3	37053589	37053589	C	T	ENST00000231790.2	75	GRCh37					stop_gained	NM_000249.3:c.676C>T,NP_000240.1:p.Arg226Ter,ENST00000231790.2:c.676C>T,NC_000003.11:g.37053589C>T	2016-12-28 21:14:02 UTC
755	https://civic.genome.wustl.edu/links/variants/755	MSH6	2956	I972F			2	48028036	48028036	A	T	ENST00000234420.5	75	GRCh37					missense_variant	ENST00000234420.5:c.2914A>T	2017-04-17 20:02:33 UTC
756	https://civic.genome.wustl.edu/links/variants/756	MLH1	4292	P536FS			3	37081726	37081726	T		ENST00000231790.2	75	GRCh37					frameshift_truncation	ENST00000231790.2:c.1608delT,NC_000003.11:g.37081726delT	2016-12-28 21:27:38 UTC
757	https://civic.genome.wustl.edu/links/variants/757	MLH1	4292	G67R			3	37038192	37038192	G	A	ENST00000231790.2	75	GRCh37					missense_variant	NP_000240.1:p.Gly67Arg,ENST00000231790.2:c.199G>A,NC_000003.11:g.37038192G>A,NM_000249.3:c.199G>A,	2016-12-18 01:34:30 UTC
758	https://civic.genome.wustl.edu/links/variants/758	MLH1	4292	I68S			3	37038196	37038196	T	G	ENST00000231790.2	75	GRCh37					missense_variant	ENST00000231790.2:c.203T>G,NC_000003.11:g.37038196T>G	2016-12-18 01:33:08 UTC
759	https://civic.genome.wustl.edu/links/variants/759	MLH1	4292	G65D			3	37038187	37038187	G	A	ENST00000231790.2	75	GRCh37					missense_variant	NM_000249.3:c.194G>A,NP_000240.1:p.Gly65Asp,ENST00000231790.2:c.194G>A,NC_000003.11:g.37038187G>A	2016-12-18 01:36:40 UTC
760	https://civic.genome.wustl.edu/links/variants/760	MLH1	4292	A681V			3	37090447	37090447	C	T	ENST00000231790.2	75	GRCh37					missense_variant	NM_000249.3:c.2042C>T,NP_000240.1:p.Ala681Val,ENST00000231790.2:c.2042C>T,NC_000003.11:g.37090447C>T	2016-12-18 01:22:33 UTC
761	https://civic.genome.wustl.edu/links/variants/761	MSH6	2956	P138T			2	48018217	48018217	C	A	ENST00000234420.5	75	GRCh37					missense_variant	ENST00000234420.5:c.412C>A,NC_000002.11:g.48018217C>A	2016-12-17 06:52:53 UTC
762	https://civic.genome.wustl.edu/links/variants/762	MSH2	4436	V273FS			2	47641433	47641433	T		ENST00000233146.2	75	GRCh37					frameshift_variant	ENST00000233146.2:c.818delT	2017-04-17 20:45:52 UTC
763	https://civic.genome.wustl.edu/links/variants/763	MSH2	4436	E28FS			2	47630413	47630414		G	ENST00000233146.2	75	GRCh37					frameshift_elongation	NC_000002.11:g.47630414dupG	2016-12-28 16:36:28 UTC
764	https://civic.genome.wustl.edu/links/variants/764	VHL	7428	E55FS (c.163_164delGA)			3	10183694	10183695	GA		ENST00000256474.2	75	GRCh37					frameshift_truncation	NP_000542.1:p.Glu55fs,NC_000003.11:g.10183694_10183695del,ENST00000256474.2:c.163_164delGA	2017-03-13 01:50:35 UTC
765	https://civic.genome.wustl.edu/links/variants/765	MSH6	2956	I891FS			2	48027794	48027795	TC		ENST00000234420.5	75	GRCh37					frameshift_truncation	ENST00000234420.5:c.2672_2673delTC,NC_000002.11:g.48027794_48027795del	2016-12-28 20:57:59 UTC
766	https://civic.genome.wustl.edu/links/variants/766	VHL	7428	E55RfsTer11 (c.163delG)			3	10183694	10183694	G		ENST00000256474.2	75	GRCh37					frameshift_truncation	NP_000542.1:p.Glu55fs,NP_000542.1:p.Glu55ArgfsTer11,NM_000551.2:c.163delG,NC_000003.11:g.10183694del,ENST00000256474.2:c.163delG	2017-02-01 03:22:07 UTC
767	https://civic.genome.wustl.edu/links/variants/767	MSH6	2956	R1242H			2	48033421	48033421	G	A	ENST00000234420.5	75	GRCh37					missense_variant	NM_000179.2:c.3725G>A,NP_000170.1:p.Arg1242His,ENST00000234420.5:c.3725G>A,NC_000002.11:g.48033421G>A	2016-12-17 06:48:27 UTC
768	https://civic.genome.wustl.edu/links/variants/768	PMS2	5395	R315*			7	6031649	6031649	G	A	ENST00000265849.7	75	GRCh37					stop_gained	NM_000535.6:c.943C>T,NP_000526.2:p.Arg315Ter,NC_000007.13:g.6031649G>A	2016-12-18 01:57:25 UTC
769	https://civic.genome.wustl.edu/links/variants/769	MLH1	4292	M490T			3	37070334	37070334	T	C	ENST00000231790.2	75	GRCh37					missense_variant	ENST00000231790.2:c.1469T>C,NC_000003.11:g.37070334T>C	2016-12-18 01:29:49 UTC
770	https://civic.genome.wustl.edu/links/variants/770	MSH2	4436	K172*			2	47637380	47637380	A	T	ENST00000233146.2	75	GRCh37					stop_gained	ENST00000233146.2:c.514A>T	2017-04-18 13:47:39 UTC
771	https://civic.genome.wustl.edu/links/variants/771	VHL	7428	A56FS (c.164_165insG)			3	10183695	10183696		G	ENST00000256474.2	75	GRCh37					frameshift_truncation	NP_000542.1:p.Ala56fs,NP_000542.1:p.Ala56GlyfsTer74,NM_000551.2:c.164_165insG,NC_000003.11:g.10183695_10183696insG,NC_000003.11:g.10183697dupG	2017-03-13 01:47:01 UTC
772	https://civic.genome.wustl.edu/links/variants/772	HOXB13	10481	G84E			17	46805705	46805705	C	T	ENST00000290295.7	75	GRCh37					missense_variant		2016-12-18 02:17:34 UTC
773	https://civic.genome.wustl.edu/links/variants/773	MSH2	4436	E483G			2	47690231	47690231	A	G	ENST00000233146.2	75	GRCh37					missense_variant	NC_000002.11:g.47690231A>G,ENST00000233146.2:c.1448A>G	2016-12-18 00:22:43 UTC
774	https://civic.genome.wustl.edu/links/variants/774	PDGFRA	5156	TNKS2-PDGFRA			10	93558069	93619405			ENST00000371627.4	75	GRCh37	4	55141008	55164414	ENST00000257290.5	transcript_fusion		2017-01-23 04:28:28 UTC
775	https://civic.genome.wustl.edu/links/variants/775	MSH6	2956	V352I			2	48026176	48026176	G	A	ENST00000234420.5	75	GRCh37					missense_variant	NM_000179.2:c.1054G>A,NP_000170.1:p.Val352Ile,ENST00000234420.5:c.1054G>A,NC_000002.11:g.48026176G>A	2016-12-17 06:39:31 UTC
776	https://civic.genome.wustl.edu/links/variants/776	MSH6	2956	R1242C			2	48033420	48033420	C	T	ENST00000234420.5	75	GRCh37					missense_variant	NM_000179.2:c.3724C>T,NP_000170.1:p.Arg1242Cys,ENST00000234420.5:c.3724C>T,NC_000002.11:g.48033420C>T	2016-12-17 06:50:57 UTC
777	https://civic.genome.wustl.edu/links/variants/777	SLCO1B1	10599	RS4149056			12	21331549	21331549	T	C	ENST00000256958.2	75	GRCh37					missense_variant,polymorphic_sequence_variant		2016-12-18 02:31:13 UTC
778	https://civic.genome.wustl.edu/links/variants/778	SLCO1B1	10599	RS2306283			12	21329738	21329738	A	G	ENST00000256958.2	75	GRCh37					missense_variant		2016-12-18 02:25:25 UTC
779	https://civic.genome.wustl.edu/links/variants/779	TYMS	7298	RS34743033																	2016-12-02 13:24:50 UTC
780	https://civic.genome.wustl.edu/links/variants/780	GLI1	2735	ACTB-GLI1	Fusion of the hedgehog pathway component gene GLI1 to the -actin gene (ACTB)  has been described as a mechanism of GLI1,and by extension hedgehog pathway, activation. These fusions have been described in histologically distinctive soft tissue tumours showing a pericytic phenotype.  Gene fusions retain the DNA-binding zinc finger domains of GLI1 and it is likely that the replacement of the promoter region of GLI1with that of the ubiquitously expressed ACTB gene leads to deregulation of GLI expression and its downstream target genes.														gene_fusion		2017-01-22 17:10:51 UTC
781	https://civic.genome.wustl.edu/links/variants/781	ERBB3	2065	V855A			12	56491672	56491672	T	C	ENST000000267101.3	75	GRCh37					missense_variant		2016-12-17 07:09:12 UTC
782	https://civic.genome.wustl.edu/links/variants/782	FGFR2	2263	FGFR2-BICC1																	2016-12-02 13:42:24 UTC
783	https://civic.genome.wustl.edu/links/variants/783	FGFR2	2263	FGFR2-AHCYL1																	2016-12-02 13:43:54 UTC
784	https://civic.genome.wustl.edu/links/variants/784	CDKN2B	1030	METHYLATION			9	22009121	22009172			ENST00000276925.6	75	GRCh37					N/A		2017-02-14 17:45:53 UTC
785	https://civic.genome.wustl.edu/links/variants/785	CHEK2	11200	1100DELC			22	29091857	29091857	G		ENST00000328354.6	75	GRCh37					frameshift_truncation	NC_000022.10:g.29091857delG,NM_007194.3:c.1100delC,NP_009125.1:p.Thr367Metfs,ENST00000328354.6:c.1100delC	2017-04-17 18:39:37 UTC
787	https://civic.genome.wustl.edu/links/variants/787	CHEK2	11200	I157T			22	29121087	29121087	A	G	ENST00000328354.6	75	GRCh37					missense_variant	NM_007194.3:c.470T>C,NP_009125.1:p.Ile157Thr,ENST00000328354.6:c.470T>C,NC_000022.10:g.29121087A>G	2017-04-17 18:35:49 UTC
788	https://civic.genome.wustl.edu/links/variants/788	CHEK2	11200	IVS2+1G>A																	2016-12-02 13:56:52 UTC
792	https://civic.genome.wustl.edu/links/variants/792	PTPRD	5789	V253I			9	8521481	8521481	C	T	ENST00000381196.4	75	GRCh37					missense_variant		2016-12-18 02:21:36 UTC
793	https://civic.genome.wustl.edu/links/variants/793	VHL	7428	A56FS (c.164_165insA)			3	10183695	10183696		A	ENST00000256474.2	75	GRCh37					frameshift_truncation	NP_000542.1:p.Ala56fs,NP_000542.1:p.Ala56GlyfsTer74,NM_000551.2:c.164_165insA,NC_000003.11:g.10183695_10183696insA,NC_000003.11:g.10183695dupA	2017-03-14 16:31:01 UTC
794	https://civic.genome.wustl.edu/links/variants/794	VHL	7428	E55E (c.165G>A)			3	10183696	10183696	G	A	ENST00000256474.2	75	GRCh37					silent_mutation	NM_000551.2:c.165G>A,NC_000003.11:g.10183696G>A,ENST00000256474.2:c.165G>A	2017-02-01 03:04:41 UTC
795	https://civic.genome.wustl.edu/links/variants/795	RRM1	6240	OVEREXPRESSION																	2016-12-05 14:15:03 UTC
796	https://civic.genome.wustl.edu/links/variants/796	RRM2	6241	OVEREXPRESSION			2	10262455	10271545			ENST00000360566.2	75	GRCh37					N/A		2016-12-18 02:03:25 UTC
797	https://civic.genome.wustl.edu/links/variants/797	POLE	5426	MUTATION			12	133202900	133256623			ENST00000320574.5	75	GRCh37					gene_variant		2017-01-22 20:50:53 UTC
798	https://civic.genome.wustl.edu/links/variants/798	MET	4233	D1228V			7	116423408	116423408	A	T	ENST00000397752.3	75	GRCh37					missense_variant	ENST00000397752.3:c.3683A>T	2016-12-18 01:52:22 UTC
799	https://civic.genome.wustl.edu/links/variants/799	RB1	5925	MUTATION			13	48877911	49056122			ENST00000267163.4	75	GRCh37					loss_of_function_variant,gene_variant		2017-04-18 13:57:18 UTC
800	https://civic.genome.wustl.edu/links/variants/800	NTRK1	4914	SQSTM1-NTRK1																	2016-12-27 19:39:53 UTC
801	https://civic.genome.wustl.edu/links/variants/801	NTRK3	4916	ETV6-NTRK3																	2016-12-27 19:31:59 UTC
802	https://civic.genome.wustl.edu/links/variants/802	RUNX1	861	K83E			21	36259163	36259163	T	C	ENST00000344691.4	75	GRCh37					missense_variant	NC_000021.8:g.36259163T>C,NP_001001890.1:p.Lys83Glu,NM_001001890.2:c.247A>G,ENST00000344691.4:c.247A>G	2017-02-14 21:17:00 UTC
803	https://civic.genome.wustl.edu/links/variants/803	RUNX1	861	Y260*			21	36171704	36171704	G	T	ENST00000344691.4	75	GRCh37					stop_gained	NM_001001890.2:c.780C>A,NP_001001890.1:p.Tyr260Ter,NC_000021.8:g.36171704G>T	2017-05-23 15:21:35 UTC
804	https://civic.genome.wustl.edu/links/variants/804	RUNX1	861	R135FSX177																	2016-12-19 18:11:51 UTC
805	https://civic.genome.wustl.edu/links/variants/805	NTRK3	4916	ETV6-NTRK3 G623R			15	88476265	88476265	C	T	ENST00000394480.2	75	GRCh37					transcript_fusion,missense_variant	NC_000015.9:g.88476265C>T	2017-01-22 20:34:50 UTC
806	https://civic.genome.wustl.edu/links/variants/806	RUNX1	861	D198Y			21	36231792	36231792	C	A	ENST00000300305.3	75	GRCh37					loss_of_function_variant,missense_variant		2016-12-28 15:24:12 UTC
807	https://civic.genome.wustl.edu/links/variants/807	RUNX1	861	A107P			21	36252962	36252962	C	G	ENST00000344691.4	75	GRCh37					missense_variant	NM_001754.4:c.400G>C,NP_001745.2:p.Ala134Pro,NC_000021.8:g.36252962C>G	2017-05-22 22:23:13 UTC
808	https://civic.genome.wustl.edu/links/variants/808	MSH2	4436	LOSS			2	47630108	47710367			ENST00000233146.2	75	GRCh37					loss_of_function_variant		2017-01-23 03:13:47 UTC
809	https://civic.genome.wustl.edu/links/variants/809	MSH6	2956	LOSS			2	48010221	48037240			ENST00000234420.5	75	GRCh37					loss_of_function_variant		2017-01-23 03:09:48 UTC
810	https://civic.genome.wustl.edu/links/variants/810	RUNX1	861	T148HFSX9			21	36252913	36252920	GCTGCGGT		ENST00000300305.3	75	GRCh37					frameshift_truncation	NM_001754.4:c.442_449delACCGCAGC,NP_001745.2:p.Thr148Hisfs	2017-02-11 22:52:51 UTC
811	https://civic.genome.wustl.edu/links/variants/811	ETV6	2120	R399C			12	12038902	12038902	C	T	ENST00000396373.4	75	GRCh37					missense_variant	NM_001987.4:c.1195C>T,NP_001978.1:p.Arg399Cys,ENST00000396373.4:c.1195C>T	2017-01-12 20:10:53 UTC
812	https://civic.genome.wustl.edu/links/variants/812	ETV6	2120	R369Q			12	12037475	12037475	G	A	ENST00000396373.4	75	GRCh37					missense_variant	NM_001987.4:c.1106G>A,NP_001978.1:p.Arg369Gln,ENST00000396373.4:c.1106G>A	2017-01-12 23:00:43 UTC
813	https://civic.genome.wustl.edu/links/variants/813	ETV6	2120	P214L																	2017-01-09 05:47:41 UTC
814	https://civic.genome.wustl.edu/links/variants/814	DDX41	51428	R164W																	2017-01-09 11:11:18 UTC
815	https://civic.genome.wustl.edu/links/variants/815	ERBB2	2064	Y772_A775DUP			17	37880996	37880997			ENST00000269571.5	75	GRCh37					inframe_insertion	NM_001005862.2:c.2223_2234dupATACGTGATGGC	2017-05-23 16:38:13 UTC
816	https://civic.genome.wustl.edu/links/variants/816	ERBB2	2064	G776L																	2017-01-10 20:38:30 UTC
817	https://civic.genome.wustl.edu/links/variants/817	ERBB2	2064	G778_P780DUP			17	37881011	37881012			ENST00000269571.5	75	GRCh37						NM_004448.3:c.2331_2339dupGGGCTCCCC	2017-05-24 05:07:45 UTC
818	https://civic.genome.wustl.edu/links/variants/818	ERBB2	2064	M774DELINSWLV																	2017-01-10 21:01:31 UTC
819	https://civic.genome.wustl.edu/links/variants/819	PTPRB	5787	LOSS-OF-FUNCTION			12	70910630	71031220			ENST00000334414.6	75	GRCh37					loss_of_function_variant		2017-01-23 03:04:48 UTC
820	https://civic.genome.wustl.edu/links/variants/820	VHL	7428	A149S (c.445G>T)			3	10188302	10188302	G	T	ENST00000256474.2	75	GRCh37					missense_variant	NP_000542.1:p.Ala149Ser,NM_000551.2:c.445G>T,ENST00000256474.2:c.445G>T,NC_000003.11:g.10188302G>T	2017-02-01 02:25:11 UTC
821	https://civic.genome.wustl.edu/links/variants/821	HLA-C	3107	COPY-NEUTRAL LOSS OF HETEROZYGOSITY																	2017-01-31 16:51:06 UTC
822	https://civic.genome.wustl.edu/links/variants/822	JAK1	3716	S703I			1	65311203	65311203	C	A	ENST00000342505.4	75	GRCh37					missense_variant	ENST00000342505.4:c.2108G>T	2017-02-23 20:10:10 UTC
823	https://civic.genome.wustl.edu/links/variants/823	EPCAM	4072	3' EXON DELETION																	2017-02-02 21:56:12 UTC
824	https://civic.genome.wustl.edu/links/variants/824	MAP2K1	5604	K57T																	2017-02-13 12:55:10 UTC
825	https://civic.genome.wustl.edu/links/variants/825	ARAF	369	S490T																	2017-02-13 12:58:01 UTC
826	https://civic.genome.wustl.edu/links/variants/826	GNAS	2778	R201C			20	57484420	57484420	C	T	ENST00000371085.3	75	GRCh37					missense_variant	NM_000516.5:c.601C>T,NP_000507.1:p.Arg201Cys,NC_000020.10:g.57484420C>T,ENST00000371085.3:c.601C>T	2017-05-23 15:08:58 UTC
827	https://civic.genome.wustl.edu/links/variants/827	FGFR3	2261	MUTATION																	2017-02-13 16:42:18 UTC
828	https://civic.genome.wustl.edu/links/variants/828	FGFR2	2263	FUSION																	2017-02-13 16:48:59 UTC
829	https://civic.genome.wustl.edu/links/variants/829	VHL	7428	M54IFS (c.162_166delGGAGG)			3	10183693	10183697	GGAGG		ENST00000256474.2	75	GRCh37					frameshift_truncation	NM_000551.2:c.162_166delGGAGG,NP_000542.1:p.Met54IlefsTer76,NC_000003.11:g.10183693_10183697del,ENST00000256474.2:c.162_166delGGAGG	2017-03-17 12:49:50 UTC
830	https://civic.genome.wustl.edu/links/variants/830	FGFR3	2261	FGFR3-TACC3																	2017-02-17 16:27:58 UTC
837	https://civic.genome.wustl.edu/links/variants/837	SMO	6608	W535L			7	128850341	128850341	G	T	ENST00000249373.3	75	GRCh37					missense_variant	NM_005631.4:c.1604G>T,NP_005622.1:p.Trp535Leu,ENST00000249373.3:c.1604G>T,NC_000007.13:g.128850341G>T	2017-05-23 15:27:48 UTC
838	https://civic.genome.wustl.edu/links/variants/838	PTEN	5728	R173C			10	89711899	89711899	C	T	ENST00000371953.3	75	GRCh37					missense_variant	NM_000314.6:c.517C>T,NP_000305.3:p.Arg173Cys,ENST00000371953.3:c.517C>T,NC_000010.10:g.89711899C>T	2017-02-28 22:42:33 UTC
839	https://civic.genome.wustl.edu/links/variants/839	ALK	238	ALTERNATIVE TRANSCRIPT (ATI)	This novel ALK transcript (alternative isoform) initiates from a de novo alternative transcription initiation (ATI) site in ALK intron 19.																2017-05-17 21:52:37 UTC
840	https://civic.genome.wustl.edu/links/variants/840	BRAF	673	G469R			7	140481403	140481403	C	G	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1405G>C,NP_004324.2:p.Gly469Arg,NC_000007.13:g.140481403C>G,ENST00000288602.6c.1405G>C	2017-04-25 15:54:36 UTC
841	https://civic.genome.wustl.edu/links/variants/841	BRAF	673	G469V			7	140481402	140481402	C	A	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1406G>T,NP_004324.2:p.Gly469Val,ENST00000288602.6:c.1406G>T,NC_000007.13:g.140481402C>A	2017-04-25 15:56:19 UTC
842	https://civic.genome.wustl.edu/links/variants/842	BRAF	673	APC																	2017-03-09 19:04:42 UTC
843	https://civic.genome.wustl.edu/links/variants/843	VHL	7428	EXON 1-3 DELETION			3	10183532	10191649			ENST00000256474.2	75	GRCh37					exon_loss_variant	ENST00000256474.2:c.1-?_642+?del	2017-03-16 16:26:30 UTC
844	https://civic.genome.wustl.edu/links/variants/844	VHL	7428	EXON 1 DELETION			3	10183532	10183871			ENST00000256474.2	75	GRCh37					exon_loss_variant	ENST00000256474.2:c.1-?_340+?del	2017-03-13 01:59:36 UTC
845	https://civic.genome.wustl.edu/links/variants/845	VHL	7428	EXON 1-2 DELETION			3	10183532	10188320			ENST00000256474.2	75	GRCh37					exon_loss_variant	ENST00000256474.2:c.1-?_463+?del	2017-03-13 20:19:30 UTC
846	https://civic.genome.wustl.edu/links/variants/846	VHL	7428	M1FS (c.1_17del17)			3	10183532	10183548	ATGCCCCGGAGGGCGGA		ENST00000256474.2	75	GRCh37					start_lost	ENST00000256474.2:c.1_17del17	2017-03-30 15:52:19 UTC
847	https://civic.genome.wustl.edu/links/variants/847	VHL	7428	M1? (c.1-1_20del21)			3	10183531	10183551	AATGCCCCGGAGGGCGGAGAA		ENST00000256474.2	75	GRCh37					start_lost	NP_000542.1:p.0,NP_000542.1:p.Met1?,NM_000551.3:c.1-1_20del21,ENST00000256474.2:c.1-1_20del21,NC_000003.11:g.10183531_10183551del	2017-03-18 01:24:46 UTC
848	https://civic.genome.wustl.edu/links/variants/848	VHL	7428	M1? (c.3G>A)			3	10183534	10183534	G	A	ENST00000256474.2	75	GRCh37					start_lost	NP_000542.1:p.0,NP_000542.1:p.Met1?,NM_000551.3:c.3G>A,ENST00000256474.2:c.3G>A	2017-03-17 12:14:04 UTC
849	https://civic.genome.wustl.edu/links/variants/849	VHL	7428	N7D (c.19A>G)			3	10183550	10183550	A	G	ENST00000256474.2	75	GRCh37					missense_variant	NC_000003.11:g.10183550A>G,NM_000551.3:c.19A>G,ENST00000256474.2:c.19A>G,NP_000542.1:c.Asn7Asp	2017-03-17 10:00:37 UTC
850	https://civic.genome.wustl.edu/links/variants/850	VHL	7428	P25L (c.74C>T)			3	10183605	10183605	C	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.74C>T,NP_000542.1:p.Pro25Leu,ENST00000256474.2:c.74C>T,NC_000003.11:g.10183605C>T	2017-03-13 02:18:06 UTC
851	https://civic.genome.wustl.edu/links/variants/851	VHL	7428	P59fs (c.173_174insC)			3	10183704	10183705		C	ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.173_174insC,NP_000542.1:p.Pro59AlafsTer73,NM_000551.3:c.173_174insC	2017-03-19 21:17:22 UTC
852	https://civic.genome.wustl.edu/links/variants/852	VHL	7428	Y98FS (C.291_310DEL20)			3	10183822	10183841	CTACCCAACGCTGCCGCCTG		ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.291_310del	2017-03-30 15:58:23 UTC
853	https://civic.genome.wustl.edu/links/variants/853	NBN	4683	LOSS			8	90945564	90996944			ENST00000265433.3	75	GRCh37					loss_of_function_variant		2017-04-18 18:47:34 UTC
854	https://civic.genome.wustl.edu/links/variants/854	HRAS	3265	Q61L			11	533874	533874	T	A	ENST00000451590.1	75	GRCh37					missense_variant	NM_005343.3:c.182A>T,NP_005334.1:p.Gln61Leu,ENST00000451590.1:c.182A>T,NC_000011.9:g.533874T>A	2017-05-14 04:13:36 UTC
855	https://civic.genome.wustl.edu/links/variants/855	KIT	3815	EXON 8 MUTATION																	2017-03-16 08:07:46 UTC
856	https://civic.genome.wustl.edu/links/variants/856	CREBBP	1387	DELETION																	2017-03-16 08:32:28 UTC
857	https://civic.genome.wustl.edu/links/variants/857	NTRK3	4916	EXPRESSION			15	88418230	88799978			ENST00000394480.2	75	GRCh37					N/A		2017-05-22 19:39:38 UTC
858	https://civic.genome.wustl.edu/links/variants/858	CSF1	1435	OVEREXPRESSION																	2017-03-16 08:55:41 UTC
859	https://civic.genome.wustl.edu/links/variants/859	ROS1	6098	OVEREXPRESSION																	2017-03-16 09:00:39 UTC
860	https://civic.genome.wustl.edu/links/variants/860	NTRK1	4914	EXPRESSION																	2017-03-16 09:06:40 UTC
861	https://civic.genome.wustl.edu/links/variants/861	EGFR	1956	T725M			7	55241726	55241726	C	T	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2174C>T	2017-05-16 19:17:43 UTC
862	https://civic.genome.wustl.edu/links/variants/862	PDGFRA	5156	P577S			4	55141083	55141083	C	T	ENST00000257290.5	75	GRCh37					missense_variant	NM_006206.4:c.1729C>T,NP_006197.1:p.Pro577Ser,NC_000004.11:g.55141083C>T,ENST00000257290.5:c.1729C>T	2017-04-18 22:02:35 UTC
863	https://civic.genome.wustl.edu/links/variants/863	PDGFRA	5156	R841K			4	55152090	55152090	G	A	ENST00000257290.5	75	GRCh37					missense_variant	NM_006206.4:c.2522G>A,NP_006197.1:p.Arg841Lys,NC_000004.11:g.55152090G>A,ENST00000257290.5:c.2522G>A	2017-04-18 22:11:01 UTC
864	https://civic.genome.wustl.edu/links/variants/864	PDGFRA	5156	H845Y			4	55152101	55152101	C	T	ENST00000257290.5	75	GRCh37					missense_variant	NM_006206.4:c.2533C>T,NP_006197.1:p.His845Tyr,NC_000004.11:g.55152101C>T,ENST00000257290.5:c.2533C>T	2017-04-18 22:29:03 UTC
865	https://civic.genome.wustl.edu/links/variants/865	PDGFRA	5156	G853D			4	55152126	55152126	G	A	ENST00000257290.5	75	GRCh37					missense_variant	NM_006206.4:c.2558G>A,NP_006197.1:p.Gly853Asp,NC_000004.11:g.55152126G>A,ENST00000257290.5:c.2558G>A	2017-04-12 16:02:43 UTC
866	https://civic.genome.wustl.edu/links/variants/866	MITF	4286	OVEREXPRESSION																	2017-03-17 08:45:39 UTC
867	https://civic.genome.wustl.edu/links/variants/867	MTAP	4507	DELETION																	2017-03-20 10:46:10 UTC
868	https://civic.genome.wustl.edu/links/variants/868	VPS37A	137492	UNDEREXPRESSION																	2017-03-20 16:21:29 UTC
869	https://civic.genome.wustl.edu/links/variants/869	YAP1	10413	OVEREXPRESSION																	2017-03-21 11:20:58 UTC
870	https://civic.genome.wustl.edu/links/variants/870	BTK	695	T316A			X	100613633	100613633	T	C	ENST00000308731.7	75	GRCh37					missense_variant	ENST00000308731.7:c.946T>C,NM_000061:c.946T>C	2017-05-23 15:46:35 UTC
871	https://civic.genome.wustl.edu/links/variants/871	ERBB2	2064	T862A			17	37881392	37881392	A	G	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2584A>G	2017-05-23 15:50:59 UTC
872	https://civic.genome.wustl.edu/links/variants/872	ERBB2	2064	V773A			17	37880989	37880989	T	C	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2318T>C	2017-05-23 15:56:40 UTC
873	https://civic.genome.wustl.edu/links/variants/873	ERBB2	2064	N857S			17	37881378	37881378	A	G	ENST00000269571.5	75	GRCh37					missense_variant	NC_000017.10:g.37881378A>G,NP_004439.2:p.Asn857Ser,NM_004448.3:c.2570A>G,ENST00000269571.5:c.2570A>G	2017-05-23 16:02:45 UTC
874	https://civic.genome.wustl.edu/links/variants/874	ERBB2	2064	H878Y			17	37881440	37881440	C	T	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2632C>T	2017-05-23 16:09:56 UTC
875	https://civic.genome.wustl.edu/links/variants/875	ERBB2	2064	OVEREXPRESSION																	2017-03-27 12:21:57 UTC
876	https://civic.genome.wustl.edu/links/variants/876	GNAS	2778	MUTATION																	2017-03-28 20:08:40 UTC
877	https://civic.genome.wustl.edu/links/variants/877	GNAS	2778	T393C																	2017-03-28 20:46:12 UTC
878	https://civic.genome.wustl.edu/links/variants/878	NRAS	4893	G12D			1	115258747	115258747	C	T	ENST00000369535.4	75	GRCh37					missense_variant	NM_002524.4:c.35G>A,NP_002515.1:p.Gly12Asp,NC_000001.10:g.115258747C>T,ENST00000369535.4:c.35G>A	2017-04-18 14:49:36 UTC
880	https://civic.genome.wustl.edu/links/variants/880	IDH1	3417	R132L			2	209113112	209113112	C	A	ENST00000415913.1	75	GRCh37					missense_variant	NM_001282386.1:c.395G>T,NP_001269315.1:p.Arg132Leu,NC_000002.11:g.209113112C>A,ENST00000415913.1:c.395G>T	2017-05-23 16:14:37 UTC
881	https://civic.genome.wustl.edu/links/variants/881	PIK3CA	5290	E545Q			3	178936091	178936091	G	C	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1633G>C,NP_006209.2:p.Glu545Gln,NC_000003.11:g.178936091G>C,ENST00000263967.3:c.1633G>C	2017-05-15 22:26:26 UTC
882	https://civic.genome.wustl.edu/links/variants/882	PIK3CA	5290	E545A			3	178936092	178936092	A	C	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1634A>C,NP_006209.2:p.Glu545Ala,NC_000003.11:g.178936092A>C,ENST00000263967.3:c.1634A>C	2017-05-15 22:06:33 UTC
883	https://civic.genome.wustl.edu/links/variants/883	PIK3CA	5290	E545G			3	178936092	178936092	A	G	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1634A>G,NP_006209.2:p.Glu545Gly,NC_000003.11:g.178936092A>G,ENST00000263967.3:c.1634A>G	2017-05-15 22:22:36 UTC
884	https://civic.genome.wustl.edu/links/variants/884	PIK3CA	5290	E545V			3	178936092	178936092	A	T	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1634A>T,NP_006209.2:p.Glu545Val,NC_000003.11:g.178936092A>T,ENST00000263967.3:c.1634A>T	2017-05-15 22:28:01 UTC
885	https://civic.genome.wustl.edu/links/variants/885	PIK3CA	5290	Q546K			3	178936094	178936094	C	A	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1636C>A,NP_006209.2:p.Gln546Lys,NC_000003.11:g.178936094C>A,ENST00000263967.3:c.1636C>A	2017-05-15 22:54:37 UTC
886	https://civic.genome.wustl.edu/links/variants/886	PIK3CA	5290	Q546E			3	178936094	178936094	C	G	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1636C>G,NP_006209.2:p.Gln546Glu,NC_000003.11:g.178936094C>G,ENST00000263967.3:c.1636C>G	2017-05-15 22:53:33 UTC
890	https://civic.genome.wustl.edu/links/variants/890	EGFR	1956	L747_S752DELLREATS			7	55242469	55242486		-			GRCh37							2017-05-16 21:42:29 UTC
892	https://civic.genome.wustl.edu/links/variants/892	ABL1	25	F359V			9	133748414	133748414	T	G	ENST00000318560.5	75	GRCh37					missense_variant	NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G	2017-04-18 23:09:41 UTC
893	https://civic.genome.wustl.edu/links/variants/893	NRAS	4893	Q61H			1	115256528	115256528	T	G	ENST00000369535.4	75	GRCh37					missense_variant	NM_002524.4:c.183A>C,NP_002515.1:p.Gln61His,NC_000001.10:g.115256528T>G,ENST00000369535.4:c.183A>C	2017-04-18 15:24:17 UTC
895	https://civic.genome.wustl.edu/links/variants/895	NRAS	4893	G13C			1	115258745	115258745	C	A	ENST00000369535.4	75	GRCh37					missense_variant	NM_002524.4:c.37G>T,NP_002515.1:p.Gly13Cys,NC_000001.10:g.115258745C>A,ENST00000369535.4:c.37G>T	2017-04-18 14:56:14 UTC
896	https://civic.genome.wustl.edu/links/variants/896	NRAS	4893	G13R			1	115258745	115258745	C	G	ENST00000369535.4	75	GRCh37					missense_variant	NM_002524.4:c.37G>C,NP_002515.1:p.Gly13Arg,NC_000001.10:g.115258745C>G,ENST00000369535.4:c.37G>C	2017-04-18 15:01:26 UTC
897	https://civic.genome.wustl.edu/links/variants/897	NRAS	4893	G12C			1	115258748	115258748	C	A	ENST00000369535.4	75	GRCh37					missense_variant	NM_002524.4:c.34G>T,NP_002515.1:p.Gly12Cys,NC_000001.10:g.115258748C>A,ENST00000369535.4:c.34G>T	2017-04-18 14:44:29 UTC
898	https://civic.genome.wustl.edu/links/variants/898	NRAS	4893	G12S			1	115258748	115258748	C	T	ENST00000369535.4	75	GRCh37					missense_variant	NM_002524.4:c.34G>A,NP_002515.1:p.Gly12Ser,NC_000001.10:g.115258748C>T,ENST00000369535.4:c.34G>A	2017-04-18 14:52:14 UTC
901	https://civic.genome.wustl.edu/links/variants/901	ATM	472	T2666A			11	108204681	108204681	A	G			GRCh37					missense_variant		2017-05-16 03:35:57 UTC
902	https://civic.genome.wustl.edu/links/variants/902	ATM	472	L2890V			11	108218089	108218089	C	G	ENST00000278616.4	75	GRCh37					missense_variant	NM_000051.3:c.8668C>G,NP_000042.3:p.Leu2890Val,NC_000011.9:g.108218089C>G,ENST00000278616.4:c.8668C>G	2017-05-16 15:58:36 UTC
903	https://civic.genome.wustl.edu/links/variants/903	ATM	472	R3008C			11	108236086	108236086	C	T			GRCh37					missense_variant		2017-05-16 03:40:52 UTC
904	https://civic.genome.wustl.edu/links/variants/904	ATM	472	R3008H			11	108236087	108236087	G	A			GRCh37					missense_variant		2017-05-16 03:39:08 UTC
905	https://civic.genome.wustl.edu/links/variants/905	KRAS	3845	A146P			12	25378562	25378562	C	G	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.436G>C,NP_004976.2:p.Ala146Pro,NC_000012.11:g.25378562C>G,ENST00000256078.4:c.436G>C	2017-05-13 03:23:33 UTC
906	https://civic.genome.wustl.edu/links/variants/906	KRAS	3845	A146T			12	25378562	25378562	C	T	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.436G>A,NP_004976.2:p.Ala146Thr,NC_000012.11:g.25378562C>T,ENST00000256078.4:c.436G>A	2017-04-19 23:40:25 UTC
907	https://civic.genome.wustl.edu/links/variants/907	KRAS	3845	Q61H			12	25380275	25380275	T	G	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.183A>C,NP_004976.2:p.Gln61His,NC_000012.11:g.25380275T>G,ENST00000256078.4:c.183A>C	2017-05-14 19:09:47 UTC
908	https://civic.genome.wustl.edu/links/variants/908	KRAS	3845	Q61L			12	25380276	25380276	T	A	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.182A>T,NP_004976.2:p.Gln61Leu,NC_000012.11:g.25380276T>A,ENST00000256078.4:c.182A>T	2017-05-14 20:36:34 UTC
909	https://civic.genome.wustl.edu/links/variants/909	KRAS	3845	Q61R			12	25380276	25380276	T	C	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.182A>G,NP_004976.2:p.Gln61Arg,NC_000012.11:g.25380276T>C,ENST00000256078.4:c.182A>G	2017-05-14 20:52:27 UTC
910	https://civic.genome.wustl.edu/links/variants/910	KRAS	3845	Q61K			12	25380277	25380277	G	T	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.181C>A,NP_004976.2:p.Gln61Lys,NC_000012.11:g.25380277G>T,ENST00000256078.4:c.181C>A	2017-05-14 20:03:56 UTC
913	https://civic.genome.wustl.edu/links/variants/913	KRAS	3845	G12S			12	25398285	25398285	C	T	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A	2017-05-13 03:46:12 UTC
918	https://civic.genome.wustl.edu/links/variants/918	TP53	7157	R273L			17	7577120	7577120	C	A	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.818G>T,NP_000537.3:p.Arg273Leu,NC_000017.10:g.7577120C>A,ENST00000269305.4:c.818G>T	2017-05-23 16:19:48 UTC
922	https://civic.genome.wustl.edu/links/variants/922	TP53	7157	Y220C			17	7578190	7578190	T	C	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.659A>G,NP_000537.3:p.Tyr220Cys,NC_000017.10:g.7578190T>C,ENST00000269305.4:c.659A>G	2017-05-23 16:23:27 UTC
925	https://civic.genome.wustl.edu/links/variants/925	STK11	6794	LKB1										GRCh37							2017-03-30 22:09:33 UTC
927	https://civic.genome.wustl.edu/links/variants/927	IDH1	3417	R132G			2	209113113	209113113	G	C	ENST00000415913.1	75	GRCh37					missense_variant	NM_001282386.1:c.394C>G,NP_001269315.1:p.Arg132Gly,NC_000002.11:g.209113113G>C,ENST00000415913.1:c.394C>G	2017-05-23 16:29:04 UTC
928	https://civic.genome.wustl.edu/links/variants/928	IDH1	3417	R132S			2	209113113	209113113	G	T	ENST00000415913.1	75	GRCh37					missense_variant	NM_001282386.1:c.394C>A,NP_001269315.1:p.Arg132Ser,NC_000002.11:g.209113113G>T,ENST00000415913.1:c.394C>A	2017-05-23 16:31:09 UTC
931	https://civic.genome.wustl.edu/links/variants/931	PIK3CA	5290	C420R			3	178927980	178927980	T	C	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1258T>C,NP_006209.2:p.Cys420Arg,NC_000003.11:g.178927980T>C,ENST00000263967.3:c.1258T>C	2017-05-15 21:59:52 UTC
933	https://civic.genome.wustl.edu/links/variants/933	PIK3CA	5290	E542Q			3	178936082	178936082	G	C	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1624G>C,NP_006209.2:p.Glu542Gln,NC_000003.11:g.178936082G>C,ENST00000263967.3:c.1624G>C	2017-05-15 22:04:17 UTC
934	https://civic.genome.wustl.edu/links/variants/934	PIK3CA	5290	E545D			3	178936093	178936093	G	C	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1635G>C,NP_006209.2:p.Glu545Asp,NC_000003.11:g.178936093G>C,ENST00000263967.3:c.1635G>C	2017-05-15 22:21:00 UTC
935	https://civic.genome.wustl.edu/links/variants/935	PIK3CA	5290	Y1021C			3	178952007	178952007	A	G	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.3062A>G,NP_006209.2:p.Tyr1021Cys,NC_000003.11:g.178952007A>G,ENST00000263967.3:c.3062A>G	2017-05-15 22:56:04 UTC
937	https://civic.genome.wustl.edu/links/variants/937	PIK3CA	5290	M1043I			3	178952074	178952074	G	T			GRCh37					missense_variant	NM_006218.3:c.3129G>T,NP_006209.2:p.Met1043Ile,NC_000003.11:g.178952074G>T	2017-05-15 22:47:50 UTC
938	https://civic.genome.wustl.edu/links/variants/938	PIK3CA	5290	H1047Y			3	178952084	178952084	C	T	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.3139C>T,NP_006209.2:p.His1047Tyr,NC_000003.11:g.178952084C>T,ENST00000263967.3:c.3139C>T	2017-05-15 22:42:18 UTC
939	https://civic.genome.wustl.edu/links/variants/939	PIK3CA	5290	G1049S			3	178952090	178952090	G	A	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.3145G>A,NP_006209.2:p.Gly1049Ser,NC_000003.11:g.178952090G>A,ENST00000263967.3:c.3145G>A	2017-05-15 22:31:39 UTC
940	https://civic.genome.wustl.edu/links/variants/940	PIK3CA	5290	G1049R			3	178952090	178952090	G	C	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.3145G>C,NP_006209.2:p.Gly1049Arg,NC_000003.11:g.178952090G>C,ENST00000263967.3:c.3145G>C	2017-05-15 22:30:22 UTC
946	https://civic.genome.wustl.edu/links/variants/946	KIT	3815	Y503_F504INSAY			4	55592185	55592186		GCCTAT			GRCh37							2017-05-18 20:44:13 UTC
948	https://civic.genome.wustl.edu/links/variants/948	KIT	3815	K550_W557DEL			4	55593582	55593605		-			GRCh37							2017-05-12 18:25:13 UTC
949	https://civic.genome.wustl.edu/links/variants/949	KIT	3815	K550_K558DEL			4	55593582	55593608		-	ENST00000288135.5	75	GRCh37					inframe_deletion	NM_000222.2:c.1648_1674del27,NP_000213.1:p.Lys550_Lys558del,NC_000004.11:g.55593582_55593608del27,ENST00000288135.5:c.1648_1674del27	2017-05-18 20:44:13 UTC
950	https://civic.genome.wustl.edu/links/variants/950	KIT	3815	P551L								ENST00000288135.5	75	GRCh37					missense_variant	ENST00000288135.5:c.1652C>T	2017-05-12 19:22:42 UTC
951	https://civic.genome.wustl.edu/links/variants/951	KIT	3815	M552_W557DEL			4	55593588	55593605		-	ENST00000288135.5	75	GRCh37					inframe_deletion	ENST00000288135.5:c.1654_1671delATGTATGAAGTACAGTGG	2017-05-18 20:44:13 UTC
952	https://civic.genome.wustl.edu/links/variants/952	KIT	3815	Y553D			4	55593591	55593591	T	G	ENST00000288135.5	75	GRCh37					missense_variant	ENST00000288135.5:c.1657T>G	2017-05-12 23:01:34 UTC
953	https://civic.genome.wustl.edu/links/variants/953	KIT	3815	Y553_K558DEL			4	55593591	55593608		-			GRCh37					inframe_deletion		2017-05-12 23:02:35 UTC
954	https://civic.genome.wustl.edu/links/variants/954	KIT	3815	DEL 554-558			4	55593594	55593608		-	ENST00000288135.5	75	GRCh37					inframe_deletion	ENST00000288135.5:c.1660_1674delGAAGTACAGTGGAAG	2017-05-18 20:44:13 UTC
955	https://civic.genome.wustl.edu/links/variants/955	KIT	3815	E554D			4	55593596	55593596	A	C	ENST00000288135.5	75	GRCh37					missense_variant	ENST00000288135.5:c.1662A>C	2017-04-19 17:08:32 UTC
956	https://civic.genome.wustl.edu/links/variants/956	KIT	3815	V555_Q556DEL			4	55593597	55593602		-	ENST00000288135.5	75	GRCh37					inframe_deletion	ENST00000288135.5:c.1663_1668delGTACAG	2017-05-18 20:44:13 UTC
957	https://civic.genome.wustl.edu/links/variants/957	KIT	3815	V555-P573DELVQWKVVEEINGNNYVYIDP			4	55593597	55593653		-			GRCh37					inframe_deletion		2017-05-12 19:53:19 UTC
958	https://civic.genome.wustl.edu/links/variants/958	KIT	3815	W557R			4	55593603	55593603	T	C	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.1669T>C,NP_000213.1:p.Trp557Arg,NC_000004.11:g.55593603T>C,ENST00000288135.5:c.1669T>C	2017-05-12 22:50:27 UTC
959	https://civic.genome.wustl.edu/links/variants/959	KIT	3815	W557G			4	55593603	55593603	T	G	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.1669T>G,NP_000213.1:p.Trp557Gly,NC_000004.11:g.55593603T>G,ENST00000288135.5:c.1669T>G	2017-05-12 22:49:26 UTC
960	https://civic.genome.wustl.edu/links/variants/960	KIT	3815	W557FS										GRCh37							2017-03-30 22:09:36 UTC
961	https://civic.genome.wustl.edu/links/variants/961	KIT	3815	W557_K558DELWK			4	55593603	55593608		-			GRCh37							2017-05-18 20:44:13 UTC
962	https://civic.genome.wustl.edu/links/variants/962	KIT	3815	W557_E561DEL			4	55593603	55593617		-			GRCh37							2017-05-12 22:16:24 UTC
963	https://civic.genome.wustl.edu/links/variants/963	KIT	3815	K558Q			4	55593606	55593606	A	C	ENST00000288135.5	75	GRCh37						NM_000222.2:c.1672A>C,NP_000213.1:p.Lys558Gln,NC_000004.11:g.55593606A>C,ENST00000288135.5:c.1672A>C	2017-05-12 19:05:52 UTC
964	https://civic.genome.wustl.edu/links/variants/964	KIT	3815	K558_V559DEL			4	55593606	55593611		-	ENST00000288135.5	75	GRCh37						ENST00000288135.5:c.1672_1677delAAGGTT	2017-05-18 20:44:13 UTC
965	https://civic.genome.wustl.edu/links/variants/965	KIT	3815	K558R			4	55593607	55593607	A	G	ENST00000288135.5	75	GRCh37					missense_variant	ENST00000288135.5:c.1673A>G	2017-05-12 19:07:02 UTC
966	https://civic.genome.wustl.edu/links/variants/966	KIT	3815	V559DEL			4	55593609	55593611		-	ENST00000288135.5	75	GRCh37						ENST00000288135.5:c.1675_1677delGTT,NM_000222.2:c.1675_1677delGTT,NP_000213.1:p.Val559del,NC_000004.11:g.55593609_55593611delGTT	2017-05-18 20:44:13 UTC
967	https://civic.genome.wustl.edu/links/variants/967	KIT	3815	V559_V560DEL			4	55593609	55593614		-	ENST00000288135.5	75	GRCh37						ENST00000288135.5:c.1675_1680delGTTGTT	2017-05-18 20:44:13 UTC
968	https://civic.genome.wustl.edu/links/variants/968	KIT	3815	V559D										GRCh37							2017-03-30 22:09:36 UTC
969	https://civic.genome.wustl.edu/links/variants/969	KIT	3815	V559A			4	55593610	55593610	T	C	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.1676T>C,NP_000213.1:p.Val559Ala,NC_000004.11:g.55593610T>C,ENST00000288135.5:c.1676T>C	2017-05-12 20:06:49 UTC
970	https://civic.genome.wustl.edu/links/variants/970	KIT	3815	V559G			4	55593610	55593610	T	G	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.1676T>G,NP_000213.1:p.Val559Gly,NC_000004.11:g.55593610T>G,ENST00000288135.5:c.1676T>G	2017-05-12 20:54:53 UTC
971	https://civic.genome.wustl.edu/links/variants/971	KIT	3815	V560D			4	55593613	55593613	T	A	ENST00000288135.5	75	GRCh37						ENST00000288135.5:c.1679T>A,NM_000222.2:c.1679T>A,NP_000213.1:p.Val560Asp,NC_000004.11:g.55593613T>A	2017-05-12 21:30:57 UTC
972	https://civic.genome.wustl.edu/links/variants/972	KIT	3815	V560G			4	55593613	55593613	T	G	ENST00000288135.5	75	GRCh37						NM_000222.2:c.1679T>G,NP_000213.1:p.Val560Gly,NC_000004.11:g.55593613T>G,ENST00000288135.5:c.1679T>G	2017-05-12 22:09:22 UTC
974	https://civic.genome.wustl.edu/links/variants/974	KIT	3815	T574A			4	55593654	55593654	A	G	ENST00000288135.5	75	GRCh37					missense_variant	ENST00000288135.5:c.1720A>G	2017-05-12 19:47:38 UTC
975	https://civic.genome.wustl.edu/links/variants/975	KIT	3815	Q575L			4	55593658	55593658	A	T	ENST00000288135.5	75	GRCh37					missense_variant	ENST00000288135.5:c.1724A>T	2017-05-12 19:31:37 UTC
976	https://civic.genome.wustl.edu/links/variants/976	KIT	3815	P577L			4	55593664	55593664	C	T	ENST00000288135.5	75	GRCh37					missense_variant	ENST00000288135.5:c.1730C>T	2017-05-12 19:27:15 UTC
977	https://civic.genome.wustl.edu/links/variants/977	KIT	3815	D579DEL			4	55593669	55593671		-	ENST00000288135.5	75	GRCh37					inframe_deletion	ENST00000288135.5:c.1735_1737delGAT	2017-05-18 20:44:13 UTC
978	https://civic.genome.wustl.edu/links/variants/978	KIT	3815	K642E			4	55594221	55594221	A	G	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.1924A>G,NP_000213.1:p.Lys642Glu,NC_000004.11:g.55594221A>G,ENST00000288135.5:c.1924A>G	2017-05-12 19:10:21 UTC
979	https://civic.genome.wustl.edu/links/variants/979	KIT	3815	T661I			4	55594279	55594279	C	T	ENST00000288135.5	75	GRCh37					missense_variant	ENST00000288135.5:c.1982C>T	2017-05-12 19:50:38 UTC
980	https://civic.genome.wustl.edu/links/variants/980	KIT	3815	S692L			4	55595585	55595585	C	T	ENST00000288135.5	75	GRCh37					missense_variant	ENST00000288135.5:c.2075C>T,NP_000213.1:p.Ser692Leu,NC_000004.11:g.55595585C>T,NM_000222.2:c.2075C>T	2017-05-12 19:42:05 UTC
981	https://civic.genome.wustl.edu/links/variants/981	KIT	3815	Q694K			4	55595590	55595590	C	A	ENST00000288135.5	75	GRCh37					missense_variant	ENST00000288135.5:c.2080C>A	2017-05-12 19:33:31 UTC
983	https://civic.genome.wustl.edu/links/variants/983	KIT	3815	D816H			4	55599320	55599320	G	C	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.2446G>C,NP_000213.1:p.Asp816His,NC_000004.11:g.55599320G>C,ENST00000288135.5:c.2446G>C	2017-04-19 05:14:31 UTC
986	https://civic.genome.wustl.edu/links/variants/986	KIT	3815	D820Y			4	55599332	55599332	G	T	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.2458G>T,NP_000213.1:p.Asp820Tyr,NC_000004.11:g.55599332G>T,ENST00000288135.5:c.2458G>T	2017-04-19 15:51:46 UTC
989	https://civic.genome.wustl.edu/links/variants/989	KIT	3815	Y823D			4	55599341	55599341	T	G	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.2467T>G,NP_000213.1:p.Tyr823Asp,NC_000004.11:g.55599341T>G,ENST00000288135.5:c.2467T>G	2017-05-12 22:58:58 UTC
999	https://civic.genome.wustl.edu/links/variants/999	EGFR	1956	G719A			7	55241708	55241708	G	C	ENST00000275493.2	75	GRCh37					missense_variant	NM_005228.4:c.2156G>C,NP_005219.2:p.Gly719Ala,NC_000007.13:g.55241708G>C,ENST00000275493.2:c.2156G>C	2017-05-16 19:11:05 UTC
1002	https://civic.genome.wustl.edu/links/variants/1002	EGFR	1956	E746_A750DELELREA			7	55242465	55242479		-			GRCh37					inframe_deletion		2017-05-17 02:41:35 UTC
1003	https://civic.genome.wustl.edu/links/variants/1003	EGFR	1956	E746_T751>I										GRCh37							2017-03-30 22:09:39 UTC
1004	https://civic.genome.wustl.edu/links/variants/1004	EGFR	1956	E746_T751>A			7	55242467	55242481		-			GRCh37							2017-05-17 02:59:37 UTC
1005	https://civic.genome.wustl.edu/links/variants/1005	EGFR	1956	E746V										GRCh37							2017-03-30 22:09:39 UTC
1006	https://civic.genome.wustl.edu/links/variants/1006	EGFR	1956	L747_A750>P			7	55242468	55242478		GC			GRCh37							2017-05-16 20:30:58 UTC
1007	https://civic.genome.wustl.edu/links/variants/1007	EGFR	1956	L747_T751DELLREAT			7	55242468	55242482		-			GRCh37							2017-05-16 22:26:49 UTC
1008	https://civic.genome.wustl.edu/links/variants/1008	EGFR	1956	L747_T751>Q			7	55242468	55242482		GCA			GRCh37							2017-05-16 22:15:25 UTC
1009	https://civic.genome.wustl.edu/links/variants/1009	EGFR	1956	E746_S752>D			7	55242468	55242485		-			GRCh37					inframe_deletion		2017-05-17 02:49:53 UTC
1010	https://civic.genome.wustl.edu/links/variants/1010	EGFR	1956	L747_T751>P			7	55242469	55242481		C			GRCh37							2017-05-16 22:06:28 UTC
1011	https://civic.genome.wustl.edu/links/variants/1011	EGFR	1956	L747_P753>Q			7	55242469	55242488		CA			GRCh37							2017-05-16 21:14:51 UTC
1012	https://civic.genome.wustl.edu/links/variants/1012	EGFR	1956	L747_P753DELINSS			7	55242470	55242487		-			GRCh37					inframe_deletion		2017-05-16 21:21:28 UTC
1017	https://civic.genome.wustl.edu/links/variants/1017	EGFR	1956	R831H			7	55259434	55259434	G	A	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2492G>A	2017-05-16 19:24:32 UTC
1021	https://civic.genome.wustl.edu/links/variants/1021	ABL1	25	M244V			9	133738330	133738330	A	G	ENST00000318560.5	75	GRCh37					missense_variant	NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G	2017-04-18 23:34:57 UTC
1022	https://civic.genome.wustl.edu/links/variants/1022	ABL1	25	L248V			9	133738342	133738342	C	G	ENST00000318560.5	75	GRCh37					missense_variant	NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G	2017-04-18 23:28:57 UTC
1023	https://civic.genome.wustl.edu/links/variants/1023	ABL1	25	G250E			9	133738349	133738349	G	A	ENST00000318560.5	75	GRCh37					missense_variant	NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A	2017-04-18 23:15:31 UTC
1024	https://civic.genome.wustl.edu/links/variants/1024	ABL1	25	Q252H			9	133738356	133738356	G	C	ENST00000318560.5	75	GRCh37					missense_variant	NM_005157.5:c.756G>C,NP_005148.2:p.Gln252His,NC_000009.11:g.133738356G>C,ENST00000318560.5:c.756G>C	2017-04-18 23:40:44 UTC
1025	https://civic.genome.wustl.edu/links/variants/1025	ABL1	25	Y253H			9	133738357	133738357	T	C	ENST00000318560.5	75	GRCh37					missense_variant	NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C	2017-04-19 04:06:32 UTC
1026	https://civic.genome.wustl.edu/links/variants/1026	ABL1	25	Y253F			9	133738358	133738358	A	T	ENST00000318560.5	75	GRCh37					missense_variant	ENST00000318560.5:c.758A>T,NM_005157.5:c.758A>T,NP_005148.2:p.Tyr253Phe,NC_000009.11:g.133738358A>T	2017-04-19 04:03:28 UTC
1027	https://civic.genome.wustl.edu/links/variants/1027	ABL1	25	D276G			9	133747520	133747520	A	G	ENST00000318560.5	75	GRCh37					missense_variant	ENST00000318560.5:c.827A>G,NP_005148.2:p.Asp276Gly,NM_005157.5:c.827A>G,NC_000009.11:g.133747520A>G	2017-04-18 22:52:14 UTC
1028	https://civic.genome.wustl.edu/links/variants/1028	ABL1	25	F317L			9	133748290	133748290	C	G	ENST00000318560.5	75	GRCh37					missense_variant	NM_005157.5:c.951C>G,NP_005148.2:p.Phe317Leu,NC_000009.11:g.133748290C>G,ENST00000318560.5:c.951C>G	2017-04-18 23:00:36 UTC
1029	https://civic.genome.wustl.edu/links/variants/1029	ABL1	25	M351T			9	133748391	133748391	T	C	ENST00000318560.5	75	GRCh37					missense_variant	NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C	2017-04-18 23:37:56 UTC
1030	https://civic.genome.wustl.edu/links/variants/1030	ABL1	25	H396R			9	133750356	133750356	A	G	ENST00000318560.5	75	GRCh37					missense_variant	NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G	2017-04-18 23:25:54 UTC
1031	https://civic.genome.wustl.edu/links/variants/1031	NOTCH1	4851	L1600P			9	139399344	139399344	A	G	ENST00000277541.6	75	GRCh37						ENST00000277541.6:c.4799T>C	2017-05-23 16:59:16 UTC
1032	https://civic.genome.wustl.edu/links/variants/1032	NOTCH1	4851	L1574P										GRCh37							2017-03-30 22:09:41 UTC
1033	https://civic.genome.wustl.edu/links/variants/1033	NOTCH1	4851	R1598P										GRCh37							2017-03-30 22:09:41 UTC
1034	https://civic.genome.wustl.edu/links/variants/1034	NOTCH1	4851	L1678P										GRCh37							2017-03-30 22:09:41 UTC
1068	https://civic.genome.wustl.edu/links/variants/1068	TP53	7157	Y234C										GRCh37							2017-03-30 22:09:44 UTC
1103	https://civic.genome.wustl.edu/links/variants/1103	KRAS	3845	Q61P			12	25380276	25380276	T	G	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.182A>C,NP_004976.2:p.Gln61Pro,NC_000012.11:g.25380276T>G,ENST00000256078.4:c.182A>C	2017-05-14 20:43:13 UTC
1104	https://civic.genome.wustl.edu/links/variants/1104	KRAS	3845	Q61E			12	25380277	25380277	G	C	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.181C>G,NP_004976.2:p.Gln61Glu,NC_000012.11:g.25380277G>C,ENST00000256078.4:c.181C>G	2017-05-14 18:14:02 UTC
1105	https://civic.genome.wustl.edu/links/variants/1105	KRAS	3845	Q61FS										GRCh37							2017-03-30 22:09:47 UTC
1106	https://civic.genome.wustl.edu/links/variants/1106	BRAF	673	G464V			7	140481417	140481417	C	A	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1391G>T,NP_004324.2:p.Gly464Val,NC_000007.13:g.140481417C>A,ENST00000288602.6:c.1391G>T	2017-04-25 15:50:00 UTC
1107	https://civic.genome.wustl.edu/links/variants/1107	BRAF	673	D594N			7	140453155	140453155	C	T	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1780G>A,NP_004324.2:p.Asp594Asn,NC_000007.13:g.140453155C>T,ENST00000288602.6:c.1780G>A	2017-04-02 02:14:39 UTC
1108	https://civic.genome.wustl.edu/links/variants/1108	TP53	7157	R282L			17	7577093	7577093	C	A	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.845G>T,NP_000537.3:p.Arg282Leu,NC_000017.10:g.7577093C>A,ENST00000269305.4:c.845G>T	2017-05-23 17:02:34 UTC
1109	https://civic.genome.wustl.edu/links/variants/1109	TP53	7157	R213P			17	7578211	7578211	C	G	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.638G>C,NP_000537.3:p.Arg213Pro,NC_000017.10:g.7578211C>G,ENST00000269305.4:c.638G>C	2017-05-23 18:47:01 UTC
1127	https://civic.genome.wustl.edu/links/variants/1127	NOTCH1	4851	F1592S			9	139399368	139399368	A	G	ENST00000277541.6	75	GRCh37						ENST00000277541.6:c.4775T>C	2017-05-23 19:21:59 UTC
1140	https://civic.genome.wustl.edu/links/variants/1140	NOTCH1	4851	L1600Q			9	139399344	139399344	A	T	ENST00000277541.6	75	GRCh37						ENST00000277541.6:c.4799T>A	2017-05-23 19:56:57 UTC
1142	https://civic.genome.wustl.edu/links/variants/1142	NOTCH1	4851	L1585R			9	139399389	139399389	A	C	ENST00000277541.6	75	GRCh37						ENST00000277541.6:c.4754T>G	2017-05-23 19:59:21 UTC
1143	https://civic.genome.wustl.edu/links/variants/1143	NOTCH1	4851	V1577A			9	139399413	139399413	A	G	ENST00000277541.6	75	GRCh37					missense_variant	ENST00000277541.6:c.4730T>G	2017-05-23 20:01:22 UTC
1144	https://civic.genome.wustl.edu/links/variants/1144	NOTCH1	4851	V1577E			9	139399413	139399413	A	T	ENST00000277541.6	75	GRCh37					missense_variant	ENST00000277541.6:c.4730T>A	2017-05-23 20:02:32 UTC
1145	https://civic.genome.wustl.edu/links/variants/1145	NOTCH1	4851	L1574Q			9	139399422	139399422	A	T	ENST00000277541.6	75	GRCh37						ENST00000277541.6:c.4721T>A	2017-05-23 20:04:22 UTC
1151	https://civic.genome.wustl.edu/links/variants/1151	PIK3CA	5290	H1047L			3	178952085	178952085	A	T	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.3140A>T,NP_006209.2:p.His1047Leu,NC_000003.11:g.178952085A>T,ENST00000263967.3:c.3140A>T	2017-05-15 22:32:46 UTC
1152	https://civic.genome.wustl.edu/links/variants/1152	ABL1	25	F486S			9	133755488	133755488	T	C	ENST00000318560.5	75	GRCh37					missense_variant	ENST00000318560.5:c.1457T>C	2017-04-18 23:12:46 UTC
1153	https://civic.genome.wustl.edu/links/variants/1153	ATM	472	P292R			11	108115727	108115727	C	G	ENST00000278616.4	75	GRCh37					missense_variant	ENST00000278616.4:c.875C>G	2017-05-16 15:46:28 UTC
1154	https://civic.genome.wustl.edu/links/variants/1154	ATM	472	M1FS										GRCh37							2017-03-30 22:09:50 UTC
1155	https://civic.genome.wustl.edu/links/variants/1155	ATM	472	K293*			11	108115729	108115729	A	T	ENST00000278616.4	75	GRCh37					stop_gained	ENST00000278616.4:c.877A>T,NM_000051.3:c.877A>T,NP_000042.3:p.Lys293Ter,NC_000011.9:g.108115729A>T	2017-05-23 20:06:41 UTC
1156	https://civic.genome.wustl.edu/links/variants/1156	ATM	472	R2459C			11	108201008	108201008	C	T			GRCh37					missense_variant		2017-05-16 15:23:21 UTC
1157	https://civic.genome.wustl.edu/links/variants/1157	ATM	472	Q984E			11	108142006	108142006	C	G	ENST00000278616.4	75	GRCh37					missense_variant	ENST00000278616.4:c.2950C>G	2017-05-16 15:48:00 UTC
1158	https://civic.genome.wustl.edu/links/variants/1158	ATM	472	F1025L			11	108142131	108142131	T	G	ENST00000278616.4	75	GRCh37					missense_variant	ENST00000278616.4:c.3075T>G	2017-05-16 15:36:25 UTC
1159	https://civic.genome.wustl.edu/links/variants/1159	ATM	472	Q1084*			11	108143545	108143545	C	T	ENST00000278616.4	75	GRCh37					stop_gained	ENST00000278616.4:c.3250C>T	2017-05-23 20:08:48 UTC
1160	https://civic.genome.wustl.edu/links/variants/1160	ATM	472	D1930V			11	108180913	108180913	A	T	ENST00000278616.4	75	GRCh37					missense_variant	ENST00000278616.4:c.5789A>T	2017-05-16 15:32:16 UTC
1161	https://civic.genome.wustl.edu/links/variants/1161	ATM	472	R2034P			11	108186743	108186743	G	C			GRCh37							2017-05-16 15:20:19 UTC
1162	https://civic.genome.wustl.edu/links/variants/1162	ATM	472	E2187*			11	108192134	108192134	G	T	ENST00000278616.4	75	GRCh37					stop_gained	ENST00000278616.4:c.6559G>T	2017-05-23 20:10:08 UTC
1163	https://civic.genome.wustl.edu/links/variants/1163	ATM	472	L2427P			11	108199938	108199938	T	C	ENST00000278616.4	75	GRCh37					missense_variant	ENST00000278616.4:c.7280T>C	2017-05-16 03:47:29 UTC
1164	https://civic.genome.wustl.edu/links/variants/1164	ATM	472	F2732V			11	108206614	108206614	T	G	ENST00000278616.4	75	GRCh37					missense_variant	ENST00000278616.4:c.8194T>G	2017-05-16 15:38:04 UTC
1165	https://civic.genome.wustl.edu/links/variants/1165	ATM	472	R777FS										GRCh37					frameshift_variant		2017-03-30 22:09:51 UTC
1166	https://civic.genome.wustl.edu/links/variants/1166	ATM	472	K468FS			11	108121594	108121595	AA		ENST00000278616.4	75	GRCh37					frameshift_variant	NM_000051.3:c.1402_1403delAA,NP_000042.3:p.Lys468Glufs,NC_000011.9:g.108121594_108121595delAA,ENST00000278616.4:c.1402_1403delAA	2017-05-23 20:12:19 UTC
1167	https://civic.genome.wustl.edu/links/variants/1167	ATM	472	V1268FS										GRCh37					frameshift_variant		2017-03-30 22:09:51 UTC
1168	https://civic.genome.wustl.edu/links/variants/1168	ATM	472	D1682H			11	108170479	108170479	G	C	ENST00000278616.4	75	GRCh37					missense_variant	NM_000051.3:c.5044G>C,NP_000042.3:p.Asp1682His,NC_000011.9:g.108170479G>C,ENST00000278616.4:c.5044G>C	2017-05-16 03:21:49 UTC
1169	https://civic.genome.wustl.edu/links/variants/1169	ATM	472	A2062V			11	108186827	108186827	C	T	ENST00000278616.4	75	GRCh37					missense_variant	ENST00000278616.4:c.6185C>T	2017-05-16 15:31:25 UTC
1170	https://civic.genome.wustl.edu/links/variants/1170	ATM	472	R1575H			11	108164152	108164152	G	A			GRCh37					missense_variant		2017-05-16 15:50:21 UTC
1171	https://civic.genome.wustl.edu/links/variants/1171	ATM	472	A2274T			11	108196797	108196797	G	A	ENST00000278616.4	75	GRCh37					missense_variant	NM_000051.3:c.6820G>A,NP_000042.3:p.Ala2274Thr,NC_000011.9:g.108196797G>A,ENST00000278616.4:c.6820G>A	2017-05-16 03:16:28 UTC
1172	https://civic.genome.wustl.edu/links/variants/1172	ATM	472	C2488Y			11	108201096	108201096	G	A	ENST00000278616.4	75	GRCh37					missense_variant	NM_000051.3:c.7463G>A,NP_000042.3:p.Cys2488Tyr,NC_000011.9:g.108201096G>A,ENST00000278616.4:c.7463G>A	2017-05-16 03:19:15 UTC
1173	https://civic.genome.wustl.edu/links/variants/1173	ABL1	25	E255V			9	133738364	133738364	A	T	ENST00000318560.5	75	GRCh37					missense_variant	NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T	2017-04-14 15:21:51 UTC
1174	https://civic.genome.wustl.edu/links/variants/1174	NOTCH1	4851	F1592C			9	139399368	139399368	A	C	ENST00000277541.6	75	GRCh37						NM_017617.4:c.4775T>G,NP_060087.3:p.Phe1592Cys,NC_000009.11:g.139399368A>C,ENST00000277541.6:c.4775T>G	2017-05-23 20:14:38 UTC
1183	https://civic.genome.wustl.edu/links/variants/1183	ABL1	25	E292V			9	133747568	133747568	A	T	ENST00000318560.5	75	GRCh37					missense_variant	ENST00000318560.5:c.875A>T	2017-04-18 22:57:11 UTC
1184	https://civic.genome.wustl.edu/links/variants/1184	ABL1	25	F359C			9	133748415	133748415	T	G	ENST00000318560.5	75	GRCh37					missense_variant	NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G	2017-04-18 23:06:17 UTC
1206	https://civic.genome.wustl.edu/links/variants/1206	KIT	3815	S501_A502INSAY			4	55592179	55592180		GCCTAT			GRCh37					inframe_insertion		2017-05-18 20:44:13 UTC
1214	https://civic.genome.wustl.edu/links/variants/1214	EGFR	1956	E746_T751>VA			7	55242467	55242483		TTGCT			GRCh37					inframe_deletion		2017-05-17 14:59:48 UTC
1230	https://civic.genome.wustl.edu/links/variants/1230	ABL1	25	L384M			9	133750319	133750319	C	A	ENST00000318560.5	75	GRCh37					missense_variant	ENST00000318560.5:c.1150C>A	2017-04-18 23:31:03 UTC
1231	https://civic.genome.wustl.edu/links/variants/1231	ABL1	25	V299L			9	133747588	133747588	G	C	ENST00000318560.5	75	GRCh37					missense_variant	NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C	2017-04-18 23:42:46 UTC
1232	https://civic.genome.wustl.edu/links/variants/1232	ABL1	25	L387F			9	133750330	133750330	G	C	ENST00000318560.5	75	GRCh37					missense_variant	ENST00000318560.5:c.1161G>C	2017-04-18 23:33:04 UTC
1233	https://civic.genome.wustl.edu/links/variants/1233	ABL1	25	G398R			9	133750361	133750361	G	C	ENST00000318560.5	75	GRCh37					missense_variant	ENST00000318560.5:c.1192G>C	2017-04-18 23:21:02 UTC
1234	https://civic.genome.wustl.edu/links/variants/1234	PIK3CA	5290	K111N			3	178916946	178916946	G	C	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.333G>C,NP_006209.2:p.Lys111Asn,NC_000003.11:g.178916946G>C,ENST00000263967.3:c.333G>C	2017-05-15 22:44:48 UTC
1235	https://civic.genome.wustl.edu/links/variants/1235	PIK3CA	5290	I391M			3	178927410	178927410	A	G	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1173A>G,NP_006209.2:p.Ile391Met,NC_000003.11:g.178927410A>G,ENST00000263967.3:c.1173A>G	2017-05-15 22:43:35 UTC
1236	https://civic.genome.wustl.edu/links/variants/1236	BRCA1	672	M1V			17	41276113	41276113	T	C	ENST00000471181.2	75	GRCh37						NM_007294.3:c.1A>G,NP_009225.1:p.Met1Val,NC_000017.10:g.41276113T>C,ENST00000471181.2:c.1A>G	2017-05-02 05:38:25 UTC
1237	https://civic.genome.wustl.edu/links/variants/1237	BRCA1	672	M1I			17	41276111	41276111	C	A	ENST00000471181.2	75	GRCh37						NM_007294.3:c.3G>T,NP_009225.1:p.Met1Ile,NC_000017.10:g.41276111C>A,ENST00000471181.2:c.3G>T	2017-05-02 05:34:43 UTC
1238	https://civic.genome.wustl.edu/links/variants/1238	BRCA1	672	C61G			17	41258504	41258504	A	C	ENST00000471181.2	75	GRCh37					missense_variant	NM_007294.3:c.181T>G,NP_009225.1:p.Cys61Gly,NC_000017.10:g.41258504A>C,ENST00000471181.2:c.181T>G	2017-05-02 04:31:50 UTC
1239	https://civic.genome.wustl.edu/links/variants/1239	BRCA1	672	C64Y			17	41258494	41258494	C	T	ENST00000471181.2	75	GRCh37					missense_variant	NM_007294.3:c.191G>A,NP_009225.1:p.Cys64Tyr,NC_000017.10:g.41258494C>T,ENST00000471181.2:c.191G>A	2017-05-02 04:37:48 UTC
1240	https://civic.genome.wustl.edu/links/variants/1240	BRCA1	672	R71G										GRCh37							2017-03-30 22:09:56 UTC
1241	https://civic.genome.wustl.edu/links/variants/1241	BRCA1	672	R71K										GRCh37							2017-03-30 22:09:56 UTC
1242	https://civic.genome.wustl.edu/links/variants/1242	BRCA1	672	R1495M										GRCh37					missense_variant		2017-03-30 22:09:56 UTC
1243	https://civic.genome.wustl.edu/links/variants/1243	BRCA1	672	E1559K			17	41226348	41226348	C	T	ENST00000357654.3	75	GRCh37					missense_variant	NM_007294.3:c.4675G>A,NP_009225.1:p.Glu1559Lys,NC_000017.10:g.41226348C>T,ENST00000357654.3:c.4675G>A	2017-05-02 05:01:21 UTC
1244	https://civic.genome.wustl.edu/links/variants/1244	BRCA1	672	D1692N			17	41219625	41219625	C	T	ENST00000357654.3	75	GRCh37					missense_variant	NM_007294.3:c.5074G>A,NP_009225.1:p.Asp1692Asn,NC_000017.10:g.41219625C>T,ENST00000357654.3:c.5074G>A	2017-05-02 04:44:21 UTC
1245	https://civic.genome.wustl.edu/links/variants/1245	BRCA1	672	R1443X										GRCh37							2017-03-30 22:09:57 UTC
1246	https://civic.genome.wustl.edu/links/variants/1246	BRCA1	672	Q1467X										GRCh37							2017-03-30 22:09:57 UTC
1247	https://civic.genome.wustl.edu/links/variants/1247	BRCA2	675	M1R			13	32890599	32890599	T	G			GRCh37					missense_variant		2017-04-18 15:50:56 UTC
1248	https://civic.genome.wustl.edu/links/variants/1248	BRCA2	675	M1I			13	32890600	32890600	G	T			GRCh37					missense_variant		2017-04-18 15:40:56 UTC
1249	https://civic.genome.wustl.edu/links/variants/1249	BRCA2	675	V159M										GRCh37					missense_variant		2017-03-30 22:09:57 UTC
1250	https://civic.genome.wustl.edu/links/variants/1250	BRCA2	675	V211L			13	32900751	32900751	G	C			GRCh37					missense_variant		2017-04-18 18:44:57 UTC
1251	https://civic.genome.wustl.edu/links/variants/1251	BRCA2	675	V211I			13	32900751	32900751	G	A			GRCh37							2017-04-18 18:41:44 UTC
1252	https://civic.genome.wustl.edu/links/variants/1252	BRCA2	675	R2336P			13	32921033	32921033	G	C	ENST00000544455.1	75	GRCh37					missense_variant	NM_000059.3:c.7007G>C,NP_000050.2:p.Arg2336Pro,NC_000013.10:g.32921033G>C,ENST00000544455.1:c.7007G>C	2017-04-18 16:08:55 UTC
1253	https://civic.genome.wustl.edu/links/variants/1253	BRCA2	675	R2336H			13	32921033	32921033	G	A	ENST00000544455.1	75	GRCh37					missense_variant	NM_000059.3:c.7007G>A,NP_000050.2:p.Arg2336His,ENST00000544455.1:c.7007G>A,NC_000013.10:g.32921033G>A	2017-04-18 16:05:41 UTC
1254	https://civic.genome.wustl.edu/links/variants/1254	TP53	7157	V143A																	2017-03-31 06:47:23 UTC
1255	https://civic.genome.wustl.edu/links/variants/1255	MGMT	4255	UNDEREXPRESSION																	2017-04-03 14:44:42 UTC
1256	https://civic.genome.wustl.edu/links/variants/1256	TERT	7015	OVEREXPRESSION																	2017-04-03 15:10:33 UTC
1257	https://civic.genome.wustl.edu/links/variants/1257	RRM1	6240	UNDEREXPRESSION																	2017-04-03 17:28:56 UTC
1258	https://civic.genome.wustl.edu/links/variants/1258	PTPRF	5792	EXPRESSION																	2017-04-04 14:04:51 UTC
1259	https://civic.genome.wustl.edu/links/variants/1259	AEBP1	165	OVEREXPRESSION																	2017-04-04 15:44:22 UTC
1260	https://civic.genome.wustl.edu/links/variants/1260	RET	5979	C609Y	There is some functional evidence that this variant leads to reduced RET activity (PMID: 9230192) and increased cell proliferation and resistance to apoptosis (PMID: 16715139). It has been widely reported in both familial and sporadic cases of multiple endocrine neoplasia type 2 with medullary thyroid cancers. Despite extensive WGS and Exome coverage for a combined total of ~150k alleles in the GNOMAD browser, this variant has never been observed.		10	43609070	43609070	G	A	ENST00000355710.3	75	GRCh37					missense_variant	NM_020630.4:c.1826G>A,NC_000010.10:g.43609070G>A,NP_065681.1:p.Cys609Tyr,ENST00000355710.3:c.1826G>A	2017-04-05 04:01:33 UTC
1261	https://civic.genome.wustl.edu/links/variants/1261	MDM2	4193	AMPLIFICATION																	2017-04-05 13:05:30 UTC
1262	https://civic.genome.wustl.edu/links/variants/1262	MDM4	4194	EXPRESSION																	2017-04-05 13:08:01 UTC
1263	https://civic.genome.wustl.edu/links/variants/1263	KIT	3815	D822K																	2017-04-05 13:26:28 UTC
1264	https://civic.genome.wustl.edu/links/variants/1264	KIT	3815	C809G			4	55599299	55599299	T	G	ENST00000288135.5	75	GRCh37					missense_variant	ENST00000288135.5:c.2425T>G	2017-04-19 04:15:27 UTC
1265	https://civic.genome.wustl.edu/links/variants/1265	KIT	3815	D820A			4	55599333	55599333	A	C	ENST00000288135.5	75	GRCh37					missense_variant	ENST00000288135.5:c.2459A>C	2017-04-19 15:48:43 UTC
1266	https://civic.genome.wustl.edu/links/variants/1266	KIT	3815	D820G			4	55599333	55599333	A	G	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.2459A>G,NP_000213.1:p.Asp820Gly,NC_000004.11:g.55599333A>G,ENST00000288135.5:c.2459A>G	2017-04-19 15:53:44 UTC
1267	https://civic.genome.wustl.edu/links/variants/1267	KIT	3815	T670I			4	55595519	55595519	C	T	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.2009C>T,NP_000213.1:p.Thr670Ile,NC_000004.11:g.55595519C>T,ENST00000288135.5:c.2009C>T	2017-05-12 19:52:25 UTC
1268	https://civic.genome.wustl.edu/links/variants/1268	MDM4	4194	AMPLIFICATION																	2017-04-05 13:50:56 UTC
1269	https://civic.genome.wustl.edu/links/variants/1269	BRAF	673	AMPLIFICATION			7	140434279	140624564			ENST00000288602.6	75	GRCh37					transcript_amplification		2017-04-25 15:43:12 UTC
1270	https://civic.genome.wustl.edu/links/variants/1270	MAP2K1	5604	F53L																	2017-04-05 22:15:46 UTC
1271	https://civic.genome.wustl.edu/links/variants/1271	ROS1	6098	G2032R																	2017-04-11 09:15:37 UTC
1272	https://civic.genome.wustl.edu/links/variants/1272	MAP2K1	5604	K57N																	2017-04-11 09:54:59 UTC
1273	https://civic.genome.wustl.edu/links/variants/1273	CTAG1B	1485	OVEREXPRESSION																	2017-04-12 08:07:53 UTC
1274	https://civic.genome.wustl.edu/links/variants/1274	CTAG2	30848	OVEREXPRESSION																	2017-04-12 08:09:38 UTC
1275	https://civic.genome.wustl.edu/links/variants/1275	ALK	238	L1198F			2	29443625	29443625	G	A	ENST00000389048.3	75	GRCh37					missense_variant	ENST00000389048.3:c.3592C>T	2017-05-17 21:51:47 UTC
1276	https://civic.genome.wustl.edu/links/variants/1276	SMO	6608	AMPLIFICATION																	2017-04-12 11:19:19 UTC
1277	https://civic.genome.wustl.edu/links/variants/1277	NTRK3	4916	FUSIONS																	2017-04-13 11:09:54 UTC
1278	https://civic.genome.wustl.edu/links/variants/1278	NTRK1	4914	LMNA-NTRK1																	2017-04-13 11:23:02 UTC
1279	https://civic.genome.wustl.edu/links/variants/1279	BRD4	23476	OVEREXPRESSION																	2017-04-14 16:16:18 UTC
1280	https://civic.genome.wustl.edu/links/variants/1280	NTRK1	4914	AMPLIFICATION																	2017-04-15 14:16:56 UTC
1281	https://civic.genome.wustl.edu/links/variants/1281	NTRK3	4916	AMPLIFICATION			15	88418230	88799978			ENST00000394480.2	75	GRCh37					transcript_amplification		2017-05-22 19:40:05 UTC
1282	https://civic.genome.wustl.edu/links/variants/1282	NTRK1	4914	LMNA-NTRK1 G595R AND G667C																	2017-04-17 20:46:41 UTC
1283	https://civic.genome.wustl.edu/links/variants/1283	CDK2	1017	CYTOPLASMIC EXPRESSION																	2017-04-19 11:30:21 UTC
1284	https://civic.genome.wustl.edu/links/variants/1284	DCC	1630	EXPRESSION																	2017-04-19 13:01:48 UTC
1285	https://civic.genome.wustl.edu/links/variants/1285	CTNNB1	1499	T41A																	2017-04-19 13:05:17 UTC
1286	https://civic.genome.wustl.edu/links/variants/1286	CTNNB1	1499	S45F																	2017-04-19 13:07:00 UTC
1287	https://civic.genome.wustl.edu/links/variants/1287	CTNNB1	1499	S45P																	2017-04-19 13:07:57 UTC
1288	https://civic.genome.wustl.edu/links/variants/1288	JAK3	3718	M511I																	2017-04-19 13:59:40 UTC
1289	https://civic.genome.wustl.edu/links/variants/1289	JAK3	3718	V722I																	2017-04-19 14:13:40 UTC
1290	https://civic.genome.wustl.edu/links/variants/1290	JAK3	3718	S61C																	2017-04-19 14:14:29 UTC
1291	https://civic.genome.wustl.edu/links/variants/1291	JAK1	3716	P429S																	2017-04-19 14:32:37 UTC
1292	https://civic.genome.wustl.edu/links/variants/1292	JAK1	3716	W690*																	2017-04-19 14:37:04 UTC
1293	https://civic.genome.wustl.edu/links/variants/1293	ARID1A	8289	LOSS-OF-FUNCTION																	2017-04-20 11:08:15 UTC
1294	https://civic.genome.wustl.edu/links/variants/1294	VHL	7428	W8* (C.24G>A)																	2017-04-20 22:21:43 UTC
1295	https://civic.genome.wustl.edu/links/variants/1295	ALK	238	F1245V			2	29436860	29436860	A	C	ENST00000389048.3	75	GRCh37					missense_variant	NM_004304.4:c.3733T>G,NP_004295.2:p.Phe1245Val,NC_000002.11:g.29436860A>C,ENST00000389048.3:c.3733T>G	2017-05-23 15:58:25 UTC
1296	https://civic.genome.wustl.edu/links/variants/1296	CTNNB1	1499	ACTIVATING MUTATION																	2017-04-26 08:07:21 UTC
1298	https://civic.genome.wustl.edu/links/variants/1298	BRAF	673	599INST																	2017-04-27 12:25:38 UTC
1299	https://civic.genome.wustl.edu/links/variants/1299	MERTK	10461	OVEREXPRESSION																	2017-05-03 09:06:58 UTC
1300	https://civic.genome.wustl.edu/links/variants/1300	TP53	7157	CONSERVED DOMAIN MUT																	2017-05-08 13:23:41 UTC
1301	https://civic.genome.wustl.edu/links/variants/1301	AKT3	10000	OVEREXPRESSION																	2017-05-12 23:10:14 UTC
1302	https://civic.genome.wustl.edu/links/variants/1302	FLT3	2322	D835V																	2017-05-14 11:34:48 UTC
1303	https://civic.genome.wustl.edu/links/variants/1303	MYC	4609	OVEREXPRESSION																	2017-05-15 13:45:59 UTC
1304	https://civic.genome.wustl.edu/links/variants/1304	ERBB2	2064	L755P																	2017-05-15 19:41:43 UTC
1305	https://civic.genome.wustl.edu/links/variants/1305	ERBB2	2064	T798M																	2017-05-15 19:42:41 UTC
1306	https://civic.genome.wustl.edu/links/variants/1306	TP53	7157	OVEREXPRESSION																	2017-05-18 08:15:45 UTC
1307	https://civic.genome.wustl.edu/links/variants/1307	TP53	7157	ALTERATION	P53 ALTERATION is a bucket type variant used in studies which is constructed by combining all cases of p53 mutation together with p53 overexpression. This includes cases which have p53 mutation or overexpression alone or as well as cases where both occur in combination.																2017-05-18 15:38:17 UTC
1308	https://civic.genome.wustl.edu/links/variants/1308	ERBB2	2064	L768S																	2017-05-18 17:07:42 UTC
1309	https://civic.genome.wustl.edu/links/variants/1309	ERBB2	2064	L638S																	2017-05-18 17:08:15 UTC
1310	https://civic.genome.wustl.edu/links/variants/1310	ERBB2	2064	V773																	2017-05-18 17:09:30 UTC
1311	https://civic.genome.wustl.edu/links/variants/1311	ERBB2	2064	V773L																	2017-05-18 17:10:00 UTC
1312	https://civic.genome.wustl.edu/links/variants/1312	ERBB2	2064	K753E																	2017-05-18 17:15:25 UTC
1313	https://civic.genome.wustl.edu/links/variants/1313	ERBB2	2064	L753E																	2017-05-18 17:16:47 UTC
1314	https://civic.genome.wustl.edu/links/variants/1314	ERBB2	2064	K755S																	2017-05-18 17:20:16 UTC
1315	https://civic.genome.wustl.edu/links/variants/1315	KIT	3815	V559D, exon 11 point mutation																	2017-05-21 13:27:35 UTC
1316	https://civic.genome.wustl.edu/links/variants/1316	KIT	3815	V559																	2017-05-21 14:36:10 UTC
1317	https://civic.genome.wustl.edu/links/variants/1317	NRAS	4893	G13V																	2017-05-23 18:17:27 UTC
1318	https://civic.genome.wustl.edu/links/variants/1318	TP53	7157	L3 Domain Mutation																	2017-05-24 09:04:06 UTC
